<SEC-DOCUMENT>0001129928-21-000051.txt : 20210806
<SEC-HEADER>0001129928-21-000051.hdr.sgml : 20210806
<ACCEPTANCE-DATETIME>20210806084858
ACCESSION NUMBER:		0001129928-21-000051
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		6
CONFORMED PERIOD OF REPORT:	20210630
FILED AS OF DATE:		20210806
DATE AS OF CHANGE:		20210806

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ONCOLYTICS BIOTECH INC
		CENTRAL INDEX KEY:			0001129928
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38512
		FILM NUMBER:		211150950

	BUSINESS ADDRESS:	
		STREET 1:		1167 KENSINGTON CRES NW SUITE 210
		STREET 2:		CALGARY ALBERTA CANADA T2N 1X7
		CITY:			ALBERTA CANADA
		STATE:			A0
		ZIP:			00000
		BUSINESS PHONE:		4036707380

	MAIL ADDRESS:	
		STREET 1:		210 - 1167 KENSINGTON CRES NW
		CITY:			CALGARY
		STATE:			A0
		ZIP:			T2N 1X7
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>q22021form6-k.htm
<DESCRIPTION>2021 SECOND QUARTER 6-K
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="iba0bb6741077441da302c4751c41c38b_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Washington, D.C. 20549</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;  </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">Form 6-K</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Report of Foreign Private Issuer</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Pursuant to Rule&#160;13a-16 or 15d-16</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">of the Securities Exchange Act of 1934</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the month of&#160;August 2021 </font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commission File Number 001-38512</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Oncolytics Biotech Inc.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(Translation of registrant&#8217;s name into English)</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Suite&#160;804, 322 11th Avenue SW</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Calgary, Alberta, Canada T2R 0C5</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(Address of principal executive offices)</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant files or will file annual reports under cover Form&#160;20-F or Form&#160;40-F.</font></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:38.724%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.251%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.725%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Form&#160;20-F&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#254;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Form&#160;40-F&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">o</font></div></td></tr></table></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark if the registrant is submitting the Form&#160;6-K in paper as permitted by Regulation&#160;S-T Rule&#160;101(b)(1)&#58;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">o</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Regulation&#160;S-T Rule&#160;101(b)(1) only permits the submission in paper of a Form&#160;6-K if submitted solely to provide an attached annual report to security holders.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark if the registrant is submitting the Form&#160;6-K in paper as permitted by Regulation&#160;S-T Rule&#160;101(b)(7)&#58;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">o</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Regulation&#160;S-T Rule&#160;101(b)(7) only permits the submission in paper of a Form&#160;6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized (the registrant&#8217;s &#8220;home country&#8221;), or under the rules of the home country exchange on which the registrant&#8217;s securities are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the registrant&#8217;s security holders, and, if discussing a material event, has already been the subject of a Form&#160;6-K submission or other Commission filing on EDGAR.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div id="iba0bb6741077441da302c4751c41c38b_4"></div><div style="-sec-extract:summary;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:174%">INCORPORATION BY REFERENCE</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Registrant&#8217;s Management&#8217;s Discussion and Analysis of Operations and Financial Condition for the Three and Six Months Ended June&#160;30, 2021, included as Exhibit&#160;99.2 of this Form&#160;6-K and the Interim Financial Statements as of and for the Six Months Ended June&#160;30, 2021, included as Exhibit&#160;99.1 of this Form&#160;6-K (Commission File No.&#160;001-38512), furnished to the Commission on&#160;August&#160;6, 2021, are incorporated by reference into the Registrant&#8217;s Registration Statement on Form&#160;F-10 (Commission File No. 333-239025).</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"></td><td style="width:16.131%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:80.933%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">EXHIBIT<br>NUMBER</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">DESCRIPTION</font></td></tr><tr><td colspan="3" style="border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99.1</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="ex991-interimfsjune302021.htm" style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Oncolytics Biotech&#174; Inc. </a><a href="ex991-interimfsjune302021.htm" style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">June 30</a><a href="ex991-interimfsjune302021.htm" style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">, 2021 Interim Financial Statements</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99.2</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="ex992-q22021mda.htm" style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Oncolytics Biotech&#174; Inc. </a><a href="ex992-q22021mda.htm" style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">June 30</a><a href="ex992-q22021mda.htm" style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">, 2021 Management Discussion &#38; Analysis</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99.3</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="ex993-q22021certificationx.htm" style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Certification of </a><a href="ex993-q22021certificationx.htm" style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">June</a><a href="ex993-q22021certificationx.htm" style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"> 3</a><a href="ex993-q22021certificationx.htm" style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">0</a><a href="ex993-q22021certificationx.htm" style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">, 2021 interim filings - CEO</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99.4</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="ex994-q22021certificationx.htm" style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Certification of </a><a href="ex994-q22021certificationx.htm" style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">June 30</a><a href="ex994-q22021certificationx.htm" style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">, 2021 interim filings - CFO</a></font></div></td></tr></table></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:50.583%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.728%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.438%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.728%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.823%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Oncolytics Biotech Inc.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Registrant)</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; August&#160;6, 2021</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#160;Kirk Look</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kirk Look</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</font></div></td></tr></table></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ex991-interimfsjune302021.htm
<DESCRIPTION>2021 SECOND QUARTER INTERIM FINANCIAL STATEMENTS
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i19b30f85ff014dadbd058daf489ce2ff_4"></div><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><font><br></font></div><div><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Interim Consolidated Financial Statements</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">(unaudited)</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Oncolytics Biotech</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> Inc.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">June&#160;30, 2021 and 2020</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="i19b30f85ff014dadbd058daf489ce2ff_7"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><font><br></font></div><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ONCOLYTICS BIOTECH INC.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">INTERIM CONSOLIDATED STATEMENTS OF FINANCIAL POSITION</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">(unaudited)</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(in Canadian dollars, except share amounts)</font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:402.00pt"><tr><td style="width:1.0pt"></td><td style="width:226.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:28.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:70.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:70.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:33pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As at </font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Notes</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30,<br>2021<br>$</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br>2020<br>$</font></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Assets</font></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Current assets</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">3</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">50,799,432</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,219,574&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other receivables</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">135,857</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89,661&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#160;</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,503,776</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,427,200&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total current assets</font></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#160;</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">55,439,065</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,736,435&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Non-current assets</font></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</font></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">146,216</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">236,664&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">9</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">724,164</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">372,468&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total non-current assets</font></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">870,380</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">609,132&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Total assets</font></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">56,309,445</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,345,567&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:30pt"><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Liabilities And Shareholders&#8217; Equity</font></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</font></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Current Liabilities</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable and accrued liabilities</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,193,979</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,805,015&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other liabilities</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">123,985&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liabilities</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">9</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">234,139</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">248,885&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrant derivative</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">4</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">153,968</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">531,228&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total current liabilities</font></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,582,086</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,709,113&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Non-current liabilities</font></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract liability</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">8</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6,730,287</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,730,287&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liabilities</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">9</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">510,369</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">153,174&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total non-current liabilities</font></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7,240,656</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,883,461&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Total liabilities</font></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">9,822,742</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,592,574&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:23pt"><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Commitments and contingencies</font></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">9</font></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr style="height:30pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Shareholders&#8217; equity </font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr style="height:45pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share capital</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;Authorized&#58; unlimited</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;Issued&#58; June&#160;30, 2021 &#8211; 54,959,672 </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;December&#160;31, 2020 &#8211; 46,166,980</font></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">5</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">391,124,995</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">356,824,172&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">5</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,617,570</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,617,570&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contributed surplus</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">6</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">32,224,806</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,022,356&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated other comprehensive income</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">311,543</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">400,225&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated deficit</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(380,792,211)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(367,111,330)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Total shareholders&#8217; equity </font></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">46,486,703</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,752,993&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Total liabilities and shareholder's equity</font></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">56,309,445</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,345,567&#160;</font></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> See accompanying notes</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</font></div></div></div><div id="i19b30f85ff014dadbd058daf489ce2ff_13"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ONCOLYTICS BIOTECH INC.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">INTERIM CONSOLIDATED STATEMENTS OF LOSS AND COMPREHENSIVE LOSS</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">(unaudited)</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(in Canadian dollars, except share amounts) </font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:504.00pt"><tr><td style="width:1.0pt"></td><td style="width:183.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:54.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:63.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:63.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:64.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:64.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:63pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Notes</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended June 30, 2021<br>$</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended June 30, 2020<br>$</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended June 30, 2021<br>$</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended June 30, 2020<br>$</font></td></tr><tr style="height:18pt"><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Expenses</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Research and development</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">6, 13, 14</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,203,181</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,499,128&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5,962,195</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,028,774&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Operating</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">6, 13, 14</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,520,986</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,048,572&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6,662,876</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,041,960&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Loss before the following</font></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#160;</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(6,724,167)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,547,700)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(12,625,071)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,070,734)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Change in fair value of warrant derivative</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">4</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">80,159</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(507,150)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(84,621)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,644,832&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange (loss) gain</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">13</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(631,352)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(805,098)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(1,021,906)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">899,707&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Interest income, net</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#160;</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">29,224</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,533&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">50,717</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98,442&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Loss before income taxes</font></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#160;</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(7,246,136)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,827,415)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(13,680,881)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,427,753)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Income tax expense</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Net loss</font></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#160;</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(7,246,136)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,827,415)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(13,680,881)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,427,753)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:24pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Other comprehensive (loss) income items that may be reclassified to net loss</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;Translation adjustment</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(48,370)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(146,443)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(88,682)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">148,769&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:27pt"><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Net comprehensive loss</font></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(7,294,506)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,973,858)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(13,769,563)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,278,984)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Basic and diluted loss per common share</font></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">7</font></td><td colspan="2" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(0.13)</font></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.17)</font></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(0.26)</font></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.17)</font></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:29pt"><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Weighted average number of shares (basic and diluted)</font></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">7</font></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">54,325,212</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,603,671&#160;</font></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">52,008,768</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,734,689&#160;</font></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:22.5pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;See accompanying notes</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</font></div></div></div><div id="i19b30f85ff014dadbd058daf489ce2ff_22"></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ONCOLYTICS BIOTECH INC.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">INTERIM CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">(unaudited)</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(in Canadian dollars)</font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:666.00pt"><tr><td style="width:1.0pt"></td><td style="width:193.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:52.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:66.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:66.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:66.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:73.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:66.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:66.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:54pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Notes</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Share Capital<br>$</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Warrants<br>$</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Contributed Surplus<br>$</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated Other Comprehensive Income<br>$</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated Deficit<br>$</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total<br>$</font></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As at December 31, 2019</font></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">311,077,859&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,617,570&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,338,849&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">464,101&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(344,606,273)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(107,894)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss and other comprehensive loss</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">148,769&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,427,753)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,278,984)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued pursuant to stock option plan</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">5, 6</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">162,812&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(60,024)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102,788&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued pursuant to incentive share award plan</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">5, 6</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">289,686&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(289,686)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued pursuant to &#34;At the Market&#34; Agreement</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">5</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,359,150&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,359,150&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued pursuant to warrant derivative exercised</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">4, 5</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,332,778&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,332,778&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">6</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">653,445&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">653,445&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share issue costs</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">5</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,072,119)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,072,119)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As at June 30, 2020</font></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">341,150,166&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,617,570&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,642,584&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">612,870&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(351,034,026)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,989,164&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As at December 31, 2020</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">356,824,172&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,617,570&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,022,356&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">400,225&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(367,111,330)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,752,993&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss and other comprehensive income</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(88,682)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,680,881)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,769,563)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued pursuant to stock option plan</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">5, 6</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">313,867&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(117,751)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">196,116&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued pursuant to incentive share award plan</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">5, 6</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">370,117&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(370,117)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued pursuant to &#34;At the Market&#34; Agreement</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">5</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,168,071&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,168,071&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued pursuant to warrant derivative exercised</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">4, 5</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">686,616&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">686,616&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">6</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,690,318&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,690,318&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share issue costs</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">5</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,237,848)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,237,848)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As at June 30, 2021</font></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">391,124,995</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,617,570</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">32,224,806</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">311,543</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(380,792,211)</font></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">46,486,703</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See accompanying notes</font></div><div><font><br></font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</font></div></div></div><div id="i19b30f85ff014dadbd058daf489ce2ff_25"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ONCOLYTICS BIOTECH INC.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">INTERIM CONSOLIDATED STATEMENTS OF CASH FLOWS</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">(unaudited)</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(in Canadian dollars)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:511.50pt"><tr><td style="width:1.0pt"></td><td style="width:217.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:40.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:61.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:61.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:60.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:58.75pt"></td><td style="width:1.0pt"></td></tr><tr style="height:63pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Notes</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended June 30, 2021<br>$</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended June 30, 2020<br>$</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended June 30, 2021<br>$</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended June 30, 2020<br>$</font></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr style="height:24pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating Activities</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss for the period</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(7,246,136)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,827,415)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(13,680,881)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,427,753)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation - property and equipment</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">13</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">75,340</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,584&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">95,890</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,629&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation - right-of-use-assets</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">13</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">88,493</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92,133&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">174,677</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">183,156&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">6, 13, 14</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,032,242</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">260,640&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,690,318</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">653,445&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense on lease liabilities</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">24,450</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,885&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">38,259</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,094&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized foreign exchange loss (gain)</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">713,763</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">699,079&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,233,131</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(728,677)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of warrant derivative</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">4</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(80,159)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">507,150&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">84,621</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,644,832)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net change in non-cash working capital</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">12</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(1,404,875)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,027,687)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(2,001,354)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(327,950)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash used in operating activities</font></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(6,796,882)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,258,631)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(12,365,339)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,213,888)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:24pt"><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Investing Activities</font></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</font></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition of property and equipment</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(6,598)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,034)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(6,598)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,749)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash used in investing activities</font></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#160;</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(6,598)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,034)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(6,598)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,749)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:24pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Financing Activities</font></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</font></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from exercise of stock options</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">6</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6,766</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,638&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">196,116</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102,788&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from exercise of warrant derivative</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">4, 5</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">263,318&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">230,946</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,696,460&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:24pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from &#34;At the Market&#34; equity distribution agreement</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">5</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8,072,561</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,449,218&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">32,930,223</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,287,031&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payment of lease liabilities</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(98,555)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(119,634)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(210,228)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(233,108)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash provided by financing activities</font></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#160;</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7,980,772</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,610,540&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">33,147,057</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,853,171&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:21pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Increase in cash</font></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#160;</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,177,292</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">348,875&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">20,775,120</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,625,534&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents, beginning of period</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#160;</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">50,362,162</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,567,480&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">31,219,574</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,148,021&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:24pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impact of foreign exchange on cash and cash equivalents</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#160;</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(740,022)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,005,004)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(1,195,262)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,137,796&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Cash and cash equivalents, end of period</font></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#160;</font></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">50,799,432</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,911,351&#160;</font></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">50,799,432</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,911,351&#160;</font></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:4.5pt;text-indent:-4.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See accompanying notes</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</font></div></div></div><div id="i19b30f85ff014dadbd058daf489ce2ff_31"></div><hr style="page-break-after:always"><div style="min-height:90pt;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ONCOLYTICS BIOTECH INC.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">(unaudited)</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">June 30, 2021</font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"> </font></div><div id="i19b30f85ff014dadbd058daf489ce2ff_34"></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">Note 1&#58; Incorporation and Nature of Operations</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Oncolytics Biotech Inc. was incorporated on April 2, 1998 under the Business Corporations Act (Alberta) as 779738 Alberta Ltd.  On April 8, 1998, we changed our name to Oncolytics Biotech Inc.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our interim consolidated financial statements for the period ended June&#160;30, 2021, were authorized for issue in accordance with a resolution of the Board of Directors (the &#34;Board&#34;) on August&#160;5, 2021. We are a limited company incorporated and domiciled in Canada. Our shares are publicly traded on the Nasdaq Capital Markets and the Toronto Stock Exchange. Our principal place of business is located at 804, 322 11</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Avenue SW, Calgary, Alberta, Canada. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a development stage biopharmaceutical company that focuses on the discovery and development of pharmaceutical products for the treatment of cancers that have not been successfully treated with conventional therapeutics. Our lead product, pelareorep, is a potential immuno-oncology viral-agent that may be a novel treatment for certain types of cancer and may be an alternative to or used in combination with existing cytotoxic or cytostatic therapies. Our clinical development program for pelareorep centers on key immunotherapy combinations. Specifically, immunotherapy combinations in which pelareorep has the potential to provoke specific innate and adaptive immune responses when combined with checkpoint blockade therapy, chemotherapy and&#47;or targeted therapies.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The full extent to which the coronavirus infectious disease 2019 (&#34;COVID-19&#34;) pandemic may directly or indirectly impact our business, results of operations and financial condition, including our ability to finance our operations, expenses, clinical trials, and research and development costs, will depend on future developments that are evolving and highly uncertain, such as the duration and severity of outbreaks, including potential future waves or cycles, and the effectiveness of actions taken to contain and treat COVID-19. We considered the potential impact of COVID-19 when making certain estimates and judgments relating to the preparation of these interim consolidated financial statements. While there was no material impact to our interim consolidated financial statements as of and for the period ended June&#160;30, 2021, our future assessment of the magnitude and duration of COVID-19, as well as other factors, could result in a material impact to our consolidated financial statements in future reporting periods.</font></div><div style="text-align:justify"><font><br></font></div><div id="i19b30f85ff014dadbd058daf489ce2ff_37"></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">Note 2&#58; Basis of Financial Statement Presentation</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our interim consolidated financial statements include our financial statements and the financial statements of our subsidiaries as at June&#160;30, 2021 and are presented in Canadian dollars, our functional currency.  </font></div><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our accounts are prepared in accordance with International Financial Reporting Standards (&#34;IFRS&#34;) issued by the International Accounting Standards Board (&#34;IASB&#34;). The accounts are prepared on the historical cost basis, except for certain assets and liabilities which are measured at fair value as explained in the notes to these financial statements.  </font></div><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These interim consolidated financial statements have been prepared in compliance with International Accounting Standard 34 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interim Financial Reporting. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The notes presented in these interim consolidated financial statements include only significant events and transactions occurring since our last fiscal year end and are not fully inclusive of all matters required to be disclosed in our annual audited consolidated financial statements.  Accordingly, these interim consolidated financial statements should be read in conjunction with our most recent annual audited consolidated financial statements, for the year ended December&#160;31, 2020. We have consistently applied the same accounting policies for all periods presented in these interim consolidated financial statements as those used in our audited consolidated financial statements for the year ended December&#160;31, 2020.</font></div><div style="text-align:justify"><font><br></font></div><div id="i19b30f85ff014dadbd058daf489ce2ff_43"></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">Note 3&#58; Cash Equivalents </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash Equivalents</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash equivalents consist of interest bearing deposits with our bank totaling $47,944,484 (December&#160;31, 2020 &#8211; $30,361,591).&#160;&#160;The current annual interest rate earned on these deposits is 0.45%  (December&#160;31, 2020 &#8211; 0.36%).</font></div><div style="text-align:justify"><font><br></font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</font></div></div></div><div id="i19b30f85ff014dadbd058daf489ce2ff_46"></div><hr style="page-break-after:always"><div style="min-height:90pt;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ONCOLYTICS BIOTECH INC.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">(unaudited)</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">June 30, 2021</font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">Note 4&#58; Warrant Derivative</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 16, 2019, pursuant to an underwritten public offering, 4,619,773 units were sold at a purchase price of US$0.81 per unit for gross proceeds of US$3,742,016. Each unit included one common share and one common share purchase warrant (see Note 5). Each common share purchase warrant entitled the holder to purchase one common share at an exercise price of US$0.90 until August 16, 2024. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under IFRS 9 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and IAS 32 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments&#58; Presentation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, warrants with an exercise price denominated in a currency that differs from an entity's functional currency are treated as a derivative measured at fair value with subsequent changes in fair value accounted for through profit and loss. Our warrants with an exercise price of US$0.90 meet this requirement and we have presented the fair value of these warrants as a current liability on the consolidated statement of financial position. As these warrants are exercised, the fair value at the date of exercise and the associated non-cash liability will be included in our share capital along with the proceeds from the exercise. If these warrants expire, the non-cash warrant liability is reversed through the consolidated statement of loss and comprehensive loss. There is no cash flow impact as a result of the accounting treatment for changes in the fair value of the warrant derivative or when warrants expire unexercised. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the change in fair value of the warrant derivative is as follows&#58;</font></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:391.50pt"><tr><td style="width:1.0pt"></td><td style="width:199.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:93.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:93.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:33pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of Warrants Outstanding</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value of Warrant Derivative<br>$</font></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As at December 31, 2019</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,684,126&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,508,764&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,418,369)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,636,317)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,491,928)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange impact</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">150,709&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As at December 31, 2020</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">265,757&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">531,228&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(201,722)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(455,670)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84,621&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange impact</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,211)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As at June 30, 2021</font></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">64,035</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">153,968</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the six months ended June&#160;30, 2021, we received cash proceeds of US$181,550 (June&#160;30, 2020 - US$1,276,532) with respect to warrants exercised.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We use the Black-Scholes valuation model to estimate fair value. The expected volatility is based on the Company's common share historical volatility less an estimated market participant risk adjustment. The risk-free interest rate is based on U.S. Department of Treasury benchmark treasury yield rates with an approximate equivalent remaining term in effect at the time of valuation and the expected life represents the estimated length of time the warrants are expected to remain outstanding. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated fair value of the warrant derivative was determined using the following assumptions&#58; </font></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:341.25pt"><tr><td style="width:1.0pt"></td><td style="width:202.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:66.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:66.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:24pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2021</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</font></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value per warrant</font></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">US$1.94</font></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US$1.57</font></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Underlying share price</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">US$2.77</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US$2.38</font></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">0.07%</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.10%</font></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected hold period to exercise</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1.0 year</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0 year</font></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected share price volatility</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">90.00%</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90.00%</font></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</font></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nil</font></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nil</font></td></tr></table></div><div><font><br></font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</font></div></div></div><div id="i19b30f85ff014dadbd058daf489ce2ff_49"></div><hr style="page-break-after:always"><div style="min-height:90pt;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ONCOLYTICS BIOTECH INC.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">(unaudited)</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">June 30, 2021</font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">Note 5&#58; Share Capital</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Authorized&#58;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unlimited number of no par value common shares</font></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:504.75pt"><tr><td style="width:1.0pt"></td><td style="width:327.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:85.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:85.75pt"></td><td style="width:1.0pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Shares</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:24pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number</font></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, December 31, 2019</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,198,453&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">311,077,859&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued pursuant to stock option plan</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">133,454&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">385,022&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued pursuant to incentive share award plan</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">234,172&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">732,367&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued pursuant to &#34;At the Market&#34; (ATM) equity distribution agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a)(c)</font></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,182,532&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,037,786&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued pursuant to warrant derivative exercised</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(b)</font></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,418,369&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,332,778&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share issue costs</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,741,640)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, December 31, 2020</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,166,980&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">356,824,172&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued pursuant to stock option plan</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93,159&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">313,867&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued pursuant to incentive share award plan</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96,782&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">370,117&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued pursuant to &#34;At the Market&#34; (ATM) equity distribution agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(c)(d)</font></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,401,029&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,168,071&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued pursuant to warrant derivative exercised</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(b)</font></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">201,722&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">686,616&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share issue costs</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,237,848)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance, June 30, 2021</font></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">54,959,672</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">391,124,995</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="padding-left:18pt;text-align:justify"><font><br></font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">On October 24, 2018, we entered into an ATM equity offering sales agreement with Canaccord Genuity Inc. The ATM allowed us, at our sole discretion, to issue common shares, at prevailing market prices, with an aggregate offering value of up to US$30,000,000 over a 19-month period through the facilities of the Nasdaq Capital Market in the United States. This sales agreement expired on June 4, 2020 and no shares were issued during the six months ended June&#160;30, 2021. During the six months ended June&#160;30, 2020, we sold 6,741,518 common shares for gross proceeds of US$17,538,342 at an average price of US$2.60. We received, net of commissions of US$526,150, proceeds of US$17,012,192. In total, we incurred share issue costs (including commissions) of $856,754.   </font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">On August 16, 2019, pursuant to an underwritten public offering, 4,619,773 units were sold at a purchase price of US$0.81 per unit. Each unit included one common share with a fair value of US$0.54 and one common share purchase warrant with a fair value of US$0.27. These warrants were classified as a financial liability. Each common share purchase warrant entitled the holder to purchase one common share at an exercise price of US$0.90 until August 16, 2024. During the six months ended June&#160;30, 2021, our share capital included fair value of $455,670 (June&#160;30, 2020 - $4,636,317) in addition to gross proceeds of US$181,550 (June&#160;30, 2020 - US$1,276,532) for the 201,722 (June&#160;30, 2020 - 1,418,369) warrants that were exercised (see Note 4).  </font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">On June 15, 2020, we entered into an ATM equity distribution agreement with Canaccord Genuity Inc. The ATM allowed us, at our sole discretion, to issue common shares, at prevailing market prices, with an aggregate offering value of up to US$40,000,000 over a 25-month period through the facilities of the Nasdaq Capital Market in the United States. During the six months ended June&#160;30, 2021, we sold 5,685,097 (June&#160;30, 2020 - 314,109) common shares for gross proceeds of US$18,503,188 (June&#160;30, 2020 - US$650,004) at an average price of US$3.25 (June&#160;30, 2020 - US$2.07). We received, net of commissions of US$555,096 (June&#160;30, 2020 - US$19,500), proceeds of US$17,948,092 (June&#160;30, 2020 - US$630,504). In total, we incurred share issue costs (including commissions) of $707,421 (June&#160;30, 2020 - $215,365). On March 4, 2021, we terminated the June 15, 2020 ATM equity distribution agreement.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">On March 5, 2021, we entered into an ATM equity distribution agreement with Canaccord Genuity Inc. The ATM allows us, at our sole discretion, to issue common shares, at prevailing market prices, with an aggregate offering value of up to US$80,000,000 over a 16-month period through the facilities of the Nasdaq Capital Market in the United States. During the six months ended June&#160;30, 2021, we sold 2,715,932 common shares for gross proceeds of US$8,654,892 at an average </font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</font></div></div></div><hr style="page-break-after:always"><div style="min-height:90pt;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ONCOLYTICS BIOTECH INC.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">(unaudited)</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">June 30, 2021</font></div></div><div style="padding-left:18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">price of US$3.19. We received, net of commissions of US$259,647, proceeds of US$8,395,245. In total, we incurred share issue costs (including commissions) of $530,427. </font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Equity Warrants</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 1, 2017, pursuant to an underwritten public offering, 16,445,000 units were sold for gross proceeds of $11,511,500. Each unit included one common share and one common share purchase warrant. Following the 2018 share consolidation, 9.5 common share purchase warrants entitled the holder to purchase one common share in the capital of the Company until June 1, 2022, at an exercise price of approximately $9.025. These warrants were classified as equity. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our outstanding equity warrants&#58;</font></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:391.50pt"><tr><td style="width:1.0pt"></td><td style="width:199.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:93.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:93.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:33pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of Warrants Outstanding</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</font></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Warrant <br>$</font></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As at December 31, 2020</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,443,500&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,617,570&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As at June 30, 2021</font></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,443,500&#160;</font></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,617,570&#160;</font></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">                               (1) Exercisable into 1,730,894 common shares.</font></div><div><font><br></font></div><div id="i19b30f85ff014dadbd058daf489ce2ff_55"></div><div style="margin-top:1pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">Note 6&#58; Share-Based Compensation</font></div><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Stock Option Plan</font></div><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have issued stock options to acquire common stock through our stock option plan of which the following are outstanding at June&#160;30&#58;</font></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:492.00pt"><tr><td style="width:1.0pt"></td><td style="width:160.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:76.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:82.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:82.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:82.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:24pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</font></td><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</font></td></tr><tr style="height:44pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Stock Options</font></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Exercise Price<br>$</font></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Stock Options</font></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Exercise Price<br>$</font></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, beginning of the period</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,764,055</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4.08</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,246,947&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.31</font></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted during the period</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,172,500</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3.42</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,000&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.23</font></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited during the period</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(56,226)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4.08</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18,085)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.83</font></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expired during the period</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(526)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">52.63</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</font></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised during the period</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(93,159)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2.11</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(45,120)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.28</font></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, end of the period</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,786,644</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3.95</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,243,742&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.30</font></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options exercisable, end of the period</font></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,174,143</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4.99</font></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,359,448&#160;</font></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.23</font></td></tr></table></div><div style="text-align:center"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</font></div></div></div><hr style="page-break-after:always"><div style="min-height:90pt;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ONCOLYTICS BIOTECH INC.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">(unaudited)</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">June 30, 2021</font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes information about the stock options outstanding and exercisable at June&#160;30, 2021&#58;</font></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:512.25pt"><tr><td style="width:1.0pt"></td><td style="width:135.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:73.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:73.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:73.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:73.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:73.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:51pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Range of Exercise Prices</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Number Outstanding</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted Average Remaining Contractual Life (years)</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted Average Exercise Price</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</font></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Number Exercisable</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted Average Exercise Price</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</font></div></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$0.54 - $1.79</font></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">756,665&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.53</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.39</font></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">495,007&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.36</font></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$1.80 - $3.01</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">421,573&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.10</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.67</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">261,573&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.68</font></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$3.02 - $3.90</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,962,382&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.88</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.29</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">791,539&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.28</font></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$3.91 - $7.41</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">478,516&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.23</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.09</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">458,516&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.13</font></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$7.42 - $40.96</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">167,508&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.83</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.23</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">167,508&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.23</font></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;border-bottom:3pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,786,644&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.45</font></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.95</font></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,174,143&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.99</font></td></tr></table></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-exercisable options vest either immediately or annually over periods ranging from one to three years.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We use the Black-Scholes valuation model to estimate fair value. We use historical data to estimate the expected dividend yield and expected volatility of our stock in determining the fair value of the stock options. The risk-free interest rate is based on the Government of Canada benchmark bond yield rates in effect at the time of grant and the expected life of the options represents the estimated length of time the options are expected to remain outstanding. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated fair value of stock options granted during the period was determined using the Black-Scholes valuation model using the following weighted average assumptions&#58; </font></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:336.75pt"><tr><td style="width:1.0pt"></td><td style="width:202.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:66.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:61.75pt"></td><td style="width:1.0pt"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</font></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</font></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">0.49%</font></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.63%</font></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected hold period to exercise</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3.0 years</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0 years</font></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected share price volatility</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">110.87%</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110.84%</font></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nil</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nil</font></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average fair value of options</font></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$2.27</font></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$3.51</font></td></tr></table></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Incentive Share Award Plan</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restricted Share Units</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have issued restricted share units (&#34;RSUs&#34;) to non-employee directors through our incentive share award plan. Grants of RSUs to non-employee directors vest either immediately, on the third anniversary date from the grant date or when the director ceases to be a member of the board. We have also issued RSUs to certain officers and employees of the Company. Grants of RSUs to certain officers and employees of the Company vest over a three year period. The following RSUs are outstanding at June&#160;30&#58;</font></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:74.707%"><tr><td style="width:1.0%"></td><td style="width:62.500%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.099%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.101%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, beginning of the period</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">134,618</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">209,657&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted during the period</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,003&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Released during the period</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(39,941)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(99,052)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:3pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, end of the period</font></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">94,677</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">142,608&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">                                (1) The weighted average fair value of the RSUs granted was nil in 2021 (2020 - $2.90).</font></div><div style="margin-top:12pt;text-align:justify"><font><br></font></div><div style="margin-top:12pt;text-align:justify"><font><br></font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</font></div></div></div><hr style="page-break-after:always"><div style="min-height:90pt;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ONCOLYTICS BIOTECH INC.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">(unaudited)</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">June 30, 2021</font></div></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Performance Share Units</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have also issued performance share units (&#34;PSUs&#34;) to certain officers and employees of the Company. Grants of PSUs require completion of certain performance criteria and cliff vest after 3 years or vest over a three year period, depending on the grant. The following PSUs are outstanding at June&#160;30&#58;</font></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:383.25pt"><tr><td style="width:1.0pt"></td><td style="width:241.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:67.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:67.75pt"></td><td style="width:1.0pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</font></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, beginning of the period</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">56,841</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61,051&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Released during the period</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(56,841)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,210)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;border-bottom:3pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, end of the period</font></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,841&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have reserved 5,495,967 common shares for issuance relating to our outstanding equity compensation plans. Compensation expense related to stock options, RSUs and PSUs were $1,032,242 and $1,690,318 for the three and six months ended June&#160;30, 2021, respectively (June&#160;30, 2020 - $260,640 and $653,445, respectively).  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div id="i19b30f85ff014dadbd058daf489ce2ff_61"></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">Note 7&#58; Loss Per Common Share</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Loss per common share is calculated using net loss for the period and the weighted average number of common shares outstanding for the three and six months ended June&#160;30, 2021 of 54,325,212 and 52,008,768, respectively (June&#160;30, 2020 - 39,603,671 and 37,734,689, respectively). The effect of any potential exercise of our stock options and warrants outstanding during the year has been excluded from the calculation of diluted loss per common share, as it would be anti-dilutive.</font></div><div style="text-align:justify"><font><br></font></div><div id="i19b30f85ff014dadbd058daf489ce2ff_67"></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">Note 8&#58; Contract Liability</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Regional licensing agreement</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We entered into a regional licensing agreement (the &#34;Licensing Agreement&#34;) with Adlai Nortye Biopharma Co., Ltd. (&#34;Adlai&#34;) in November 2017. Under the terms of the Licensing Agreement, Adlai will have exclusive development and commercialization rights to pelareorep in China, Hong Kong, Macau, Singapore, South Korea and Taiwan. We are entitled to receive upfront license fees, development and regulatory milestone payments, royalties and sales-based milestone payments. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contract liability</font></div><div style="text-align:justify"><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our contract liability balance, which w</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">e expect to record in revenue over the next five years, is as follows&#58;</font></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:333.00pt"><tr><td style="width:1.0pt"></td><td style="width:175.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:78.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:73.75pt"></td><td style="width:1.0pt"></td></tr><tr style="height:33pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30,<br>2021<br>$</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br>2020<br>$</font></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, beginning of the period</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6,730,287</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,730,287&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Regional licensing agreement</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue recognized in the period</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, end of the period</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6,730,287</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,730,287&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract liability - non-current</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6,730,287</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,730,287&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6,730,287</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,730,287&#160;</font></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><font><br></font></div><div id="i19b30f85ff014dadbd058daf489ce2ff_73"></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">Note 9&#58; Commitments</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are committed to payments totaling $9,897,073 for activities related to our clinical trial, manufacturing and collaboration programs which are expected to occur over the next two years. </font></div><div style="text-align:justify"><font><br></font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</font></div></div></div><hr style="page-break-after:always"><div style="min-height:90pt;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ONCOLYTICS BIOTECH INC.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">(unaudited)</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">June 30, 2021</font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under a clinical trial agreement entered into with the Alberta Cancer Board (&#8220;ACB&#8221;), we have agreed to repay the amount funded under the agreement together with a royalty, to a combined maximum amount of $400,000 plus an overhead repayment of $100,000, upon sales of a specified product.&#160;We agreed to repay the ACB in annual installments in an amount equal to the lesser of&#58; (a) 5% of gross sales of a specified product&#59; or (b) $100,000 per annum once sales of a specified product commence.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our portfolio of leases consists of office spaces with initial lease terms generally between 3 to 6 years. We currently do not have leases with variable lease payments or residual value guarantees. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the first six months of 2021, we extended the office lease for one of our subsidiaries and entered into a new office space lease for our Canadian head office for which we recorded an addition of $532,758 to the lease liability and right-of-use asset. The incremental borrowing rate applied was 15%. </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our total undiscounted lease liability as at June&#160;30, 2021 is as follows&#58;</font></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:76.900%"><tr><td style="width:1.0%"></td><td style="width:78.557%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.243%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Maturity analysis - contractual undiscounted cash flows</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30,<br>2021<br>$</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less than one year</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">331,286&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">One to six years</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">617,618&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">More than six years</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total undiscounted lease liability</font></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">948,904&#160;</font></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div id="i19b30f85ff014dadbd058daf489ce2ff_76"></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">Note 10&#58; Capital Disclosures</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our objective when managing capital is to maintain a strong statement of financial position. We achieve our objective by obtaining adequate cash resources to support planned activities which include the clinical trial program, product manufacturing, administrative costs and intellectual property expansion and protection.&#160;We include shareholders&#8217; equity and cash and cash equivalents in the definition of capital.</font></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.122%"><tr><td style="width:1.0%"></td><td style="width:70.876%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.911%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.913%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30,<br>2021<br>$</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br>2020<br>$</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">50,799,432</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,219,574&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shareholders&#8217; equity</font></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">46,486,703</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,752,993&#160;</font></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not have any debt other than trade accounts payable and lease liabilities, and we have potential contingent obligations relating to the completion of our research and development of pelareorep.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In managing our capital, we estimate our future cash requirements by preparing a budget and a multi-year plan annually for review and approval by our Board. The budget establishes the approved activities for the upcoming year and estimates the costs associated with these activities. The multi-year plan estimates future activity along with the potential cash requirements and is based on our assessment of our current clinical trial progress along with the expected results from the coming year&#8217;s activity.&#160;Budget to actual variances are prepared and reviewed by management and are presented quarterly to the Board.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Historically, funding for our plan is primarily managed through the issuance of additional common shares and common share purchase warrants that upon exercise are converted to common shares.&#160;Management regularly monitors the capital markets attempting to balance the timing of issuing additional equity with our progress through our clinical trial program, general market conditions, and the availability of capital.&#160;There are no assurances that funds will be made available to us when required.</font></div><div style="text-align:justify"><font><br></font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</font></div></div></div><hr style="page-break-after:always"><div style="min-height:90pt;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ONCOLYTICS BIOTECH INC.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">(unaudited)</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">June 30, 2021</font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 12, 2020, we renewed our short form base shelf prospectus (the &#34;Base Shelf&#34;) that qualifies for distribution of up to $150,000,000 of common shares, subscription receipts, warrants, or units (the &#34;Securities&#34;) in either Canada, the US or both. Under a Base Shelf, we may sell Securities to or through underwriters, dealers, placement agents or other intermediaries and also may sell Securities directly to purchasers or through agents, subject to obtaining any applicable exemption from registration requirements. The distribution of Securities may be effected from time to time in one or more transactions at a fixed price or prices, which may be subject to change, at market prices prevailing at the time of sale, or at prices related to such prevailing market prices to be negotiated with purchasers and as set forth in an accompanying Prospectus Supplement.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Renewing our Base Shelf provides us with additional flexibility when managing our cash resources as, under certain circumstances, it shortens the time period required to close a financing and is expected to increase the number of potential investors that may be prepared to invest in our company. Funds received as a result of using our Base Shelf would be used in line with our Board approved budget and multi-year plan. Our renewed Base Shelf will be effective until July 12, 2022. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Base Shelf allowed us to enter into our ATM equity distribution agreements in June 2020 and March 2021 (see Note 5). We use these equity arrangements to assist us in achieving our capital objective. These arrangements provide us with the opportunity to raise capital at our sole discretion providing us with the ability to better manage our cash resources. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are not subject to externally imposed capital requirements and there have been no changes in how we define or manage our capital in 2021.</font></div><div style="text-align:justify"><font><br></font></div><div id="i19b30f85ff014dadbd058daf489ce2ff_79"></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">Note 11&#58; Financial Instruments</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our financial instruments consist of cash and cash equivalents, other receivables, other liabilities, accounts payable and warrant derivative.&#160;As at June&#160;30, 2021, the carrying amount of our cash and cash equivalents,&#160;other receivables, other liabilities and accounts payable approximated their fair value. The warrant derivative is a recurring Level 2 fair value measurement as these warrants have not been listed on an exchange and therefore do not trade on an active market. As at June&#160;30, 2021, the fair value of our warrant derivative was $153,968 (December&#160;31, 2020 - $531,228). &#160;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Credit risk</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Credit risk is the risk of financial loss if a counterparty to a financial instrument fails to meet its contractual obligations.&#160;We are exposed to credit risk on our cash and cash equivalents in the event of non-performance by counterparties, but we do not anticipate such non-performance.&#160;Our maximum exposure to credit risk at the end of the period is the carrying value of our cash and cash equivalents and other receivables.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We mitigate our exposure to credit risk by maintaining our primary operating and investment bank accounts with Schedule I banks in Canada.&#160;For our foreign domiciled bank accounts, we use referrals or recommendations from our Canadian banks to open foreign bank accounts and these accounts are used solely for the purpose of settling accounts payable or payroll.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest rate risk</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest rate risk is the risk that future cash flows of a financial instrument will fluctuate because of changes in market interest rates.&#160;We are exposed to interest rate risk through our cash and cash equivalents.&#160;We mitigate this risk through our investment policy that only allows investment of excess cash resources in investment grade vehicles while matching maturities with our operational requirements.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fluctuations in market rates of interest do not have a significant impact on our results of operations due to the short term to maturity of the investments held.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign exchange risk</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Foreign exchange risk arises from changes in foreign exchange rates that may affect the fair value or future cash flows of our financial assets or liabilities. We are primarily exposed to the risk of changes in the Canadian dollar relative to the U.S. dollar and Euro as a portion of our financial assets and liabilities are denominated in such currencies. The impact of a $0.01 increase in the value of the U.S. dollar against the Canadian dollar would have decreased our net comprehensive loss in 2021 by approximately $360,000.&#160;The impact of a $0.10 increase in the value of the Euro against the Canadian dollar would have decreased our net comprehensive loss in 2021 by approximately $14,000.</font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</font></div></div></div><hr style="page-break-after:always"><div style="min-height:90pt;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ONCOLYTICS BIOTECH INC.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">(unaudited)</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">June 30, 2021</font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We mitigate our foreign exchange risk by maintaining sufficient foreign currencies, through the purchase of foreign currencies or receiving foreign currencies from financing activities, to settle our foreign accounts payable.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Balances in foreign currencies at June&#160;30, 2021 are as follows&#58;</font></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:357.75pt"><tr><td style="width:1.0pt"></td><td style="width:156.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:97.75pt"></td><td style="width:1.0pt"></td><td colspan="3" style="display:none"></td><td style="width:1.0pt"></td><td style="width:97.75pt"></td><td style="width:1.0pt"></td></tr><tr style="height:35pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">US dollars <br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Euro<br>&#8364;</font></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</font></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,763,120</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">148,430</font></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other receivables</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,878</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</font></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable and other liabilities</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(333,475)</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</font></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrant derivative</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(124,228)</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</font></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;border-bottom:3pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,352,295</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">148,430</font></td></tr></table></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liquidity risk</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Liquidity risk is the risk that we will encounter difficulty in meeting obligations associated with financial liabilities.&#160;We manage liquidity risk through the management of our capital structure as outlined in Note 10. Accounts payable are all due within the current operating period.</font></div><div style="text-align:justify"><font><br></font></div><div id="i19b30f85ff014dadbd058daf489ce2ff_82"></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">Note 12&#58; Additional Cash Flow Disclosures</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Net Change In Non-Cash Working Capital</font></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:513.75pt"><tr><td style="width:1.0pt"></td><td style="width:274.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:57.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:57.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:57.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:57.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:74pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended June 30, 2021<br>$</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended June 30, 2020<br>$</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended June 30, 2021<br>$</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended June 30, 2020<br>$</font></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Change in&#58;</font></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other receivables</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(24,192)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71,310&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(46,196)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,012,587&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(1,622,046)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(900,394)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(2,076,576)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,397,116)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable and accrued liabilities</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">275,341</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(91,019)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">388,964</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(486,000)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other liabilities</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(242,475)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(123,985)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(376,708)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash impact of foreign exchange</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(33,978)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">134,891&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(143,561)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(80,713)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in non-cash working capital related to operating activities</font></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(1,404,875)</font></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,027,687)</font></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(2,001,354)</font></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(327,950)</font></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Cash Flow Disclosures</font></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:494.25pt"><tr><td style="width:1.0pt"></td><td style="width:255.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:57.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:57.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:57.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:57.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:74pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended June 30, 2021<br>$</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended June 30, 2020<br>$</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended June 30, 2021<br>$</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended June 30, 2020<br>$</font></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash interest received</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">53,674</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,418&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">88,976</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">131,536&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash taxes paid</font></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">17,088</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,211&#160;</font></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">17,088</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,211&#160;</font></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:5pt;text-align:center"><font><br></font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</font></div></div></div><div id="i19b30f85ff014dadbd058daf489ce2ff_88"></div><hr style="page-break-after:always"><div style="min-height:90pt;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ONCOLYTICS BIOTECH INC.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">(unaudited)</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">June 30, 2021</font></div></div><div style="margin-bottom:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">Note 13&#58;  Other Expenses and Adjustments</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following details highlight certain components of the research and development and operating expenses classified by nature. The foreign exchange (loss) gain as presented separately on the face of the consolidated statement of loss and comprehensive loss is also classified as a research and development expense. Remaining research and development and operating expenses include personnel costs and expenses paid to third parties.   </font></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:509.25pt"><tr><td style="width:1.0pt"></td><td style="width:219.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:70.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:70.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:70.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:70.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:54pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended June 30, 2021<br>$</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended June 30, 2020<br>$</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended June 30, 2021<br>$</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended June 30, 2020<br>$</font></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Research and development expenses</font></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash share-based compensation</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">597,345</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91,462&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">958,948</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">196,909&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Operating expenses</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation - property and equipment</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">75,340</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,584&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">95,890</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,629&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation - right-of-use-assets</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">88,493</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92,133&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">174,677</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">183,156&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash share-based compensation</font></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">434,897</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">169,178&#160;</font></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">731,370</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">456,536&#160;</font></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:center"><font><br></font></div><div id="i19b30f85ff014dadbd058daf489ce2ff_94"></div><div style="margin-bottom:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">Note 14&#58;  Related Party Transactions</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Compensation of Key Management Personnel</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Key management personnel are those persons having authority and responsibility for planning, directing and controlling our activities as a whole. We have determined that key management personnel consists of the members of the Board of Directors along with certain employees of the Company.    </font></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:483.00pt"><tr><td style="width:1.0pt"></td><td style="width:202.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:70.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:66.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:67.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:67.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:54pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended June 30, 2021<br>$</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended June 30, 2020<br>$</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended June 30, 2021<br>$</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended June 30, 2020<br>$</font></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term employee compensation and benefits</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">771,934</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">779,067&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,556,565</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,572,699&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Termination benefits</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">217,015&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">217,015&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">707,778</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">190,567&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,167,071</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">443,754&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,479,712</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,186,649&#160;</font></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,723,636</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,233,468&#160;</font></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><font><br></font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.2
<SEQUENCE>3
<FILENAME>ex992-q22021mda.htm
<DESCRIPTION>2021 SECOND QUARTER MD&A
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="id23e26cc9f284c11832157637a690746_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><img alt="oncolyticslogotaglinebluea.jpg" src="oncolyticslogotaglinebluea.jpg" style="height:297px;margin-bottom:5pt;vertical-align:text-bottom;width:682px"></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">MANAGEMENT DISCUSSION &#38; ANALYSIS</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">June&#160;30, 2021 </font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="id23e26cc9f284c11832157637a690746_4"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">August&#160;5, 2021 </font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This discussion and analysis should be read in conjunction with the unaudited interim consolidated financial statements of Oncolytics Biotech</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Inc. as at and for the six months ended June&#160;30, 2021 and 2020, and should also be read in conjunction with the audited consolidated financial statements and Management's Discussion and Analysis of Financial Condition and Results of Operations (&#8220;MD&#38;A&#8221;) contained in our annual report for the year ended December&#160;31, 2020. The financial statements have been prepared in accordance with International Financial Reporting Standards (&#34;IFRS&#34;) as issued by the International Accounting Standards Board (&#34;IASB&#34;). Unless otherwise indicated, all references to &#34;$&#34; and &#34;dollars&#34; in this discussion and analysis mean Canadian dollars.  </font></div><div style="text-align:justify"><font><br></font></div><div id="id23e26cc9f284c11832157637a690746_7"></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">FORWARD-LOOKING STATEMENTS</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following discussion contains forward-looking statements, within the meaning of Section 21E of the United States Securities Exchange Act of 1934, as amended and forward-looking information under applicable Canadian securities laws (such forward-looking statements and forward-looking information are collectively referred to herein as &#8220;forward-looking statements&#8221;). Forward-looking statements, including&#58; our belief as to the potential and mode of action of pelareorep, an intravenously delivered immuno-oncolytic virus, as a cancer therapeutic&#59; our expectation that we will incur substantial losses and will not generate significant revenues until and unless pelareorep becomes commercially viable&#59; our business strategy, goals, focus and objectives for the development of pelareorep&#59; the impact of the COVID-19 pandemic on our research and development activities, business operations and financial condition, our plans to mitigate any such impact&#59; the potential impact of the COVID-19 pandemic on stock markets and global economic activity&#59; our plan to actively manage the development of our clinical trial program, our pre-clinical and collaborative programs, our manufacturing process and pelareorep supply&#59; our plans respecting regulatory approval for pelareorep&#59; our planned clinical development program, including the timing thereof&#59; our expectations regarding the anticipated benefits and value to us of additional clinical data&#59; our expectations as to the purpose, design, outcomes and benefits of our current or pending clinical trials involving pelareorep&#59; our expectations regarding enrollment under our various clinical trials&#59; our expectations respecting the delivery of additional clinical data and the timing thereof&#59; our anticipated milestones and catalysts&#59; our planned 2021 development activity for pelareorep&#59; our 2021 manufacturing program&#59; our anticipated 2021 cash requirements  to fund our operations&#59; our anticipated 2021 expenses relating to clinical trials, manufacturing, intellectual property, research collaborations, personnel-related and other and operating expenses&#59; our plans respecting the maintenance of adequate cash reserves to support our planned activities&#59; our anticipated cash usage in 2021&#59; our plans for funding our capital expenditure requirements&#59; our approach to credit rate, interest rate, foreign exchange and liquidity risk mitigation&#59; and other statements that are not historical facts or which are related to anticipated developments in our business and technologies. In any forward-looking statement in which we express an expectation or belief as to future results, such expectations or beliefs are expressed in good faith and are believed to have a reasonable basis, but there can be no assurance that the statement or expectation or belief will be achieved. Forward-looking statements, involve known and unknown risks and uncertainties, which could cause our actual results to differ materially from those in the forward-looking statements. We may be impacted by business interruptions resulting from COVID-19 coronavirus, including operating, manufacturing supply chain, clinical trial and project development delays and disruptions, labor shortages, travel and shipping disruption and shutdowns (including as a result of government regulation and prevention measures). It is unknown whether and how the Company may be affected if the COVID-19 pandemic persists for an extended period of time. We may incur expenses or delays relating to such events outside of our control, which could have a material adverse impact on our business, operating results and financial condition.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Such risks and uncertainties include, among others, the need for and availability of funds and resources to pursue research and development projects, the efficacy of pelareorep as a cancer treatment, the success and timely completion of clinical studies and trials, our ability to successfully commercialize pelareorep, uncertainties related to the research, development and manufacturing of pelareorep, uncertainties related to competition, changes in technology, the regulatory process and general changes to the economic environment.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With respect to the forward-looking statements made within this MD&#38;A, we have made numerous assumptions regarding among other things&#58; our ability to recruit and retain talented employees, our continued ability to obtain financing to fund our clinical development plan, our ability to receive regulatory approval to commence enrollment in the clinical studies which are part of our clinical development plan, our ability to maintain our supply of pelareorep and future expense levels being within our current expectations.</font></div><div style="text-align:justify"><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investors should consult our quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to the forward-looking statements. Forward-looking statements are based on assumptions, projections, estimates, and expectations of management at the time such forward-looking statements are made, and such assumptions, projections, estimates and&#47;or expectations could change or prove to be incorrect or inaccurate. Investors are cautioned against placing undue reliance on forward-looking statements. We do not undertake any obligation to update these forward-looking statements except as required by applicable law.</font></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div id="id23e26cc9f284c11832157637a690746_10"></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">Pelareorep Development Update For 2021</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Oncolytics Biotech Inc. is a Development Stage Company</font></div><div><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since our inception in April of 1998, Oncolytics Biotech Inc. has been a development stage company. We have focused our research and development efforts on the development of pelareorep, an intravenously delivered immunotherapeutic agent with the potential to treat a variety of cancers. We have not been profitable since our inception and expect to continue to incur substantial losses as we continue research and development efforts. We do not expect to generate significant revenues until, and unless, pelareorep becomes commercially viable.  </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our goal each year is to advance pelareorep through the various steps and stages of development required for potential pharmaceutical products. In order to achieve this goal, we proactively manage all aspects of the development of our clinical trial program, our pre-clinical and collaborative programs, our manufacturing process and pelareorep</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">supply, and our intellectual property.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">Potential Impact of COVID-19</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">During the first six months of 2021, the ongoing coronavirus infectious disease 2019 (COVID-19) pandemic did not significantly disrupt our business operations. While COVID-19 has created challenges, to date, our clinical trial activities, including patient enrollment and site activation, along with our manufacturing supply, have not been materially impacted. Also, our financial condition, liquidity and longer-term strategic development remain on track. However, COVID-19 has caused and may continue to cause significant fluctuations in stock markets, global economic activity and healthcare systems. The scale and duration of these developments remain uncertain and could affect our ability to finance and execute our operations.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The extent to which COVID-19 might prolong and&#47;or cause significant disruptions to our business and materially impact our results of operations and our ongoing and planned clinical studies will depend on future developments. These future developments are highly uncertain and cannot be predicted, such as the duration and severity of outbreaks, including future potential waves or cycles, travel restrictions and social distancing, business closures or business disruptions and the effectiveness of actions taken to contain and treat the disease and to address its impact, including on financial markets. A lack of coordinated responses on risk mitigation and vaccination deployment with respect to the COVID-19 pandemic could result in significant increases to the duration and severity of the pandemic and could have a corresponding negative impact on our business. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We continue to collaborate with our investigators to ensure the safety of patients and employees, as well as the productivity of our clinical programs. We expect these measures will allow us to build on the positive momentum of the past quarter, despite any COVID-19-related challenges that may arise. Moving forward, we plan to remain in contact with relevant stakeholders and keep the market apprised of any new information that may materially impact clinical timelines.</font></div><div style="text-align:justify"><font><br></font></div><div id="id23e26cc9f284c11832157637a690746_13"></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">Clinical Trial Program</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The ultimate objective of our clinical development plan is to obtain regulatory approval for pelareorep and is based on the compelling efficacy data from previous studies in breast, multiple myeloma, and selected gastrointestinal cancers. Our current clinical development program centers on the role of pelareorep in immuno-oncology mechanisms, particularly in combination with key immune checkpoint inhibitors and potentially other immune-based therapies. Our primary focus is to demonstrate enhanced antitumor efficacy with checkpoint inhibitors, as we believe this may be the most immediately impactful clinical data and the most expeditious path to approval.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We believe pelareorep has the potential to provoke specific innate and adaptive immune responses when combined with different classes of immunotherapies. Therefore, as our clinical development program evolves and delivers additional data, we will consider appropriate expansion of our plan to investigate potential opportunities with such immunotherapies.</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-style:italic;font-weight:700;line-height:115%">Second Quarter 2021 Developments</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Clinical studies aiding our breast cancer program</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Collaboration with Pfizer Inc. and Merck KGaA, Darmstadt, Germany&#58; BRACELET-1 study </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2019, we entered into a co-development agreement with Merck KGaA, Darmstadt, Germany and Pfizer Inc. to co-develop pelareorep in combination with paclitaxel and avelumab (Bavencio</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">), a human anti-PD-L1 antibody, for the treatment of hormone receptor-positive &#47; human epidermal growth factor 2-negative (HR+ &#47; HER2-) metastatic breast cancer (mBC). This phase 2 clinical trial is jointly funded by Oncolytics and Pfizer. The study, known as BRACELET-1, is an open-label study planned to enroll 48 patients into three cohorts&#58; paclitaxel alone, paclitaxel in combination with pelareorep, and paclitaxel in combination with both pelareorep and avelumab. PrECOG LLC, a leading cancer research network, is managing the BRACELET-1 study. We dosed the first patient in 2020.   </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The study is examining the expression of immune-related biomarkers to identify changes in T cell population between pretreatment and on-therapy biopsies and seek to confirm our previously identified biomarker and is designed to assess efficacy in terms of overall response rate at week 16 per RECIST 1.1 and iRECIST. The safety of the combination is also being evaluated.&#160;Similar to the AWARE-1 study (see below), the results of this study may provide an opportunity to add an arm to our proposed registration study that includes a checkpoint inhibitor in addition to the chemotherapy-virus combination. Furthermore, the results of the BRACELET-1 study may provide important confirmatory data in the same patient population where we presented compelling mBC survival data at the 2017 AACR Annual Meeting. These endpoints, including the biomarker data, are expected to further de-risk our contemplated registration study, permitting for a smaller study with a higher likelihood of clinical success. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the second quarter of 2021, we continued patient enrollment and treatment.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Collaboration with SOLTI&#58; AWARE-1 study</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2019, we received approval for our AWARE-1 study from the Spanish Agency for Medicine and Health Products. This clinical collaboration with SOLTI, an academic research group dedicated to breast cancer research, is a window of opportunity study in the neoadjuvant setting for breast cancer using pelareorep in combination with F. Hoffmann-La Roche (Roche)'s anti-PD-L1 checkpoint inhibitor, atezolizumab (Tecentriq</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">), which we are utilizing under our Master Clinical Supply Agreement with Roche. In 2020, we published various clinical data demonstrating the ability of pelareorep to promote a pro-inflammatory tumor microenvironment (TME) and provided a basis for the findings of a prior successful phase 2 trial (IND-213) that showed a near doubling of overall survival with pelareorep treatment in HR+&#47;HER2- breast cancer patients. These data also highlighted the potential of a predictive biomarker (T cell clonality) to identify patients with breast cancer most likely to respond to pelareorep.   </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the second quarter of 2021, we published the results at the AACR Annual Meeting 2021 showing the first two cohorts of patients receiving pelareorep plus checkpoint blockade therapy met the trial's primary endpoint. These patients were treated with pelareorep and letrozole without (cohort 1) or with (cohort 2) the PD-L1 inhibitor atezolizumab prior to surgery. Evaluation of cohorts 1 and 2 was the core objective of AWARE-1, as HR+&#47;HER2- is the breast cancer subtype we intend to examine in a future registrational study. Key data and conclusions included&#58;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">60% of cohort 2 patients (n&#61;10) saw a CelTIL increase of at least 30% from baseline (pre-pelareorep administration) to surgery (21-days post-administration), exceeding the study's pre-specified primary endpoint&#59;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Cohort 1 also showed a promising trend towards an increased CelTIL score, with 40% of patients showing a 30% increase in the CelTIL value&#59;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Treatment with pelareorep alone or in combination with atezolizumab increased tumor PD-L1 expression and led to the conversion of PD-L1 negative tumors into PD-L1 positive tumors&#59;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Pelareorep profoundly reverses immunosuppressive tumor microenvironments and promotes immune effector cell infiltration into solid tumors, positioning it as an enabling technology for a variety of immunotherapeutic agents&#59;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Tumor-cell specific pelareorep replication was observed in all evaluated patients following intravenous pelareorep administration&#59;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">70% of all cohort 1 and 2 patients (n&#61;20) saw an increase in CelTIL from baseline to surgery&#59;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The addition of atezolizumab enhances pelareorep's ability to generate and expand new anti-viral and anti-tumor T cell clones in the tumor and periphery&#59; and</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Compared to cohort 1, cohort 2 patients had a higher ratio of CD8+ T cells to regulatory T cells, suggesting pelareorep and checkpoint inhibition enhances inflammation within the tumor microenvironment.</font></div><div><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Additional checkpoint inhibitor combinations </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Triple-negative breast cancer study combining pelareorep and retifanlimab </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the second quarter of 2021, we continued patient recruitment and enrollment activities in our investigator-sponsored trial (IST) managed by Rutgers Cancer Institute of New Jersey. This single-arm, open-label, phase 2 trial, known as IRENE, is investigating the use of pelareorep in combination with Incyte's anti-PD-1 checkpoint inhibitor, retifanlimab, in patients with metastatic triple-negative breast cancer (TNBC). This study plans to enroll 25 patients. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The IRENE study represents an expansion of our lead breast cancer program into a new disease subtype (TNBC). In addition to investigating the safety and efficacy of pelareorep-anti-PD-1 combination treatment in TNBC patients, the study is also evaluating changes in PD-L1 expression and correlations between treatment outcomes and peripheral T cell clonality, a previously identified biomarker of pelareorep response that may enable the success of future pivotal studies by facilitating the patient selection process. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Collaboration with Roche and AIO-Studien-gGmbH&#58; GOBLET platform study</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2020, we entered into a collaboration with Roche and AIO-Studien-gGmbH, a leading academic cooperative medical oncology group based in Germany. The phase 1&#47;2 trial, known as GOBLET, will investigate the use of pelareorep, in combination with Roche's anti-PD-L1 checkpoint inhibitor atezolizumab (Tecentriq</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">), in patients with metastatic pancreatic, metastatic colorectal and advanced anal cancers. The study is expected to be conducted at 25 centers in Germany. The primary endpoint of the study is safety, with overall response rate and blood-based biomarkers (T cell clonality and CEACAM6) as exploratory endpoints. Approximately 55 patients are planned for enrollment across four separate cohorts&#58; pelareorep in combination with atezolizumab, gemcitabine, and nab-paclitaxel in 1st line metastatic pancreatic cancer patients, pelareorep in combination with atezolizumab in 2nd and 3rd line metastatic colorectal cancer patients that are diagnosed as MSI high (microsatellite instability), pelareorep in combination with atezolizumab and TAS-102 in 3rd line metastatic colorectal cancer patients, and pelareorep in combination with atezolizumab in 2nd line advanced and unresectable anal cancer patients. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the second quarter of 2021, we continued with initial regulatory activities seeking approval to commence enrollment from the German federal agency, The Paul Ehrlich Institute, along with startup activities. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Pancreatic cancer study combining pelareorep and Keytruda</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the second quarter of 2021, we continued patient follow-up activities and published data at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting indicating that pelareorep and Keytruda</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (pembrolizumab) synergize and show anti-cancer activity in second-line pancreatic cancer patients, which is mediated through the complementary immunotherapeutic effects of the two agents. Key data and conclusions included&#58;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Disease control was achieved in 42% (5&#47;12) of patients, with one patient achieving a partial response and four patients achieving stable disease</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">On-treatment tumor biopsies showed pelareorep replication and increased infiltration of CD8+ T cells and PD-L1+ cells relative to pre-treatment samples</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Patients achieving disease control showed reductions in pro-tumor regulatory T cells in the peripheral blood and tumor tissue compared to those with progressive disease</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Patients achieving disease control showed increased activation of anti-cancer CD8+ T cells in the peripheral blood compared to those with progressive disease</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Pelareorep-pembrolizumab combination therapy was found to be well tolerated, with most treatment-related adverse events being grade 1 or 2</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Multiple myeloma study combining pelareorep and Opdivo</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the second quarter of 2021, we continued patient enrollment and treatment in our IST with Emory University and the University of Utah investigating the combination of pelareorep and Bristol-Myers Squibb's anti-PD1 checkpoint inhibitor Opdivo</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in 40 - 50 relapsed or refractory myeloma patients. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">CAR T Preclinical Activities</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2021, we published results at the CAR-TCR Summit Europe 2021, in collaboration with investigators at the Mayo Clinic, showing that loading CAR T cells with pelareorep vastly improved their persistence and efficacy in a murine solid tumor model in contrast to preclinical studies using intratumoral infection with the VSV oncolytic virus that weakened CAR T cells. In the second quarter of 2021, we initiated further collaboration activities to develop and evaluate pelareorep and CAR T cell combination therapy. </font></div><div style="text-align:justify"><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</font></div></div></div><div id="id23e26cc9f284c11832157637a690746_16"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">Manufacturing and Process Development </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">During the second quarter of 2021, we continued distribution and storage activities with the product supply and completed various vendor quality control audits. As well, we continued our activities to maintain clinical and commercial production capabilities to manufacture pelareorep at the 100-liter scale. Ongoing bulk manufacturing and expanded filling capabilities are both part of the process validation master plan. Process validation is required to ensure that the resulting product meets required specifications and quality standards and will form part of our submission to regulators, including the FDA, for product approval.</font></div><div style="text-align:justify"><font><br></font></div><div id="id23e26cc9f284c11832157637a690746_19"></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">Intellectual Property</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the end of the second quarter of 2021, we had been issued over 344 patents including 39 US and 15 Canadian patents as well as issuances in other jurisdictions. We have an extensive patent portfolio covering the oncolytic reovirus that we use in our clinical trial program including a composition of matter patent that expires in 2028. Our patent portfolio also includes methods for treating proliferative disorders using modified adenovirus, HSV, parapoxvirus and vaccinia virus.</font></div><div style="text-align:justify"><font><br></font></div><div id="id23e26cc9f284c11832157637a690746_22"></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">Financing Activity</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">U.S. &#34;at-the-market&#34; equity distribution </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended June&#160;30, 2021, we sold 2,087,810 common shares for gross proceeds of US$6,717,829 at an average price of US$3.22. We received, net of commissions of US$201,535, proceeds of US$6,516,294. In total, we incurred share issue costs (including commissions) of $263,601.  </font></div><div style="text-align:justify"><font><br></font></div><div id="id23e26cc9f284c11832157637a690746_25"></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">Financial Impact</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We estimated at the beginning of the second quarter of 2021 that our cash requirements to fund our operations for the year will be between $28 - $30 million. Our actual cash usage for the six months ended June&#160;30, 2021 was $12,365,339 for operating activities, $6,598 for the acquisition of property and equipment and $210,228 for the payment of office leases. Our net loss for the period was $13,680,881, which included a non-cash change in fair value of warrant derivative loss of $84,621 and a foreign exchange loss of </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$1,021,906</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> primarily due to unrealized translation loss on U.S. dollar denominated cash balances.  </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font></div><div id="id23e26cc9f284c11832157637a690746_28"></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">Cash Resources </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We ended the second quarter of 2021 with cash and cash equivalents totaling $50,799,432 (see </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8220;Liquidity and Capital Resources&#8221;)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</font></div><div style="text-align:justify"><font><br></font></div><div id="id23e26cc9f284c11832157637a690746_34"></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">Pelareorep Development for the Remainder of 2021</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our planned 2021 development activity for pelareorep focuses on our clinical development plan along with our manufacturing and intellectual property programs. Our primary 2021 clinical objectives will focus on BRACELET-1 enrollment, the commencement of enrollment in our GOBLET platform study and the assessment of our clinical data to help form the nature of our registration strategy, our path to approval and possible other clinical development opportunities. While we are making every effort to maintain the timing of our future milestones, the full impact of the COVID-19 pandemic on these milestones is not known. Patient safety is our foremost concern and we will provide updates as they become known.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our 2021 manufacturing program includes product fills and the associated analytical testing, process development activities as well as labeling, packaging and shipping of pelareorep to our various clinical sites for ongoing and upcoming activities. We also intend to assess a process development plan investigating application of single-use equipment to our drug substance production process. These activities are consistent with our process validation master plan. Finally, our intellectual property program includes filings for additional patents along with monitoring activities required to protect our patent portfolio.   </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently estimate the cash requirements to fund our operations for 2021 will be approximately $28 - $30 million but will depend on our ultimate clinical program.  (see </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8220;Liquidity and Capital Resources&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">).</font></div><div style="text-align:justify"><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</font></div></div></div><div id="id23e26cc9f284c11832157637a690746_37"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">Second Quarter Results of Operations</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(for the three months ended June&#160;30, 2021 and 2020)</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss for the three months ended June&#160;30, 2021 was $7,246,136 compared to $6,827,415 for the three months ended June&#160;30, 2020. </font></div><div style="text-align:justify"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expenses (&#8220;R&#38;D&#8221;)</font></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:408.00pt"><tr><td style="width:1.0pt"></td><td style="width:286.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:58.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:58.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:24pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021<br>$</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020<br>$</font></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clinical trial expenses</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,012,684</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">447,129&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Manufacturing and related process development expenses</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">434,107</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">879,698&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intellectual property expenses</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">94,013</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">161,426&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research collaboration expenses</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">91,482</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">162,289&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Personnel-related and other expenses</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,570,895</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">848,586&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expenses</font></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,203,181</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,499,128&#160;</font></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Clinical Trial Expenses</font></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:79.678%"><tr><td style="width:1.0%"></td><td style="width:68.074%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.312%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.314%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021<br>$</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020<br>$</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clinical trial expenses</font></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,012,684</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">447,129&#160;</font></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our clinical trial expenses for the second quarter of 2021 were $1,012,684 compared to $447,129 for the second quarter of 2020. In the second quarter of 2021, costs related to our breast cancer program included direct patient expenses for our AWARE-1 study and our portion (net of Pfizer's contribution) of patient enrollment and treatment for our BRACELET-1 study. In the second quarter of 2020, activities related to our breast cancer program included continued patient enrollment and treatment as well as data analysis for our AWARE-1 study and our portion (net of Pfizer's contribution) of trial initiation activities and patient enrollment and treatment related to our BRACELET-1 study. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the second quarter of 2021, in addition to activities related to our breast cancer program, we also incurred trial initiation costs for our GOBLET study and costs related to a quality audit of one of our contract research organizations. In the second quarter of 2020, our other clinical costs related to data management consultants and our Opdivo</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> combination study. </font></div><div style="text-align:justify"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Manufacturing &#38; Related Process Development Expenses (&#8220;M&#38;P&#8221;)</font></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:78.654%"><tr><td style="width:1.0%"></td><td style="width:68.974%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.513%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.213%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021<br>$</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020<br>$</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product manufacturing expenses</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">421,699</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">836,321&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Process development expenses</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">12,408</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,377&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Manufacturing and related process development expenses</font></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">434,107</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">879,698&#160;</font></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our M&#38;P expenses for the second quarter of 2021 were $434,107 compared to $879,698 for the second quarter of 2020. During the second quarter of 2021, our product manufacturing costs primarily related to shipping and storage costs of our bulk and vialed product, as well as sourcing materials required for our planned product fills in the upcoming years. During the second quarter of 2020, our product manufacturing costs primarily related to the start of a cGMP production run and the associated testing, as well as shipping and storage costs of our bulk and vialed product.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our process development expenses for the second quarter of 2021 and 2020 focused on stability studies and analytical development. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Intellectual Property Expenses</font></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:78.508%"><tr><td style="width:1.0%"></td><td style="width:69.104%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.797%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.799%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021<br>$</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020<br>$</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intellectual property expenses</font></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">94,013</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">161,426&#160;</font></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our intellectual property expenses for the second quarter of 2021 were $94,013 compared to $161,426 for the second quarter of 2020. The change in intellectual property expenditures mainly reflected the lapsing of patents in certain jurisdictions and foreign exchange difference as a result of a weakened U.S dollar against the Canadian dollar in the second quarter of 2021 compared to the same period in 2020. At the end of the second quarter of 2021, we had been issued over 344 patents including 39 US and 15 Canadian patents, as well as issuances in other jurisdictions.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Research Collaboration Expenses </font></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:78.508%"><tr><td style="width:1.0%"></td><td style="width:69.104%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.797%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.799%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021<br>$</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020<br>$</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research collaboration expenses</font></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">91,482</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">162,289&#160;</font></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our research collaboration expenses were $91,482 for the second quarter of 2021 compared to $162,289 for the second quarter of 2020. Our research collaborations in the second quarters of 2021 and 2020 included studies investigating the interaction of the immune system and pelareorep, including CAR T therapy. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Personnel-Related and Other Expenses</font></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:78.508%"><tr><td style="width:1.0%"></td><td style="width:69.104%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.797%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.799%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021<br>$</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020<br>$</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">R&#38;D personnel-related expenses</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">967,079</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">750,740&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other R&#38;D expenses</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6,471</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,384&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation </font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">597,345</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91,462</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Personnel-related and other expenses</font></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,570,895</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">848,586&#160;</font></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our personnel-related and other expenses were $1,570,895 for the second quarter of 2021 compared to $848,586 for the second quarter of 2020. The change in R&#38;D personnel-related expenses in the second quarter of 2021 compared to the second quarter of 2020 was primarily due to salary adjustments and increased headcount in our U.S. office to support our clinical program, partly offset by recruitment-related costs that were not incurred in the second quarter of 2021.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other R&#38;D expenses in the second quarter of 2021 remained consistent with the second quarter of 2020.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-cash share-based compensation for the second quarter of</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2021 was $597,345 compared to $91,462 for the second quarter of 2020. The change in non-cash share-based compensation in the second quarter of 2021 compared to the second quarter of 2020 was primarily due to a higher number of vesting options with a higher grant date fair value that were previously granted to officers, employees and consultants. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Operating Expenses</font></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:402.75pt"><tr><td style="width:1.0pt"></td><td style="width:280.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:58.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:58.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:24pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021<br>$</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020<br>$</font></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Public company related expenses</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,278,722</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,899,491&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Office expenses</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">643,534</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">865,186&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation - property and equipment</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">75,340</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,584&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation - right-of-use assets</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">88,493</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92,133&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">434,897</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">169,178&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses</font></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,520,986</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,048,572&#160;</font></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operating expenses for the second quarter of 2021 were $3,520,986 compared to $3,048,572 for the second quarter of 2020. Public company related expenses include costs associated with investor relations, business development and financial advisory activities, legal and accounting fees, corporate insurance, director fees and transfer agent and other fees relating to our Canadian and U.S. stock listings. Our public company related expenses were $2,278,722 for the second quarter of 2021 compared to $1,899,491 for the second quarter of 2020. The change in our public company related expenses in the second quarter of 2021 was primarily due to higher investor relations activities and increased director and officers insurance premiums, partly offset by lower business development consulting activities. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Office expenses include compensation costs (excluding share-based compensation), rent related to short-term leases and other office related costs. During the second quarter of 2021, our office expenses were $643,534 compared to $865,186 for the second quarter of 2020. The change was primarily related to costs associated with changes in personnel in the second quarter of 2020.        </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-cash share-based compensation in the second quarter of 2021 was $434,897 compared to $169,178 in the second quarter of 2020. The change in non-cash share-based compensation in the second quarter of 2021 compared to the second quarter of 2020 was primarily due to a higher number of vesting options with a higher grant date fair value that were previously granted to officers, employees, consultants and independent board members. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Change in Fair Value of Warrant Derivative</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We issued warrants in connection with our August 2019 underwritten public offering. Warrants issued with an exercise price denominated in a foreign currency are reported as a liability until they are exercised or expire. These warrants are adjusted to fair value at each exercise date and at each reporting period and any change in fair value is recorded in the consolidated statements of loss and comprehensive loss. Gains and losses resulting from the revaluation of the warrant derivative are non-cash and do not impact our cash flows. </font></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:78.508%"><tr><td style="width:1.0%"></td><td style="width:69.104%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.797%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.799%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021<br>$</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020<br>$</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of warrant derivative</font></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">80,159</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(507,150)</font></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the second quarter of 2021, we recognized a gain of $80,159 on the change in fair value of our warrant derivative compared to a loss of $507,150 in the second quarter of 2020. The change in fair value in the second quarter of 2021 was as a result of several factors including changes in the market price of our shares to US$2.77 on June 30, 2021 from US$3.81 on March 30, 2021. The change in fair value in the second quarter of 2020 was as a result of several factors including changes in the market price of our shares to US$1.88 on June 30, 2020 from US$1.38 on March 31, 2020, and the revaluation of warrants exercised. The number of outstanding warrants was 64,035 and 265,757 as at June&#160;30, 2021 and June&#160;30, 2020, respectively. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Foreign Exchange Loss</font></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:78.508%"><tr><td style="width:1.0%"></td><td style="width:69.104%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.797%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.799%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021<br>$</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020<br>$</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange loss</font></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(631,352)</font></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(805,098)</font></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our foreign exchange loss was $631,352 for the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">second</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> quarter of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2021</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> compared to a loss of $805,098 for the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">second</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> quarter of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2020</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The foreign exchange loss incurred in the second quarters of 2021 and 2020 was primarily due to unrealized translation loss on U.S. dollar denominated cash balances.</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</font></div></div></div><div id="id23e26cc9f284c11832157637a690746_40"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">Results of Operations</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(for the six months ended June&#160;30, 2021 and 2020)</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss for the six months ended June&#160;30, 2021 was $13,680,881 compared to $6,427,753 for the six months ended June&#160;30, 2020.    </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expenses (&#8220;R&#38;D&#8221;)</font></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:408.00pt"><tr><td style="width:1.0pt"></td><td style="width:286.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:58.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:58.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:33pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021<br>$</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020<br>$</font></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clinical trial expenses</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,778,316</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,085,641&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Manufacturing and related process development expenses</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">812,056</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,346,675&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intellectual property expenditures</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">371,439</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">587,585&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research collaboration expenses</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">142,684</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">205,476&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Personnel-related and other expenses</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,857,700</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,803,397&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expenses</font></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5,962,195</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,028,774&#160;</font></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Clinical Trial Program</font></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:396.75pt"><tr><td style="width:1.0pt"></td><td style="width:280.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:58.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:52.75pt"></td><td style="width:1.0pt"></td></tr><tr style="height:33pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021<br>$</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020<br>$</font></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clinical trial expenses</font></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,778,316</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,085,641&#160;</font></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our clinical trial expenses were $1,778,316 for the six months ended June&#160;30, 2021 compared to $1,085,641 for the six months ended June&#160;30, 2020. During the six months ended June&#160;30, 2021, costs related to our breast cancer program included direct patient expenses as well as patient sample analysis expenses for our AWARE-1 study and our portion (net of Pfizer's contribution) of patient enrollment and treatment for our BRACELET-1 study. During the six months ended June&#160;30, 2020, activities related to our breast cancer program included continued patient enrollment and treatment as well as data analysis for our AWARE-1 study, and our portion (net of Pfizer's contribution) of trial initiation activities and patient enrollment and treatment related to the BRACELET-1 study.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the six months ended June&#160;30, 2021, in addition to activities related to our breast cancer program, we also incurred trial initiation costs related to our GOBLET study, costs related to our ongoing ISTs, costs related to a quality audit of one of our contract research organizations and data management consulting costs. During the six months ended June&#160;30, 2020, our other clinical activities included consulting costs related to data management, close out costs related to our fully enrolled legacy clinical trials and costs related to our Opdivo</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> combination study.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We still expect our clinical trial expenses to increase in 2021 compared to 2020. During 2021, we will focus on BRACELET-1 enrollment, the commencement of enrollment in our GOBLET platform study and the assessment of our clinical data to help form the nature of our registration strategy, our path to approval and possible other clinical development opportunities.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Manufacturing &#38; Related Process Development (&#8220;M&#38;P&#8221;)</font></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:78.070%"><tr><td style="width:1.0%"></td><td style="width:69.499%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.881%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.320%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021<br>$</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020<br>$</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product manufacturing expenses</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">746,627</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,272,181&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Process development expenses</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">65,429</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74,494&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Manufacturing and related process development expenses</font></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">812,056</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,346,675&#160;</font></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our M&#38;P expenses for the six months ended June&#160;30, 2021 were $812,056 compared to $1,346,675 for the six months ended June&#160;30, 2020. During the six months ended June&#160;30, 2021, our product manufacturing costs primarily related to shipping and storage costs of our bulk and vialed product, sourcing materials required for our planned product fills in the upcoming years as well as drug product release testing related to a product fill completed at the end of 2020. During the six months ended June&#160;30, </font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2020, our product manufacturing costs primarily related to the start of a cGMP production run, a product fill and the associated consulting and testing expenses, as well as shipping and storage costs of our bulk and vialed product.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our process development expenses for the six months ended June&#160;30, 2021 were $65,429 compared to $74,494 for the six months ended June&#160;30, 2020. During the six months ended June&#160;30, 2021 and 2020, our process development activities focused on stability studies and analytical development. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We now expect our M&#38;P expenses for 2021 to be consistent with 2020. For the remainder of 2021, we expect to fill products and perform the associated analytical testing, carry out process development activities as well as labeling, packaging and shipping of pelareorep to our various clinical sites for ongoing and upcoming activities. We also intend to assess a process development plan investigating application of single-use equipment to our drug substance production process. These activities are consistent with our process validation master plan.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Intellectual Property Expenses</font></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:77.631%"><tr><td style="width:1.0%"></td><td style="width:73.287%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.764%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.649%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021<br>$</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020<br>$</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intellectual property expenses</font></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">371,439</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">587,585&#160;</font></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our intellectual property expenses for the six months ended June&#160;30, 2021 were $371,439 compared to $587,585 for the six months ended June&#160;30, 2020. The change in intellectual property expenditures mainly reflected the lapsing of patents in certain jurisdictions and foreign exchange difference as a result of a weakened U.S dollar against the Canadian dollar in the second quarter of 2021 compared to the same period in 2020. At June&#160;30, 2021, we had been issued over 344 patents including 39 U.S. and 15 Canadian patents, as well as issuances in other jurisdictions.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We still expect our intellectual property expenses will remain consistent in 2021 compared to 2020.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Research Collaborations</font></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:77.339%"><tr><td style="width:1.0%"></td><td style="width:75.081%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.809%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.810%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021<br>$</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020<br>$</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research collaborations</font></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">142,684</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">205,476&#160;</font></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our research collaboration expenses for the six months ended June&#160;30, 2021 were $142,684 compared to $205,476 for the six months ended June&#160;30, 2020. During the six months ended June&#160;30, 2021 and 2020, our research collaborations included studies investigating the interaction of the immune system and pelareorep, including CAR T therapy. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We still expect that our research collaborations in 2021 will increase compared to 2020. We expect to complete our ongoing collaborative program carried over from 2020 and will continue to be selective in the types of new collaborations we enter into in 2021.    </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Personnel-Related and Other Expenses</font></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:77.631%"><tr><td style="width:1.0%"></td><td style="width:69.898%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.400%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.402%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021<br>$</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020<br>$</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">R&#38;D personnel-related expenses</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,885,259</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,540,598&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other R&#38;D expenses</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">13,493</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65,890&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">958,948</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">196,909</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Personnel-related and other expenses</font></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,857,700</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,803,397&#160;</font></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our personnel-related and other expenses for the six months ended June&#160;30, 2021 were $2,857,700 compared to $1,803,397 for the six months ended June&#160;30, 2020. The change in R&#38;D personnel-related expenses for the six months ended June&#160;30, 2021 compared to the six months ended June&#160;30, 2020 was due to salary adjustments and an increase in headcount as we expand our U.S. office, partly offset by recruitment-related costs that were not incurred in 2021.</font></div><div style="text-align:justify"><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The change in Other R&#38;D expenses for the six months ended June&#160;30, 2021 compared to the six months ended June&#160;30, 2020 was primarily due to decreased travel expenses as a result of COVID-19.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the six months ended June&#160;30, 2021, our non-cash share-based compensation was $958,948 compared to $196,909 for the six months ended June&#160;30, 2020. The change in non-cash share-based compensation for the six months ended June 30, 2021 compared to the six months ended June 30, 2020 was primarily due to a higher number of options granted in 2021, in addition to a higher number of vesting options with a higher grant date fair value that were previously granted to officers, employees and consultants. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We still expect our personnel-related and other expenses in 2021 to increase compared to 2020 as a result of our need for additional U.S. personnel to implement our clinical program. </font></div><div style="text-align:justify"><font><br></font></div><div style="margin-top:5pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Operating Expenses</font></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:77.631%"><tr><td style="width:1.0%"></td><td style="width:69.898%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.400%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.402%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021<br>$</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020<br>$</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Public company related expenses</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,365,873</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,797,179&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Office expenses</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,295,066</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,559,460&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation - property and equipment</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">95,890</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,629&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation - right-of-use assets</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">174,677</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">183,156&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">731,370</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">456,536&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses</font></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6,662,876</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,041,960&#160;</font></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operating expenses for the six months ended June&#160;30, 2021 were $6,662,876 compared to $6,041,960 for the six months ended June&#160;30, 2020. Public company related expenses include costs associated with investor relations, business development and financial advisory activities, legal and accounting fees, corporate insurance, director fees and transfer agent and other fees relating to our Canadian and U.S. stock listings. During the six months ended June&#160;30, 2021, our public company related expenses were $4,365,873 compared to $3,797,179 for the six months ended June&#160;30, 2020. The change was due to increased directors and officers insurance premiums and higher investor relations activities, partly offset by lower business development consulting activities. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Office expenses include compensation costs (excluding share-based compensation), rent related to short-term leases and other office related costs. During the six months ended June&#160;30, 2021, our office expenses were $1,295,066 compared to $1,559,460 during the six months ended June&#160;30, 2020. The change was primarily related to costs associated with changes in personnel in 2020.    </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the six months ended June&#160;30, 2021, our non-cash share-based compensation was $731,370 compared to $456,536 for the six months ended June&#160;30, 2020. The change in non-cash share-based compensation for the six months ended June 30, 2021 compared to the six months ended June 30, 2020 was primarily due to a higher number of options granted in 2021, in addition to a higher number of vesting options with a higher grant date fair value that were previously granted to officers, employees, consultants and independent board members. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We still expect our operating expenses in 2021 to increase compared to 2020. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Change in Fair Value of Warrant Derivative</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We issued warrants in connection with our August 2019 underwritten public offering. Warrants issued with an exercise price denominated in a foreign currency are reported as a liability until they are exercised or expire. These warrants are adjusted to fair value at each exercise date and at each reporting period and any change in fair value is recorded in the consolidated statements of (loss) income and comprehensive (loss) income. Gains and losses resulting from the revaluation of the warrant derivative are non-cash and do not impact our cash flows. </font></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:78.508%"><tr><td style="width:1.0%"></td><td style="width:69.104%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.797%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.799%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021<br>$</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020<br>$</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of warrant derivative</font></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(84,621)</font></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,644,832</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the six months ended June&#160;30, 2021, we recognized a loss of $84,621 on the change in fair value of our warrant derivative compared to a gain of $3,644,832 for the six months ended June&#160;30, 2020. The change in fair value during the six months ended June&#160;30, 2021 was as a result of several factors including changes in the market price of our shares to US$2.77 on June 30, 2021 from US$2.38 on December 31, 2020, and the revaluation on warrants exercised. The change in fair value in the six months ended June&#160;30, 2020 was as a result of several factors including changes in the market price of our shares to US$1.88 on June 30, 2020 from US$4.76 on December 31, 2019, and the revaluation on warrants exercised. The number of outstanding warrants was 64,035 and 265,757 as at June&#160;30, 2021 and June&#160;30, 2020, respectively. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Foreign Exchange (Loss) Gain</font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:78.508%"><tr><td style="width:1.0%"></td><td style="width:69.104%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.797%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.799%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021<br>$</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020<br>$</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange (loss) gain</font></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(1,021,906)</font></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">899,707</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our foreign exchange (loss) gain for the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">six</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> months ended </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">June&#160;30, 2021</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> was a loss of $1,021,906 compared to a gain of $899,707 for the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">six months ended</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">June&#160;30, 2020</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The foreign exchange (loss) gain in the six months ended June 30, 2021 and 2020 was primarily due to unrealized translation (loss) gain on U.S. dollar denominated cash balances.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">   </font></div><div id="id23e26cc9f284c11832157637a690746_43"></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Commitments</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As at June&#160;30, 2021, we were committed to payments totaling approximately $9,897,073 for activities related to our clinical trial, manufacturing and collaboration programs which are expected to occur over the next two years. All of these committed payments are considered to be part of our normal course of business. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our portfolio of leases consists of office spaces with initial lease terms generally between 3 to 6 years. We currently do not have leases with variable lease payments or residual value guarantees. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the first six months of 2021, we extended the office lease for one of our subsidiaries and entered into a new office space lease for our Canadian head office for which we recorded an addition of $532,758 to the lease liability and right-of-use asset. The incremental borrowing rate applied was 15%.      </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our total undiscounted lease liability as at June&#160;30, 2021 is as follows&#58;</font></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:78.947%"><tr><td style="width:1.0%"></td><td style="width:68.344%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:29.456%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Maturity analysis - contractual undiscounted cash flows</font></td></tr><tr><td colspan="6" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2021</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less than one year</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">331,286&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">One to six years</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">617,618&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">More than six years</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total undiscounted lease liability</font></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">948,904&#160;</font></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</font></div></div></div><div id="id23e26cc9f284c11832157637a690746_46"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">Summary of Quarterly Results</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(in thousands, except per share data)</font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:520.50pt"><tr><td style="width:1.0pt"></td><td style="width:187.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:39.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:43.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:43.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:43.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:36.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:36.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:36.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:36.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</font></td><td colspan="12" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</font></td><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</font></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Mar</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Dec</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Sept</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Mar</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Dec</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Sept</font></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (loss) income</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)(2)</font></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,246)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,435)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,329)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,749)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,827)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">400&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19,402)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,529)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic (loss) earnings per common share</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)(2)</font></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.13)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.13)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.21)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.16)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.17)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.01&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.71)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.16)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted loss per common share</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</font></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.13)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.13)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.21)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.16)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.17)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.04)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.71)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.16)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</font></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,309</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,180</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,346</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,242&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,604&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,553&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,658&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,285&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</font></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,799&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,362</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,220</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,711&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,911&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,567&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,148&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,299&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total long-term debt</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash dividends declared</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(5)</font></div></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nil</font></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nil</font></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nil</font></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nil</font></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nil</font></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nil</font></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nil</font></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nil</font></td></tr></table></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Included in consolidated net (loss) income and (loss) earnings per common share are non-cash change in fair value of warrant derivative gain (loss) of $80,159, ($164,780), ($213,168), $60,264, ($507,150), $4,151,982, ($12,486,310) and ($122,498), respectively.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Included in net (loss) income and (loss) earnings per common share are quarterly share-based compensation of $1,032,242, $658,076, $1,704,453, $201,076, $260,640, $392,805, $658,662, and $250,384, respectively.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(3)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Q1 2020 included the effect of dilutive warrant derivative, stock options and share awards. For all other periods presented, the effect of any potential exercise of our stock options and warrants outstanding during the year has been excluded from the calculation of diluted loss per common share, as it would be anti-dilutive.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(4)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">We issued 8,792,692 common shares for net cash proceeds of $33.4 million in 2021 (2020 - 13,968,257 common shares for net cash proceeds of $40.2 million).</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(5)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">We have not declared or paid any dividends since incorporation.</font></div><div style="padding-left:36pt"><font><br></font></div><div id="id23e26cc9f284c11832157637a690746_49"></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">Liquidity and Capital Resources</font></div><div><font><br></font></div><div id="id23e26cc9f284c11832157637a690746_52"></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">2021 Financing Activities </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">U.S. &#34;at-the-market&#34; equity distribution </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the six months ended June&#160;30, 2021, we sold 8,401,029 common shares for gross proceeds of US$27,158,080 at an average price of US$3.23. We received, net of commissions of US$814,743, proceeds of US$26,343,337. In total, we incurred share issue costs (including commissions) of $1,237,848.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Warrant exercise</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the six months ended June&#160;30, 2021, 201,722 warrants in connection with our August 2019 underwritten public offering were exercised for gross proceeds of US$181,550.</font></div><div style="text-align:justify"><font><br></font></div><div id="id23e26cc9f284c11832157637a690746_55"></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">2020 Financing Activities </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">U.S. &#34;at-the-market&#34; equity distribution agreement</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the six months ended June&#160;30, 2020, we sold 7,055,627 common shares for gross proceeds of US$18,188,346 at an average price of US$2.58. We received, net of commission of US$545,650, proceeds of US$17,642,696. In total, we incurred share issue costs (including commissions) of $1,072,119.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Warrant exercise</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the six months ended June 30, 2020, 1,418,369 warrants in connection with our August 2019 underwritten public</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">offering were exercised for gross proceeds of US$1,276,532.</font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</font></div></div></div><div id="id23e26cc9f284c11832157637a690746_58"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">Liquidity</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As at June&#160;30, 2021, we had cash and cash equivalents and working capital positions as follows&#58; </font></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:79.093%"><tr><td style="width:1.0%"></td><td style="width:65.258%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.720%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.722%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30,<br>2021<br>$</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br>2020<br>$</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">50,799,432</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,219,574&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:3pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Working capital position</font></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">53,010,947</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,558,550&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not have any debt other than trade accounts payable and lease liabilities, and we have potential contingent obligations relating to the completion of our research and development of pelareorep.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In managing our capital, we estimate our future cash requirements by preparing a budget and a multi-year plan annually for review and approval by our Board. The budget establishes the approved activities for the upcoming year and estimates the costs associated with these activities. The multi-year plan estimates future activity along with the potential cash requirements and is based on our assessment of our current clinical trial progress along with the expected results from the coming year&#8217;s activity.&#160;Budget to actual variances are prepared and reviewed by management and are presented quarterly to the Board.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Historically, funding for our plan is primarily managed through the issuance of additional common shares and common share purchase warrants that upon exercise are converted to common shares.&#160;Management regularly monitors the capital markets attempting to balance the timing of issuing additional equity with our progress through our clinical trial program, general market conditions, and the availability of capital.&#160;There are no assurances that funds will be made available to us when required.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 12, 2020, we renewed our short form base shelf prospectus (the &#34;Base Shelf&#34;) that qualifies for distribution of up to $150,000,000 of common shares, subscription receipts, warrants, or units (the &#34;Securities&#34;) in either Canada, the US or both. Under a Base Shelf, we may sell Securities to or through underwriters, dealers, placement agents or other intermediaries and also may sell Securities directly to purchasers or through agents, subject to obtaining any applicable exemption from registration requirements. The distribution of Securities may be effected from time to time in one or more transactions at a fixed price or prices, which may be subject to change, at market prices prevailing at the time of sale, or at prices related to such prevailing market prices to be negotiated with purchasers and as set forth in an accompanying Prospectus Supplement.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Renewing our Base Shelf provides us with additional flexibility when managing our cash resources as, under certain circumstances, it shortens the time period required to close a financing and is expected to increase the number of potential investors that may be prepared to invest in our company. Funds received as a result of using our Base Shelf would be used in line with our Board approved budget and multi-year plan. Our renewed Base Shelf will be effective until July 12, 2022. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Base Shelf allowed us to enter into our ATM equity offering sales agreements in June 2020 and March 2021 (see Note 5 of our interim consolidated financial statements). We use these equity arrangements to assist us in achieving our capital objective. These arrangements provide us with the opportunity to raise capital at our sole discretion providing us with the ability to better manage our cash resources.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We anticipate that the expected cash usage from our operations in 2021 will be between $28 - $30 million. We continue to manage our research and development plan with the objective of ensuring optimal use of our existing resources. Additional activities continue to be subject to adequate resources and we believe we will have sufficient cash resources to fund our presently planned operations into 2023. Factors that will affect our anticipated cash usage in 2021, and for which additional funding might be required include, but are not limited to, expansion of our clinical trial program, the timing of patient enrollment in our approved clinical trials, the actual costs incurred to support each clinical trial, the number of treatments each patient will receive, the timing of R&#38;D activity with our clinical trial research collaborations, the number, timing and costs of manufacturing runs required to conclude the validation process and supply product to our clinical trial program, and the level of collaborative activity undertaken.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are not subject to externally imposed capital requirements and there have been no changes in how we define or manage our capital in 2021.</font></div><div style="text-align:justify"><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</font></div></div></div><div id="id23e26cc9f284c11832157637a690746_61"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">Financial Instruments and Other Instruments</font></div><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our financial instruments consist of cash and cash equivalents,&#160;other receivables, other liabilities, accounts payable and warrant derivative. As at June&#160;30, 2021, the carrying amount of our cash and cash equivalents,&#160;other receivables, other liabilities and accounts payable approximated their fair value. The warrant derivative is a recurring Level 2 fair value measurement as these warrants have not been listed on an exchange and therefore do not trade on an active market. As at June&#160;30, 2021, the fair value of our warrant derivative was $153,968 (December&#160;31, 2020 - $531,228). </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Credit risk</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Credit risk is the risk of financial loss if a counterparty to a financial instrument fails to meet its contractual obligations.&#160;We are exposed to credit risk on our cash and cash equivalents in the event of non-performance by counterparties, but we do not anticipate such non-performance.&#160;Our maximum exposure to credit risk at the end of the period is the carrying value of our cash and cash equivalents and other receivables.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We mitigate our exposure to credit risk by maintaining our primary operating and investment bank accounts with Schedule I banks in Canada.&#160;For our foreign domiciled bank accounts, we use referrals or recommendations from our Canadian banks to open foreign bank accounts and these accounts are used solely for the purpose of settling accounts payable or payroll.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest rate risk</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest rate risk is the risk that future cash flows of a financial instrument will fluctuate because of changes in market interest rates.&#160;We are exposed to interest rate risk through our cash and cash equivalents.&#160;We mitigate this risk through our investment policy that only allows investment of excess cash resources in investment grade vehicles while matching maturities with our operational requirements.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fluctuations in market rates of interest do not have a significant impact on our results of operations due to the short term to maturity of the investments held.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign exchange risk</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Foreign exchange risk arises from changes in foreign exchange rates that may affect the fair value or future cash flows of our financial assets or liabilities. We are primarily exposed to the risk of changes in the Canadian dollar relative to the U.S. dollar and Euro as a portion of our financial assets and liabilities are denominated in such currencies. The impact of a $0.01 increase in the value of the U.S. dollar against the Canadian dollar would have decreased our net comprehensive loss in 2021 by approximately $360,000.&#160;The impact of a $0.10 increase in the value of the Euro against the Canadian dollar would have decreased our net comprehensive loss in 2021 by approximately $14,000.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We mitigate our foreign exchange risk by maintaining sufficient foreign currencies, through the purchase of foreign currencies or receiving foreign currencies from financing activities, to settle our foreign accounts payable.</font></div><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Balances in foreign currencies at June&#160;30, 2021 are as follows&#58;</font></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:70.029%"><tr><td style="width:1.0%"></td><td style="width:43.367%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.666%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:26.667%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><br>US dollars <br>$</font></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Euro<br>&#8364;</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</font></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,763,120</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">148,430</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other receivables</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,878</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable and other liabilities</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(333,475)</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrant derivative</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(124,228)</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:3pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,352,295</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">148,430</font></td></tr></table></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liquidity risk</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Liquidity risk is the risk that we will encounter difficulty in meeting obligations associated with financial liabilities.&#160;We manage liquidity risk through the management of our capital structure as outlined in Note 10 of our interim consolidated financial statements. Accounts payable are all due within the current operating period.</font></div><div style="text-align:justify"><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</font></div></div></div><div id="id23e26cc9f284c11832157637a690746_64"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Other MD&#38;A Requirements</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have 54,959,672 common shares outstanding at August&#160;5, 2021. If all of our options, restricted share units and performance share units (4,878,480), common share purchase warrants with a $9.025 exercise price (1,730,894) and common share purchase warrants with a US$0.90 exercise price (64,035), were exercised or were to vest, we would have 61,633,081 common shares outstanding.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our 2020 annual report on Form 20-F is available on www.sedar.com.</font></div><div style="text-align:justify"><font><br></font></div><div id="id23e26cc9f284c11832157637a690746_67"></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Disclosure Controls and Procedures</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no changes in our internal controls over financial reporting during the quarter ended June&#160;30, 2021 that materially affected or are reasonably likely to materially affect, our internal controls over financial reporting.</font></div><div><font><br></font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.3
<SEQUENCE>4
<FILENAME>ex993-q22021certificationx.htm
<DESCRIPTION>Q2 2021 CERTIFICATION CEO
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i7199d3b57b7245a29e136590ce7a3b9d_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">FORM&#160;52&#8209;109F2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> <br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">CERTIFICATION OF INTERIM FILINGS <br>FULL CERTIFICATE</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">I, Matthew Coffey, President and CEO of Oncolytics Biotech Inc., certify the following&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%;padding-left:27.75pt">Review&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">  I have reviewed the interim financial report and interim MD&#38;A (together, the &#8220;interim filings&#8221;) of Oncolytics Biotech Inc. (the &#8220;issuer&#8221;) for the interim period ended June&#160;30, 2021.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">No misrepresentations&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">  Based on my knowledge, having exercised reasonable diligence, the interim filings do not contain any untrue statement of a material fact or omit to state a material fact required to be stated or that is necessary to make a statement not misleading in light of the circumstances under which it was made, with respect to the period covered by the interim filings.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Fair presentation&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">  Based on my knowledge, having exercised reasonable diligence, the interim financial report together with the other financial information included in the interim filings fairly present in all material respects the financial condition, financial performance and cash flows of the issuer, as of the date of and for the periods presented in the interim filings.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Responsibility&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">  The issuer&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (DC&#38;P) and internal control over financial reporting (ICFR), as those terms are defined in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">National Instrument&#160;52&#8209;109 Certification of Disclosure in Issuers&#8217; Annual and Interim Filings</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, for the issuer.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Design&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">  Subject to the limitations, if any, described in paragraphs&#160;5.2 and 5.3, the issuer&#8217;s other certifying officer(s) and I have, as at the end of the period covered by the interim filings&#58;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">designed DC&#38;P, or caused it to be designed under our supervision, to provide reasonable assurance that&#58;</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">material information relating to the issuer is made known to us by others, particularly during the period in which the interim filings are being prepared&#59; and</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">information required to be disclosed by the issuer in its annual filings, interim filings or other reports filed or submitted by it under securities legislation is recorded, processed, summarized and reported within the time periods specified in securities legislation&#59; and</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">designed ICFR, or caused it to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with the issuer&#8217;s GAAP.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">5.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Control framework&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">  The control framework the issuer&#8217;s other certifying officer and I used to design the issuer&#8217;s ICFR is the Internal Control -- Integrated Framework (2013) published by The Committee of Sponsoring Organizations of the Treadway Commission (COSO).</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">5.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">ICFR &#8209; material weakness relating to design&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">  N&#47;A.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">5.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Limitation on scope of design&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">  N&#47;A.  </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Reporting changes in ICFR&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">  The issuer has disclosed in its interim MD&#38;A any change in the issuer&#8217;s ICFR that occurred during the period beginning on January 1, 2021 and ended on June&#160;30, 2021 that has materially affected, or is reasonably likely to materially affect, the issuer&#8217;s ICFR.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Date&#58; &#160;&#160;&#160;&#160;August&#160;6, 2021&#160;&#160;&#160;&#160;</font></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.214%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.150%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.336%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">&#47;s&#47; Matthew Coffey</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Matthew Coffey, PhD, MBA</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">President and CEO</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%"> </font></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.4
<SEQUENCE>5
<FILENAME>ex994-q22021certificationx.htm
<DESCRIPTION>Q2 2021 CERTIFICATION CFO
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i7af1612ef8c542ee9d2b520688eaa49f_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">FORM&#160;52&#8209;109F2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> <br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">CERTIFICATION OF INTERIM FILINGS <br>FULL CERTIFICATE</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">I, Kirk Look, CFO of Oncolytics Biotech Inc., certify the following&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Review&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">  I have reviewed the interim financial report and interim MD&#38;A (together, the &#8220;interim filings&#8221;) of Oncolytics Biotech Inc. (the &#8220;issuer&#8221;) for the interim period ended June&#160;30, 2021.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">No misrepresentations&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">  Based on my knowledge, having exercised reasonable diligence, the interim filings do not contain any untrue statement of a material fact or omit to state a material fact required to be stated or that is necessary to make a statement not misleading in light of the circumstances under which it was made, with respect to the period covered by the interim filings.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Fair presentation&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">  Based on my knowledge, having exercised reasonable diligence, the interim financial report together with the other financial information included in the interim filings fairly present in all material respects the financial condition, financial performance and cash flows of the issuer, as of the date of and for the periods presented in the interim filings.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Responsibility&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">  The issuer&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (DC&#38;P) and internal control over financial reporting (ICFR), as those terms are defined in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">National Instrument&#160;52&#8209;109 Certification of Disclosure in Issuers&#8217; Annual and Interim Filings</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, for the issuer.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Design&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">  Subject to the limitations, if any, described in paragraphs&#160;5.2 and 5.3, the issuer&#8217;s other certifying officer(s) and I have, as at the end of the period covered by the interim filings&#58;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">designed DC&#38;P, or caused it to be designed under our supervision, to provide reasonable assurance that&#58;</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">material information relating to the issuer is made known to us by others, particularly during the period in which the interim filings are being prepared&#59; and</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">information required to be disclosed by the issuer in its annual filings, interim filings or other reports filed or submitted by it under securities legislation is recorded, processed, summarized and reported within the time periods specified in securities legislation&#59; and</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">designed ICFR, or caused it to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with the issuer&#8217;s GAAP.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">5.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Control framework&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">  The control framework the issuer&#8217;s other certifying officer and I used to design the issuer&#8217;s ICFR is the Internal Control -- Integrated Framework (2013) published by The Committee of Sponsoring Organizations of the Treadway Commission (COSO).</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">5.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">ICFR &#8209; material weakness relating to design&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">  N&#47;A. </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">5.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Limitation on scope of design&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">  N&#47;A.  </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Reporting changes in ICFR&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">  The issuer has disclosed in its interim MD&#38;A any change in the issuer&#8217;s ICFR that occurred during the period beginning on January 1, 2021 and ended on June&#160;30, 2021 that has materially affected, or is reasonably likely to materially affect, the issuer&#8217;s ICFR.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Date&#58; &#160;&#160;&#160;&#160;August&#160;6, 2021&#160;&#160;&#160;&#160;</font></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.214%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.150%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.336%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">&#47;s&#47; Kirk Look</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Kirk Look, CA</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">CFO</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>oncolyticslogotaglinebluea.jpg
<TEXT>
begin 644 oncolyticslogotaglinebluea.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP"$  $! 0(" @(" @(" @(" @(" @("
M @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(!
M 0$! @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
M @(" @(" @(" @(" @(" @(" O_  !$(!H\/  ,!(@ "$0$#$0'_Q  ?  $
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M$0,1 #\ S^
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                   -0  8WD
M F  #(     ,-@  ;R   U  !D
M
M
M
M
M
M
M
M
M
M
M                                                '57(=>< J I*
M]3KS*8X_]K_]@K;CF0H R"KSH<=9["F<;@%3G4XYE*?,AQSH8T7@-"KS*<<R
ME+K/8.=?0AD%7=3@I\R^KYAS+ZOF *@*?,OJ.=W>H [@Z;N]1QNOJ *ASN4N
M9?5\PYE]7S %7F4YYE*/,OJ'6>P K<RG/.I1YSGG0QIZC.A6ZSV'/.A1W0Y,
MF"MS(<[H4  2 4-SE'J8!6!3ZSV'9'H9!V!QN<@
M
M
M
M
M
M
M
M
M
M
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MN=T> 50=4>AV,@
M
M
M
M
M
M
M
M
M
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M>=0"9UGM'/[2)UGL.>= "8CD]2?$<[I[4(B*=N90"5OZE_"<HJ^Q2-SJ<H\
ME<WK11S(44D]ISS>Q/B )&YSS>M$(^_JW.R*OP@%?WOP'*;_  E#G.Z* 5.?
MUH=T4I<_QCL^#\ !6&Y33?X3GG0 K(\[HY"B!H"0"BCE0[H\ [@
M
M
M
M
M
M
M
M
M
M
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MM\"G;F7X0"O\'9[#GF5.]"DCD4[(X JHY%.Q2W1?8<]J %5%*B/(Z/13N 2
M4$4J(\P#N #(
M
M
M
M
M
M
M
M
M
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MVQ41Z%%'(<@$@%%'%5%W, Y !D
M
M
M
M
M
M
M
M
M
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MH"L#JCMSL-0  9
M
M
M
M
M
M
M
M
M
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M'='>CT@%;=4]J'=%**+\AV3V?( 52HU_K**..QAK4$@%%KMBJBC4'( ,@
M
M
M
M
M
M
M
M
M
M                                             '"KL%78HJNYA?U
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M[<J(OH7N!DK'*+L4>[N[4*B*#!71VYV(^Y6:[<P#L #.H
M
M
M
M
M
M
M
M
M
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M6NV*R+\@!(1=COMZ4(Z+M\'H*J* 5D4Y*7?VIW^H[H[< K-?ZRH1RHUWH,:
MJ  )@  R
M
M
M
M
M
M
M
M
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M9(:_UEL:\DM?\@!<FO\ 656N(#'_ "$AKOD )S7?(5$7;VI^ AM=Z4*['_H
M)*+Z4._?\)&1>WL^0JHNX!6:[T+WG<I)LO9W'=%]"@%9KO65".=VN]!AKP!5
M  3  !D
M
M
M
M
M
M
M
M
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M1%W *Z.]"G8I(N_9\BG9J^A0"LUWH*I'*C7&'^K_ +T!4 !G4
M
M
M
M
M
M
M
M
M
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MX2/[?5WH5$4 KM=Z%.Q2[_A3YSNUWR@%=KCN1T4K-=N8?B#L #(
M
M
M
M
M
M
M
M
M
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MP3=9V<Y7*YSE5SG.<]SG*KG.<Y5<YSG*JN<YSE5SG.57.5555W4X ):2T(=
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MB@$A%W.2@U=BN?/+V   ^@
M
M
M
M
M
M
M
M
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MN#!(!T8[<[GRO   'T
M
M
M
M
M
M
M
M
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MJ+Z4^, D]_PG=J_*444[KZP"JBE=%(Z*=VJ8!6 !D
M
M
M
M
M
M
M
M
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M_NC%<(1T2[VZ==).D>3M3*EDY+T^#55%ZPHKUX5P_7*7.<M6]."0 &^-"
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MD?Q(26Q^/'Z?85(XE]7XO'PDUD7LW7YOS&#)19#X\=Q+9%Z.Y"JR(ELB\>L
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MU#NUVX!78IW*"*5D4PP<@ R
M
M
M
M
M
M
M
M
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M2QWYP"0BG=?7Z"@U?1\A6;ZO6 5CNQWH*+/4=P"0#AJ[H<F$  #(
M
M
M
M
M
M
M
M
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M^ K(I&8XK)V+[% *^_I]7>5$4I-7Y#LWL78 K-=M\!6(Y6:[<^7X^ .P /H
M
M
M
M
M
M
M
M
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MH 2 =6=QV/E/N  !]
M
M
M
M
M
M
M
M
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M5OJ^0ZJW?X?45]O5^<Z*FX!%<PHJWUDQ?4ORG1S/T@$![",YGK+BYNQ0<WY
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M6>-_CVEPC> 7:-WR>/'QDQB^@MD3_036* 7%CB2B^D@L=\Y*8OH )K5W^/\
M"56K\W81F*5D7M3V]_P@$A.U/@*C5W0I-78[-7T %9B]I6(Y7:NZ&&#D &0
M
M
M
M
M
M
M
M
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MK\AV1IV !RB;G9K=RHB&-0=4:=P!I_WX   R
M                =5;N=@8T\. *"IL<$@IN9ZAJ"@K?4=>Q?8I5.KF[F045
M3T*A35-O@*_L7N]9U5-@".YOQH1U;L3.7TH4U3?T?"GJ (+F^DCN9\A/<W8H
M.: 6YS?D(DC"Z/9\A$>SQX](!:GLV^ A21EY>ST>.TA/;MV %ED9^8AR,W^$
MO$D?C\9!>P LTD9;Y&%]DC+=+'X\>L LDL?R>CV$![-_'C\Q>Y&)\7X"VRL5
M%]NWS>/G +4]I\V]*WHRZ<XNZ%SF@]3Q;T,Q65*]QC&/LXG)1(K\?E:?.BHE
MBC8Y941%:LL?60J]K9%5/IN1OI(;F^CY_">.T_6B^=4X65R<+*Y1G"47HXRB
MTXM/Q36I^.11"V$ZK(J==D90G"2UC*,EI*+7@T]#5L=(G@#J/A=K34&A-555
MJYC3]Z2K(]$_P?(5%57T<M1?VI-0R=58[5:1JJK4>Z&5&6(9HV?BQG-^78\G
MO_=,T*[B)I?&^Z->:"J.FFKU(FK;U%I1LJ29*ALU6NLW,-&^;+XZ)>LFECAN
MT:<;[%N&)^#$UR+VIZ>[T%M^AW2:&T\.%W"-T-*\B"^#:DO*2Y[EBTE#N\Z.
MK<):4SZ;=%I[)SIT<946+M<6Q\=ZIOS9/D[*GK"?JW9Z)31V !UAR(   7X5
M14[45%5%14[45JILK51>U%145%1%3M0V"/D6>G4O&3A54H9NVV;7.A&U\!J-
M7.1)LE3C8K,'GW-55<K[]&-D%^3]J_*5;4K4C;89%'K[C[U\FOTR;G _BQI_
M5JR2NT[;E9@]946/<C;6G<A+&RS91G[1UO$2]7E*;W-YN:O-61\<=R93B>GO
M1O\ =+!E&$=<BC>NQWWN27EU:^%L5IIRWU!OA$[OJ\Z4/9>T(2G+3%R-*<E=
MT8M^1=IXTRXZ\6JY6)+B;*N-WS>/G0N43C^6PN8JWZM6_1L16Z5VO#;J6H'(
M^"S6L1MFKV(GIV/CFB>R1CO2UR+V;J7V%^R[>@J;[5H_!\T7%U\.7<7N)Y<8
M7EFC=W%PB?X]H!>F+\Y.B=X]I:8W$^-_CV@%WC?X]I/8[TEIB<3XG>/: 7*-
M?'X28QQ;8W=Q-C=\X!/:I);V]GK(3%)+%[/@ )#5W0J^C?TH4$7M]BE9OJ]8
M!6.[%*+5]'J.^X!(!PBG(0
M
M
M
M
M
M
M
M
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M8[(@!P548<HW8[&.8  ,H
M            '56[E)4V*YPJ;F 4"GW=_<5G-V.ID%%6_(4E;Z4*W<OL4X5/
M5W $=4W3\*$=S=B6K?2GZ3HYO9[/P $!S?D(SV_(I/<W8H/;\@!;'L(KV>OQ
M^0N;V>@BO;ZP"T/9^DA2,\>HO$C=_'SD&1GYP"SR-_.098_'CU%XD807M_,
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M-R)8W;_"GCQ[?FUC/04Z5%W@QQ1TMKVMUSZ6.MI4U!4A]\^]IR_M7R]=L?\
MZ65E=5M5HMV\]FO$Q'LYE<FS$TKJBAFL;CLSB[4-[%Y:A3R>.NUWME@N4+]:
M.W3M0R,W;)%/7FCEC>U=G,<BIV%7^LSH[[BSNWKCI1F;UL4EPC:M.VAPY:MJ
MQ+1+2>D>$66PZJNDWN[9RHMEKDX6[3/5ZRG3I[Q9QXOR4ZY/GK7O2XRX_P!G
M"_<N$3BRQ.V5"YL<1N2@7J%Y<(W%FB=X]I<HG %VB=X]I/C=W%HC=X]I<8G
M%UC=Z/'L^0F1J6V-_9X^/U_"3F.[E +@QWI)35[2!&I+:O8 3.]/@_ 544H,
M=Z2JWTH 5]^U%]94*3>U-OC.[5[ "NQ3N46KVH5C'_\ @  ,@
M
M
M
M
M
M
M
M
M                                  %!5*KE["B$P='G1QV[U^!"FJ@'
M15[?@(\B_.5?1\)'<NZ_, 47KZ"(]W>2'N])"D4 H/4@RKX\>TD/=V^OQ[/:
M0)'?F (TSO'J]9;Y'$F5WY"!([O (TKMMRV2N)4KBVR. (TCMD^$MTCN]?A^
M;Q\Q)G?^0@2. //[RFG2YCX+\']3ZMAFBCSUB#ZAZ5C>]$?+J#*LD@J31L54
M<]<>SKLD]&([E945[VNB:]#6ROF?(]\LLCY99'NDEED<KY))9'*^221SE5SG
MO>JO>]RJKG*JJJJJF05YP]TLUUCQ4Q_#K&6>? \-JCDOMCD58K6K\NQDN0D>
MU/>N7$XU*>.@5R<\4\V4Y56.PU3'S+0]66P/<>SXW26EV9NW3U7%5:/L(?FM
MV>*=FCY%3>M;I#[MVE*B$M:,'>HCIR=S:>1+ZIQC7X>])KF  2.1B   <*I[
M)>1'Z$;.+G%AF7S-1;&C>'7N'4&:21J^YKN7EFE73F'?LJ<_NBQ3LY":-JJG
MN;'/;-[V5D<WCO2I3VIX*M:*2>S9GAK5H(FJZ6>Q/(V*&&-J=KI)9'-C8B=[
MG(AL?/)C=#B'@EPDP&E9H(FZCOM3/:PLQHU7V-09"*-9X7R(UJOCQE=D&,KH
MNZ,BJHC5=NKW1YUC](_<.#*%<M,C+3JJT>CA#3WVU:<?)BU&+X:3G&2\TDCJ
MPZ,?NAM&-ED=<;#W;K=5K&=FK[&KP>LH[\D]4X0<7YR/0AB;)W(GJ1.Y$]2>
MSV>@F1M[OG*+$W)K&?*I5HMP5HV;^/3X[BY1L[D^,H1,3L7U%PB8 5XV>/Q%
MQB8486$]C?F *L;"?&SQ["C$WQ^(N$; #O&PGQM3U%-C/'CU?A);&^CT '=C
M?22F-^4ZL;Z22Q-@#LU/02&,.K&E;;T)\:@'9.WX$^<J-;ZCA$.Z^I !W]B>
M/:5-@B;'9$!G4(FY61-@B;')@P  9
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M9KHKV(MC&QL>Y(GR([C^G.P?W0V==7%:W5+MZ/%VUJ3W%\Y%RK\-91;Y':=
M.D3V;M.BV3THN:Q\A=RKMDDK'\U/=L??NQDES-E4QW87*%^_CQ^DL5.U'+''
M-#(R6&9C)8I8W(Z.6.1J/CDC<G8YCV.1S7)V.:Y%3L4ND3ORIX^8J.7,+S$X
MN<+O'X2S1J7&)_C\(!>(U+A$_N\?"6F-WCV$^)P!=XW$Z-?'L_1VEJC=V%PC
M=W>/@ +C&OS$UB_.6V->WQ\1-8O9\ !-8OH)"+W+\2D1J]RDIOJ *Z*=T[%V
M*+5["KOW+\0!5*Z+V% J,4P^0*@ ,I@
M
M
M
M
M
M
M
M
M               ,%)ZE-5[#LJE-Z^CUA Z>CX2D]?1ZRJ[U>HHKW_ @!T>[
MYNPB.7L*S_01GJ 4'J0I%\?,2)'=_P Q#D4 C2N\?-^<@2N)4KNWV%NE=^4
MB2.^8@RN),B_E+?,[Q^  ARN_(6Z1WI^)"5*XMTSOF3\/Y@"'([M^ ^;^ECT
M@,=PLX<:RX@91T;:^F,':OP1/>V-;N2?RU</C8G/W;U^3R]BECX$5JM6:RSF
M3EW5/HJ1WSF*GYROTH4K8G1_"&A/M+E+":PU'&QZ?O&@^2I@Z\S-T=R37EM6
MV;\T<CJ;5['PM5.@Z+;']WY^-C:/<G8G;IW4P\NSCW-P3BG\9HYSI;MM;.V=
ME9>J4ZZVJ=>^^?D4K3O2G)2E^*F^XQ,=::PR6HLQE<_F+"V\MF\C<RN2LNW_
M &:[?GDLV'M1?VK.LD<V*-/>11(V-B(UK43^; +C0@HI1BDDDDDN"27!)+P2
MX+U%))2<FY2;<I-RDVVVY-ZMMOBVWQ;  /H^0%!RUKG*C6,=(]RHUC&-5[WO
M<NS6,8U%<Y[G*C6M:BN<Y41$551##![E^03Z&[>(G%J/6F8I+8TQPR6MFTZV
M-5JV]6.>KM.UGJK.63ZFRL?FUC21KDGJ4%>V2!\S%SPF)Z>]5/-WR4G1)_N.
M\%=+:?NPLCU+F(EU1JQZ(G,W-9IK;"4%<B>^;AJ'N3%(J*Z-\U6>Q&NUA=_2
M>-"I73O;_P"Z&T;9QEK12W11H_)=<&]9KYR6L]>>ZXKE%%R>K[HXMF[-IKE'
M=ON2R,G7FK+(K2M_-0W:_#>4I<Y,KQM^8G0LW[?B0CL;Z"XPM_(GXSC3MR3&
MWN]A<8F>/:1HFERA8 2(V[(3HV^/:48V_D0N$3 "M&SQ[2=&THQL^8GL;\P!
M48WN\?$2V,*;$])+8WT %1C2NUNYU:GH)+43XD .43Y?P>/P%5$V.K4])53L
M[?D .R)M\*_,=FIL<-3TG< Y1"LU-CAK=CL8Y@  R
M                                             4%38KG"IN8Y CJA
M3]B_$55.KDW,@HJGH*2IZ/D*_?\ "A3<W< BO;Z2@]/235]?RD=R; %O>SY/
MP$1["Y/;Z"(]ORH 6N1OCQZB%(S\Y=I&D&1OI3QX[@"T2M\>P@2-_,7>5GCV
M?F($C?F +-*PMTC=B]RL+9*P LLS-OPIX\=Y!E;\_C\Q=YF=GP%N>G>GR?C_
M "@%L<WT&)IYR!T.FK^I[C;A:;DD:VOI/6SH6+ROB:LC].9BQLJ(V2)SYL//
M.K7/E@=C(W.;%2:9:$C3\6Z07!+$<1]%:GT-G45,7JC#W,38F8QKY:;[,:I6
MOP-<K6NL4+20W(6N<UKI(6L<J-<XZ#HOMR6SLZC)6NY&6[=%?"IGPL6G>TO*
MBOCQB^:1SG2S8,=I8&1B/3>G#>ID_@7P\JJ6O<MY;LO&$I+DS5I[@_N^*'#/
M,Z+U)G=(ZAKI6SFF\K<PV3B;SK'[JHS.A?+ Y[(W2U;+4;9J3<C4GJS0S-1&
MO0_A"XM=BG&,HM2C)*49+E*+6J:\4UQ3[T4ELKE"4H3BXRBW&46M'&47I*+7
M<TTTUW-  'V? .KVHJ;+W+V+\"]YV!AH&PB\B=TL7<4^!V%;D+?NC4NAIUT9
MJ#K'[V)?<%>&;"Y.1%7G<S(X>:MO/LV)]ZKD8(DWJO1/8"-?3\OZ/8I@=>;[
M=*!-$<9I-'W9UCP_$S'IB-G/5(F:@Q3;%_"S.:JI&CY(GY"DDCO?)[IZMB.=
M*U#/ C<5,Z?[%]P[3OA&.[5<_=%/#1*-FKE%>J%BG&*[HI%Q^KK;W[H;*QYS
MEO74:XUWCOU:*,I>N=3KFW\:3\"[0N[/@+C$\LT+^[Y/E_/L7*-QQ9W)>H7>
M/P%PC7N+/"XN4;NX NT3OR?D+A$XM,3BX1N[E\>-P"Z1N[";&O<6Z-?'CY"9
M&O8 7!BDEB]A"8O<2F+V@$I.Q=OC0JIZ?E(^_8B^KL*[5[0"JQ>SYBHU>TI(
MO:J'< D X:O8<F$  #(
M
M
M
M
M
M
M
M                                                          !P
MY>Q3DIO4^=>*!3*:]_P%0HIW*OQ'T#JJE'?L^$J/7L*3E^9 "@Y>TB/7O*[E
M["*]0"-(I#D7Q\Q)>O>OCV$"1>SQ\ !%D=W_ "%NE=X]A,E4MTK@"+([O4ML
MKORDV5Q:Y7>/8 1)'?E+9*[M^'M7Q\Q-E=V?"6QZ]Z@$.S8CC:^261D44;7/
MDEE>C(XV-17/DD>Y4:QC&HKGO<J-:U%<Y41-S69^4*Z24O%GC+KW6O6/?C;>
M<M8[3K'N_<--861V,PB-:O[DZU4KMR5F--T;=OV=G.:J*9S7E?.DBO#+@+K3
M*UIDAR^<K,TGA-G(V1;^H>>G))&BJG6+5Q_NVV]K5YDA@E<B>]-<RQJ(B(GH
M38G;J=V/Y.5G27G-8U3]2TLMT]K=:U_%DO'6OG7=MK5XFSX2Y)Y5R];WJZ%]
M7OS:]<7X'8 $Y$!    ]6O(Q]%9.*G'+ 17JGNG3NC(EUIJ!9&*ZLYF,L01X
MBE*Y=F]9=S$U58H=UD?%6LS)&Z*O/R^4IG5^;\]%AFB.#CM978.3.<3KD>8D
M>]C4DBT]C?=%33]5'_MEB<DM_);.1KDFR$C%1S6,4XGK VY[AV;=*+TMO7N>
MG3FI6)[TEWK<K4Y)_&W5WG>=7&P?=^U:(R6M./\ OJ[AJG&IQ<(/N>_:X1:^
M)O/N/>)B=G9\2)V(B>A$1.Q$3T(G<G8A-C;W>PCL3YB=&WY_'X"II<0KQ)^1
M/'CT%TC:186_-V>/P%QB;X^$ DQ,+E&PC0L+A&@!(B;^1"X1M(\3?R%PC: 5
MHV^@G,;Z"C&GYB6QOS@%:-OS$IB=A38WYB2U-P"HQOSE9$W^!/G.GX^PK(FP
M!V1#NB;_  ''L0J(FP!R5&-])U:G:5C#\/\ O0  &4
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M#N4F+VE4Q_W_ -_D  !D
M
M
M
M
M
M
M
M
MHO7M*Q051J#H_N*:]R)\9W?^,Z.7M *2]Z?*4'K\Y55>_P"0CO4 H/4AR+W^
M/82GKWD*10"+(I"E<2WK^ MTB]X!$E=X^ MSU)DSOR%OD=W@$*9WC\!;)7?D
M)TKBVR+^4 @SN^;\9;Y%]!*E7?Y57\?XD+?8F1B.>]=F,:KGKZFM3F<OMV1-
M]O9\0!AO^<P=(5<CJ[07#&E9<M;3.,NZKSE9C_V-^8SJQTL,V9FW[MC\34NS
M0N3_ -'G9&][5VQASZ[Z>_'MW$WC%Q UDD[;%/(ZANUL1(QW-$N&Q;UQN,=
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M0#NU/3\A5:GI.J)Z#NO?LG< =F)Z3N"HQ/2&P=VIL<@&$  #(
M
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MH+7DK)$:=:^Q/=>R;+(KWW"DLF'BX13C='7P[.3GPYRKB87B X0Y+2E2D
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MN1RNB@'(
M
M
M
M
M
M
M
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MX>PJH@!W;Z_45&=WPG1?0GJ*H!RB;E9#JQ#N8  !D
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M^JI09ZBKZ/@4 K%5B]A11>PJQ^D J  )@
M                                                          '&
MX!R#CQX[SD  X.0
M     <*H!R#A#D  X&X!R
M
M
M
M                                 #C<* <@'"@'(.-SD
M                                 '" '(!P <@Z[J=@
M                                             "F_T%)3N[O*3^X
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MQ.Q/'>2V)\P!W3O3V%9J>GU%-O<5/1\(!W9Z_6=T"%1B>D J( #"  !D
M
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M89HG-?'(QRM<U45%V+L5R:TX-:-<&O LVGKQ7%/DT  8,@
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M7--/BFO D6,E))IIII--/5-/DTUP:?<P #Y/H
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M?:DU_P#SGIC^W&#<!]R[8_X"?Z>[_&/NM;;_  ]7]'I_PF<C^NQ>&WVI-?\
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M/5_1Z?\ "9R/Z[%X;?:DU_\ SGIC^W#]=B\-OM2:_P#YSTQ_;C!N ^Y=L?\
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MB^<FV^+[RR'0[:=V9LS#RKVI775;\VHJ*;WI+A%:)+1)<  #GCI@
M 6+4^<;C,;D,E(QTL>/HV[SXF;(^1E2O)8=&Q7>]1STC5K57L1515[$4OI_
M<5_X+:E_D#,_1UD^ZUK**?)M+\K/BQZ1DUS2;_(C&!=YV'PV17-_N2\0/>N<
MW_I/3'^*JM_[=[#K^NQ>&WVI-?\ \YZ8_MQ@YS_NDG\;)_3<4BT7W+MC_@+/
MT]W^,J7'K:VWHO?ZN2_\O3_A,Y']=B\-OM2:_P#YSTQ_;A^NQ>&WVI-?_P Y
MZ8_MQ@W ?<NV/^ G^GN_QF?NM;;_  ]7]'I_PF<;+YV3PV8QSUX2<0%1K7.5
M/JGIC_%15_[=[#*;T1JAF;PN'S443X(LOB\?E(X)'-=)"S(5(;;(GN9[USXV
MRHQSF^]5R*J=FQIS;W[A-_%2?T%-P!P"_@)HK[DM.?0],C#K*Z*X>S88;Q*Y
M0=TKU9O63GKN*EQTWY/33?ERY_42QU6]+L[:DLU9ED)]@L=U[M<*].T=V]KN
M):^9'37EQ\3]: !%)+P                            . #D'FGTQ_*V\
M"^"'7TM7:RIW=21-W32.FW,S>HV.<USH_=M.I(YF*8_9NS\I-45S'=9$R5B*
MIBQ=+3SHCBCJ-UK'<(]/8OAWC'<S(,]F8*FIM5N:K4Y9H:EN.736.D:Y7(L5
MBCGF.1&N1\:JYB=9L3H1M+/TE3CN%3T]^NUKJT?>FTY37S<9G';>Z>[+V=K&
M_)C.U<.PHTMNU\)134:W\Y*"]9G6:BU-CL15DO97(4L93B_=+>0M04ZS.Q7>
M_GL/CC1>5KE1%=W-5?0IY2<>_+J=&/A\MB"[Q'J:DR4"/3ZDZ)IVM46GS1]C
MJ[K5!BX>I.B^]Y<CDZ;$=V.>B[FN;XU]*'B1Q(M27->ZYU1JV:1VZMS67MVJ
MK??<R-AH=8VC!&QVW5QP5HXXFHC8V-:U&GX4B(B;(FR>I.Q"4-E]3M*T>9EV
M3?!N&/%5Q]G:6*<I+^9!^&G=$NU>NZZ6JPL.NM=UF3)V2_1UN$8O3CQLFM6N
M#2XYL7%KSL?2T2RQ:"X1:DR+>5>HO:PS>)P:I)Z%DQ>$74?/&O?V9>&3;O8B
M[HGG9Q&\Z,X^9-ZKI_3^@-+Q[[-;]3LAG'HFZ;<SKM^%JOV14548C=U549LB
M(8V(.VQ>KO8]7+#C-^-L[+/RJ4]S_=7J.$S.LO;=SXYTJEP\FFNJI+3PDH;_
M .63U[]3U^U?Y>CI699[GLXHSX=KMT6/"X#3M>--U<OO?=>,OR-[';(K9$<B
M(W945.8^>\]Y5'I(9-)/=?&OB!^RL1C_ '+FWXY>5O:G(N-BJ=4[UOBY'N[G
M.5#X%!O:>CN!7YF%B1]:QZ4_R[FK^MG/W=)-HV:]IGYDT]7H\F[3CX+?T2T[
MDM/4?8W]\1X_?;LXJ?Z=:B_MY4B\HMQ_8YKV\;.*7,QR.3FUQJ"1N[5W3F9)
M><QZ;IVM>US7)V.14W0^-0>O]R\;^3T?H:_\)XUM3*_E.1^GM_Q'HYI_RO?2
M<Q;D?3XUZT1W.K_\+GQV3;S*Q6=K,ICKK%;RK^T5O(CMGHWG1')]%:(\X0Z5
M.%5JRZ\Q^=Y43LSVF</81^W+^W]P0XSM7;M5O*OOG;;;MV\60>&_HSL^SS\'
M$>O?[FJU_.44_P"L]]'2G:=;6YM#,CIR7NFYQ[O@N;B_K1D]\-O.H>,V.2-F
MI=#Z%U(SF9ULM9<K@["L1V[TB2*Q<KM<]B[-5\<B-5$=LJ;HOHSPG\Z\X;7'
M10ZWX7:XT\Y_5,=;TY>P6J:D;G.Y9)IXKMK3-V*!B;/5M:'(6-E5C8Y'-:K\
M&L&BR^KC8]NO[T5;??59;#3V1WW#_=T]1T.%UG;;HT_?G;12TW;ZJK-?;+<5
MC]N_J].+-HGP"\LIT;.)#J]?3_%+!5,E9<V./$:F2UI7*NG<W=T$=7/5Z/NE
M\?:CY*;[-==N:.:1FSE]+,7E:UV".U3LU[=:5O-%8JS1V()4WVWCFB<^-Z(J
M*F[7*GH[T--Z]B.39R(Y/4J;I\A]/< ^FKQ<X6V&6.'W$356E^3JT2K1R;[&
M+>V)5<R.?"Y%MW#6H6N[4@LT)8%7]M$J;'$;3ZG(/5X>7*/A#)BI+]+4HM?H
MI,[S977?--1SL*,EWV8LG%K_ -JUR3_2KU(VVH,&/HE>=+:[PWN3&<8](X[6
M5)G)'-J?2[8L!J#E;'LMBYAEWP5^9\FSY78_ZAPL:CFP4G*K4,I?H@>5#X(\
M<&QP:$UOCI<ZZ-TLND\N]N&U3"UB(Z5[,/=6.>]#$CF];9QJW:T?,ULLS'+R
MD8;:Z&;1P-7=CRE4OX^GWVG3Q<HK6"^<C!^HEC8/3K9FT=U49$8VO_R]VE5V
MK[E&3TF_FI37K/04'&YR<L=<                      <'DWT\_+,<%^ B
MV<5F<U^J;6T+$5-$Z7D@OY:L][7.C;FITD]PX%'M:CDBR,T=UT<D,T=-\$K)
M#V8.S[\JQ58]4[K'RA7%R>GB].$8KOD](KO:/#M#:>/B5.[)NKHJCSG9)16O
M@M>,I/NC%.3[DSUD4^2>D5T[N#_">)\O$'B%IK3<K622-Q]J_'/EY^J3=[*V
M'II9R=J7U0P57RN7L8U5V1<"SIE><#\?N*DUNA@\TWA?I*97QLPFCG=7E[5=
MZ<J-RVK)HOJO,_E61LD6'7"4962=79JV5C9*>(^4REJ_9FNWK5F]=L.Y[%RY
M/+:MSN_ZTUF=SYI7>U[W>Q=B7-C=3]T]V6=D1J3XNFA=I8OQ96279Q?R5:O!
M^$,;<ZZZ8.4-GXTKFM4KLC6NIZ?"C5'WR<?ENE^HSKN.7G5'"3$/GK:!T+K7
M6TT3E9'DLI]3](8.PBM3DGK+9ER>?>U'+[Z&[@,8]=E:CF[HY/*GBCYTMQPR
MCG)I?2>A-*Q(O[&Z:OD=03\NZJG6K9M4X5?LJ(O5Q,:FVZ-55,9D$BX75OLB
ME+][=K)?"OG.QOVQWHU_D@B,\_K/VU>W^^^PBWYN/776EQUT4G&5G#DO+U\=
M3USUKY=WI59M[U_NJ7,/'(BM?!@\)I^E&B*FRHR2;&7+,>_?S1V&/1>YVQ\Z
M9[RG72)R;E?;XU\1^997S*M34U[&ISR*JN][C7U&HSM][$C4BC[HV-1$/A<'
M24='\&OS,/%CZXX]2?Y=S5_6SF;^D6T+=>TSLR>KUTEDW-<>/!;^B6O'1+0^
MQO[XCQ^^W9Q4_P!.M1?V\N>*\I1TA*3W20<:^)G,YO*ONC5V7N-VWW[&7+%A
MC7?^\UK7>C?;L/B8'H>RL5K1XU#7@Z:]/V3RQVKE)ZK*R4UWJ^U/]L].=/>6
M@Z4V+Y4K<:=4R-:C&\EZM@,BUS8]T:USK^&L2_XR\SVR->__ !WJK4V^H-$>
M<=]*+#M8RSJ'3&>C;R\ZYC2U5TTB-39?V:A/11BN[U<V-4W7L:B;;>$P-?=T
M6V;9Y^#B/V8]47^6,4_ZS8T=+-JUO6&T<U<--'D6R6GJC*32?KTU,L#AIYUY
MK^HZ%FK>%>ELU"SEZZ7!YO)82W,G,JN5$MU\K5C<K51K52%6M5-U:[<],N"_
MG27 ?.RPUM7Z<U_H*9_[K>L8RCJ7!1=W9[IP%ZQG7JB[[_\ X--8C>5W.JJK
M6X!H.?S.K+8]R>F/*EOX5-MD6N?%1G*</9Y&G#3D=+@]:NVZ=-[)A>DUY-]-
M;Y:<-ZM5SXI:/R]>+>NNC6V5X!=/7@WQ0B9+H3B/I34$CT9O1KY6"#*1.D=R
MLBL8FXZOD:\[EVY8)JT<JM5KN7E<BK]=FFSJV9:\\5FO++7LP/;)#9@D?#/"
M]O:U\,T2MEC>U>U',>UR+NJ*G8>IG1?\M-TC>%$M2+$<0+VI,'61K%TQKEGZ
MI\1) Q5Y88K%I[,[CFHCG*GU)S%%KGKS3LG:U&'!;5ZG;%K+"RHSYZ5Y$7"7
M#N5M:E%M]VM<%XM<R0=D==]4FHYV'.ODG;C2WXZ][=5F[**\4K)OP3Y&T !C
M)=#/SFOA7K):>)XJXRSPPSDSF0NRB/ES&CI97*YK9'9&*%E_%Q.Y6J]<A2]S
MUW2(C[CXHWV#)'T=K+#Z@QM3,X#+8W.8?(0LLT,KB+U7)8V[7D3=D]2]2EFJ
MV87IVLDAD>QR=J*J$5;6V%EX,]S*HLJ>ND9-:US^19'6$_YLGIWZ$P[&Z0X6
MT(=IAY%=R2UE&+TLA\NN6ED/YT5ZC^F !J#<@
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M$A$[?@3YP"HB=R%7T_ =&_@[3NP [E9J=A2;WE<P  #(
M
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M<M]JP755T^U4-EYL^*TCAW3EJY<7ICSD^]<.Q;?%>]<U!/*;!QN<D'D_
M                    &*EYV#]:GA7]\J?^J><,%PSH_.P?K4\*_OE3_P!4
M\X8+A:+JL]$5?.W_ &DBIO6[Z:L^CX_[+  )&(Q!DS^:Q?7TUC][BU].XDQF
M#)G\UB^OIK'[W%KZ=Q)R'3ST1G?,_P!^!V75YZ;V=\]+[*9GT@ J,7.
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M\4Y*+X;VJ>EM>C.W/W1PJ<SL;*.V3?9V::^3)Q<HOAO0DTW"3C%RCH]W1IL
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MO6F#>=&/26S_ *=B?VBLY[I=Z)VG_P"GYO\ 9K369@ N84@
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M*^-;G')KCI&<8):N^*\FN6KT4XZ0G)J.Y%Z;WO2 ")29
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M .["J=6)V'8QW@  R
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M)C,&3/YK%]?36/WN+7T[B3D.GGHC.^9_OP.RZO/3>SOGI?93,^D %1BYP
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MJ==_UFO'O24ZZ6^E-H?3,G[61=[H=Z)V;]"QOLH@ '/'2
M            '&QA=^<U>3G]RST^D-I2CO!8DJ8/B37K1(G4S.Y*^"U2]&K[
MZ.5W)A<I)R(Z.5<7,YSXWSN@S13^%XG<-L+K'3N:TKJ.A!D\%J#&6\1EL?9C
M9+#:HW8703Q/9(U[%7D>JL<K5Y'HUZ)NU#?]&=O6;-S*LJ&K47NVP7#M*I>?
M#PU^%!O@IQB^XYSI7T=KVI@W8EG!R6_39WU70XUS7JU\F:7.$I1X:ZFGG1?'
MC\QV/M+R@W0SS7 7BOJ?AWEF324Z5A,AIC*O:O5YS2N05TV(R,+U1.LDC8DF
M.R*)^X9:A>@17MC9*_XM+@8F5"^JNZJ2G7;"-D)+OC))I^W1\5W/@4JR\2S'
MMMHNCN6TSE79%\U*#T:_*N:X-<4  >D\X,KGS9CRAGZF=1WN NI;O+A-6V[.
M;T/+9E_8\?J?J&NRF$A5[MHJ^=KUTO5Z\:)&F4KVY&,2?)3O?BC%UP.>OXF_
M1RV)NV<9E<7=JY+&9*E*^"YC\C1G99I7JD\:H^&S4LQ1SP2L5',E8UR+V&CZ
M1;$KVAB6XMG!3CK">FKKLCQKFODRYKOBY1Y-F\Z-[=MV;FTY=7'LY:60UT5E
M4N%E;Y^='S7IY,E&7-(W'2*<GG-Y+7IV8_I!<(\#K)LE=FI:<<>%UOCH.5ON
M#4]*&-+CV0IVQ5,DUS,G0:J;-K6FQ-<_JE>OHR4]S<.S'NLHMCNV53E"<7W2
MB]'IXI\T^36C7!EV<#.JR::LBF2G5="-D)+OC):KV-<FN:::?%  'E/6
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MFVL%Y6'EXT9*$LC&OHC)IM1=U4ZU)I<6DY:M+CHC3Q]OL';[#:\?WM'HX_\
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M5+RI/5)ZM<'RU  -*;T         '\!Q7_@MJ7^0,S]'63^_/X#BO_!;4O\
M(&9^CK)^E/GQ^5']:/SM\R7R9?J9I\Y_W23^,D_IN*15G_=)/XR3^FXI%Y"@
M,.2]B_4  #Z(M[]PF_BI/Z"FX X!?P$T5]R6G/H>F:?^]^X3?Q4G]!3< < O
MX":*^Y+3GT/3(1ZZ/O>SOEY7[..3YU&>?M/Y.)^O)/UH $"EA
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MZ(_N9A=I='3+RU&RY/G5#3WJCU.*>]8OPDG'5J$6  1Z22
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M2M_5-$UB=WQ?,A<84_)^(@QIW>/47&+N3VJ<F=B7")/'P%TB_$6V$ND2=GS
M$Z)"XQ=WR$"/\A<HT^=0";'W)X]"$YG?\I#C\>/B)T?X@"6SN)C4[2)&G<3&
M=X!73N^'8K(A1_ZOCTDAG> =D[_'P%0Z,]*^TJ(G: 5D.0#$?^(  ,@
M
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M/GJ]7&,-*@]8/32>ULIQKE)85$G&B')626J>1-=\I_ 3\R&BT4G/4 #O"/P
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MREST:U+,]'>A6S]F17N:A.WX61;I9?+Q\MKR$_BUJ$>_37B  <P=6
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M4G]!3< < OX":*^Y+3GT/3(1ZZ/O>SOEY7[..3YU&>?M/Y.)^O)/UH $"EA
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MA)#/3\!13O\ B_(54[E\=X".[.XJL[RFSN*K "J #"  !D
M
M          %)Y37N*KRF87) I+W(4'=Z%;?L^,IN]'PF01G]Q&D]!+D]/P_C
M(KP"#)Z2%)X^4GR>GQZ"#)W+\/XD_( 6^3O+;,G>7.7O+=.G?\?S %ND3O\
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MIIR@VFE-*3BW%Z:22DG%M:I--,[  _0^#KMV[F2MY!3RO\G"?-U^$O$;*_\
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M'[W%KZ=Q)C,&3/YK%]?36/WN+7T[B3D.GGHC.^9_OP.RZO/3>SOGI?93,^D
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MQBM%&,5HDDN"2X(  _,_4
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M&E%Q;36C3::?--<&G[&7/C)22DFFFDTUQ33XII^#0 !@^@
M :N7RS?V4_&[[KXOH'#&T:-7+Y9O[*?C=]U\7T#AB7NIO^'Y7T-_;TD,]=GH
M[%^F+[&T\R0 6**R@ 'S/D?,^1L9_-L?L5-+_=3KO^LUX]Z3P6\VQ^Q4TO\
M=3KO^LUX]Z2G72WTIM#Z9D_:R+O=#O1.S?H6-]E$  YXZ0
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MIB0><W^4+?A<%C^ .E[ZQ9'4T4&9X@35G[30:;CD<_&:><]OOHOJY>B9<O\
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MOG9+G5%KWN.DVM]Q[,AR 0J3N
M       >3GER=;+@NBMQ?E9*D4V1P-7!1>^:WK&YK+X['6HDYE17+)0GMIRM
M1SE3?9-MU36(IX\>/@-C?YR%DI*_19U,V/EVM:DTC5DYDW_8Y,LQ[N7U.WC;
MV]NR;]AKD$+(=4%6FSK9_'R[/]VJE?\ '^LJ[UU7Z[5HK^)A5O\ /NO?]TY
M!+!$(/TO@MPS?K76>C]&1O?&[5VJ].:726/]O F?S%+%/L(J-?R^YV6W3.>K
M'-C;&KW(K6J?FA]L>38FJ,Z0?!9UYO-7_NE:3;LJ.=_A#\I RFNS51?>W'5W
M(O<U4YG>]13R;0N==%]D?.A39..G%ZQA*2T7M1[-G51LR,>N6F[9?5"6KT6[
M.R,7Q7+@^?<;63"8>KCJ=3'T8(ZM*C6@ITZT+4;%7JU8FP5X(F)V-CBB8R-C
M>Y&M1$[BZ'5/2=BD;>O%\R^:6G!<$@ #!D
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M/XR;'Z/'I(4?X_RD^/T $QA(9W$=G<2H_0 5T[U^([^A?B_&4V]ZE7T?'^(
MJM[D*L?I*2=R%6/T@%0
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ME6'CTXM$=VJF"A%=[TYREISE.6LIOODV^\  \)L
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MVA],R?M9%WNAWHG9OT+&^RB  <\=(
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M.&"*.&&&-D4,,3&QQ111M1D<<<;$1D<<;$1K&-1&M:B(U$1-B0 58+=
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M8OBFB\G1W;5>T,*C+K:TM@G.*_B[5PLK??K"::]:TDN#3.0 :<W0
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M ! %5.Y"K'Z2DG<A5C](!4
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MZ>/2 3HN[Y"='Z/'H(,7=\A.C]'CT $IG>2/^KX])'9WDA/0 5V=YC"^=/\
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MM":U<=,6EZ<FU&RYKUZ.J/BDY+E([@ @DL(
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M*4FY2D^+E*3U;;[VV]67@JJC",80BHPA%1C%+11C%:1BEW))))>  !\'V
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MLB[W0[T3LWZ%C?91  .>.D                                    ,
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M^^K&^?OB791]BJ4.'QG)][  .")#
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M5145%0JG%G<@
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M0
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M[.19'CWPNQBKF:==\_$?2]"!'.S%.!O-^J[%P1-YOJK2@1S,Y5:CTR-*.&[
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M3E*+?%_Q>XEZDN"  .(.]
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MLS\K):_@^.H1]4[Y\]/D537AY7+EI]+  KJ69
M       !P<@ UNGG$' MFC.DSJ2]6K+7H:XQ.&U;"Y&-CAEN30+C,HZ%K?>H
MB6L>CI7(C>>>221R+(]ZKX=&8EYV9PS:RYP6UE&UROL0:OTM<<J-Y6I6?A\O
MC&HNW,KGK8RZJBKLU(DY4[7&':6YZ!YKOV3A3;UDJNR?_LSE2OKW8)__ **8
M]86"L?;6T*TM%*Y7+_WX1N>GJWIR7U>( !UYQH,GWS5GBN[&\9]>:.?(C*^K
M.'WU68CM_P!DR.DLY19!%'ZI%HZDR<R]B(Z.JJ*[F9&UV,$>OOD%-</P72QX
M42=9R096QJ? VF[HG6QY72&>BJL5>5W=DX\?,B(B<SHFLYFHY7)S/3+%[;96
M?7IK^]K+$OQJ5VT?]ZM:>O0ZGH3F^Y]K[.L_^ZJJ?JC>^PD_8HV/7U:HV:8
M*>EUP               :N7RS?V4_&[[KXOH'#&T:-7+Y9O[*?C=]U\7T#AB
M7NIO^'Y7T-_;TD,]=GH[%^F+[&T\R0 6**R@ 'S/D?,^1L9_-L?L5-+_ '4Z
M[_K->/>D\%O-L?L5-+_=3KO^LUX]Z2G72WTIM#Z9D_:R+O=#O1.S?H6-]E$
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M3D/:5\/>,66[CIKA9D<W/CSC0M&FN#LE'1ZURBO[38Y *[%F@
M                         8MOG67UG.'WWQ6_U?RIE)&+;YUE]9SA]]\5
MO]7\J==T#],8'SW]R9Q/6/Z#VC\POM(&"" "W*Y(IG#D  9/H]E_(!?94\._
MXG4/T-9-ER:T;R 7V5/#O^)U#]#639<E;.M[TG5]$K^UN+0]2WHN[Z99]E2
M 142^                           #^ XK_P6U+_(&9^CK)_?G\!Q7_@M
MJ7^0,S]'63]*?/C\J/ZT?G;YDODR_4S3YS_NDG\9)_3<4BK/^Z2?QDG]-Q2+
MR% 8<E[%^H  'T1;W[A-_%2?T%-P!P"_@)HK[DM.?0],T_\ >_<)OXJ3^@IN
M . 7\!-%?<EISZ'ID(]='WO9WR\K]G')\ZC//VG\G$_7DGZT "!2P@
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M-_6V7SQZ8U5PK@M(5PC"*\(PBHQ7U)(  _(_8
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M1G"2UC*$E*+7BI)M->QG( /S/T
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M!(9W@)G=G<5&=Y285$7M *X ,+D  #(
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M-HT:N7RS?V4_&[[KXOH'#$O=3?\ #\KZ&_MZ2&>NST=B_3%]C:>9( +%%90
M#YGR/F?(V,_FV/V*FE_NIUW_ %FO'O2>"WFV/V*FE_NIUW_6:\>])3KI;Z4V
MA],R?M9%WNAWHG9OT+&^RB  <\=(
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M)LN2MG6]Z3J^B5_:W%H>I;T7=],L^RI  (J)?
M    !_ <5_X+:E_D#,_1UD_OS^ XK_P6U+_(&9^CK)^E/GQ^5']:/SM\R7R9
M?J9I\Y_W23^,D_IN*15G_=)/XR3^FXI%Y"@,.2]B_4  #Z(M[]PF_BI/Z"FX
M X!?P$T5]R6G/H>F:?\ O?N$W\5)_04W ' +^ FBON2TY]#TR$>NC[WL[Y>5
M^SCD^=1GG[3^3B?KR3]: ! I80               PX?.T=2.96X)8='KR6;
M6M,HL?6N1%=1@P51']3OR.Y4R2MZU4YH^?D:NTKD7#-0R[_.U+D3M2\"8&O1
M9H<'Q&FDC[=V16;^B60/5=N7:1U6PUNRJJ+$[F1$5O-B(%KNK:&FQ<)_&5[?
M]*N6OY$BG_6D]=NYO'718Z7J_>U/#\NK^L  [HC\'KEY";3"Y/I5<*EV<OU,
MNYG++RL<_;W-@LC#N[E5.1J>Z>UZ[M1=D5.T\C3W5\W&Q:6>E/IA5?R>Y=+Z
MPMILWFYUCQT;.K[TY47K=^;WW[7;;MW3G^E=NYLS/E_]I>OSJY1_XG2=#J>T
MVKLZ/_WF/+GIYED9K^N)L>P<(<E-R[@
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M)*4)1?)QDM4UZTSD 'Y'[
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MG#^,M,:]GP?E+E"IQ9W9=H5+I$O86B)?Q%TA4 N<2_@+C&O86N%>[XRY1+^
M N4:DZ/\Q;HU[O'L+A&O;X]7Y0";&O<3&+VD)G<2T7N )2=WP*5T792@GI\=
MQ510"JU>U4]JE0I[]J+X\(5 "0B@X:O8<@
M
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ME9%>;-\$HRB5(ZPN@\MDW]K2I2P;I>\R?%U3T;=%CYZI)NN3\Z"XMRC(_"0
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M?^J><,%PSH_.P?K4\*_OE3_U3SA@N%HNJST15\[?]I(J;UN^FK/H^/\ LL
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M.&C  ),(J!]2]!FI+8XT\)X86.DEDXA:4:QC>USG?5BJNR)Z^Q3Y:/OKR5>
M^JG22X(TEC61K^(VGK$C$5Z*L-&RMV==X_?MVAK/55141J(KG.:U'*FMVQ/=
MQ,F7Q<>]_DJD_P#@;#9%6_F8<.6]E8\?SKH+U_J-JL "E)?
M   &KE\LW]E/QN^Z^+Z!PQM&C5R^6;^RGXW?=?%] X8E[J;_ (?E?0W]O20S
MUV>CL7Z8OL;3S) !8HK*  ?,^1\SY&QG\VQ^Q4TO]U.N_P"LUX]Z3P6\VQ^Q
M4TO]U.N_ZS7CWI*==+?2FT/IF3]K(N]T.]$[-^A8WV40 #GCI
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M[NNC^^<R*W$UHZL;76"7@[=%9+\7LUS3.0 162\
M                  #%M\ZR^LYP^^^*W^K^5,I(Q;?.LOK.</OOBM_J_E3K
MN@?IC ^>_N3.)ZQ_0>T?F%]I P00 6Y7)%,X<@ #)]'LOY +[*GAW_$ZA^AK
M)LN36C>0"^RIX=_Q.H?H:R;+DK9UO>DZOHE?VMQ:'J6]%W?3+/LJ0 "*B7P
M                          ?P'%?^"VI?Y S/T=9/[\_@.*_\%M2_R!F?
MHZR?I3Y\?E1_6C\[?,E\F7ZF:?.?]TD_C)/Z;BD59_W23^,D_IN*1>0H##DO
M8OU   ^B+>_<)OXJ3^@IN . 7\!-%?<EISZ'IFG_ +W[A-_%2?T%-P!P"_@)
MHK[DM.?0],A'KH^][.^7E?LXY/G49Y^T_DXGZ\D_6@ 0*6$
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MIENL#.JR::\BB:LJM@IPFN3B_P!37*47QBTTTFF<@ \IZP
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M&+W>/856>KU$>-20U-E4 K>A/8I512BWTH5&+V %9BE0HM7M*Q@  &0
M
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M^OIK'[W%KZ=Q)R'3ST1G?,_WX'9=7GIO9WSTOLIF?2 "HQ<X
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M[X^M3@HR?Z2$UW\O$M_U6[05^Q<5:^5CNS'DM=='7-N"YM_>I5O3AIKP6F@
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MCMZ>Z<=2CZYT2U2Y?$LL?-+R3(7 !7,LT
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MVWKL8Z>O6Q'5=!L/M]L;.KX\,JNUZ:<L?W]II]S5?'U:Z<3.Q !3\NL
M          #5R^6;^RGXW?=?%] X8VC1JY?+-_93\;ONOB^@<,2]U-_P_*^A
MO[>DAGKL]'8OTQ?8VGF2 "Q164  ^9\CYGR-C/YMC]BII?[J==_UFO'O2>"W
MFV/V*FE_NIUW_6:\>])3KI;Z4VA],R?M9%WNAWHG9OT+&^RB  <\=(
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M\M+RJV^Z-L?)?<I;DGYNAJMP4*\W6,8].Q'L:]$]7,U';?$B_F*Y;5,INF
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M-9-ER5LZWO2=7T2O[6XM#U+>B[OIEGV5( !%1+X
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MJR=<OE0DXO\ K1?3#R8W4U70\VVN%D?DSBI+EJN3  /.>@
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M3CU,])G"^S9=LO>[5*[&3?FVQ6];6O59!.Q)<$ZY-+6;,E0'"') !8\
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M7CY0"Y1J36.+?&I,8O8 3F+VE=%[OA(K5[E)*+W@$A%[2HG>ORE!J]A6W[E
M*A712@BE5BF&#N #(
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M=I6MVV*]<J]V:7A5)GNR " 2Q@
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MZ23]:::9>*FZ-D(V0DI0G&,X27%2C))QDO4TTUZ@ #\S]
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MW0[T3LWZ%C?91  .>.D
M !_"<4OX,:C_ )"R_P!'V#^[/X3BE_!C4?\ (67^C[!^E/GQ^5']:/SM\R7R
M9?J9IWL=^]X/XF+^@TF$/'?O>#^)B_H-)A>*/?[64"7-^U@ 'T9(M[]PF_BI
M/Z"FWVZ.GUOM"?<;ICZ$HFH)O?N$W\5)_04V^W1T^M]H3[C=,?0E$A/KG^];
M/^<R?V:2>.HW[[M'YO&_:N/V0 $!EB
M             8MOG67UG.'WWQ6_U?RIE)&+;YUE]9SA]]\5O]7\J==T#],8
M'SW]R9Q/6/Z#VC\POM(&"" "W*Y(IG#D  9/H]E_(!?94\._XG4/T-9-ER:T
M;R 7V5/#O^)U#]#639<E;.M[TG5]$K^UN+0]2WHN[Z99]E2  142^
M                    #^ XK_P6U+_(&9^CK)_?G\!Q7_@MJ7^0,S]'63]*
M?/C\J/ZT?G;YDODR_4S3YS_NDG\9)_3<4BK/^Z2?QDG]-Q2+R% 8<E[%^H
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M%]W:>;='V[ZWVNY61+:=5&W%E[*KJD];<)^YYK7CV:\JB6G/3LWN:]\JY'<
M$=DF
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M*#E%\.39M^@4H94>QCTV5'M:Y-N[9R(J;>SM*I2PO4
M                        4GE-4W*ST*0!27N3Y"BO>GR>/E*WH^<I._
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M 544 K-7L.[5[2EZ?8I4 ) .K5[#L87@  #(
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M:\.*?%,NUL+;5.T,2G+H?D6P3<==77-<)UR_&A+6+\=-5P:  -4;<
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MQ(Q:\]I5EZWNEBRLB.S:):TXLMZ]KE/)W=%%-<U3&4HO_62DM-8)G( )>(9
M!PJ[>/0G>OQ?@ U/9'R#_127BGTB])NMU^OP6@E77F9YH^>%7X>6),'!(J.:
MK%DSDM*=CMG(JU%8YNSU4V8!CG>;9]"Z3AWP9LZ_S5/J-3<5[L.7B2:-&V*6
MC<;&^OIJJJJKE:N0?+D<\_E5G/#DZ,%B))J.YD8E5>LC;:S-IV1A+>JQ5[GK
M:Y.46W;)=SUM<HJ7PHQB^6A;KJNV"\'954IQW;LMO)L3YJ,TE3%Z\5I4HR<?
M@RE+OU  .!)&               !JY?+-_93\;ONOB^@<,;1HU<OEF_LI^-W
MW7Q?0.&)>ZF_X?E?0W]O20SUV>CL7Z8OL;3S) !8HK*  ?,^1\SY&QG\VQ^Q
M4TO]U.N_ZS7CWI/!;S;'[%32_P!U.N_ZS7CWI*==+?2FT/IF3]K(N]T.]$[-
M^A8WV40 #GCI                                           ?PG%+
M^#&H_P"0LO\ 1]@_NS^$XI?P8U'_ "%E_H^P?I3Y\?E1_6C\[?,E\F7ZF:=[
M'?O>#^)B_H-)A#QW[W@_B8OZ#287BCW^UE ES?M8 !]&2+>_<)OXJ3^@IM]N
MCI];[0GW&Z8^A*)J";W[A-_%2?T%-OMT=/K?:$^XW3'T)1(3ZY_O6S_G,G]F
MDGCJ-^^[1^;QOVKC]D ! 98@
M      &+;YUE]9SA]]\5O]7\J921BV^=9?6<X???%;_5_*G7= _3&!\]_<F<
M3UC^@]H_,+[2!@@@ MRN2*9PY  &3Z/9?R 7V5/#O^)U#]#639<FM&\@%]E3
MP[_B=0_0UDV7)6SK>])U?1*_M;BT/4MZ+N^F6?94@ $5$O@
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M<6$U)*46I1DDXR33336J::X--<4UP:  ,'T
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MK$<K-7<PS!V !D
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MSQ# [\U2^N_Q$^X*M]-0F>(59ZT/3%WS6/\ 91+;=4OH3'^=R?MY@ $>DE
M             'FIY4'R;NE^DCH"73V32+&ZKPWNB_HC5+8][&%RLD2-DK6.
M79UG"95(XJ^6H.56/:R"Y"C+M*I-%K).,W![4?#[5>?T1JW&RXC4FFLC-C,M
M0F1=XYHMG1S0/5$;/2NUWPW<?;CWAN4;$%J!SHI6.7<#'@_Y;KR2];I :2=J
MK2%2I7XMZ3HJN&F<C8&ZKQ%>22Q/I6_91JJD[DDL3Z?L3HL-?)R>Y9I*U.]9
MMUY2ZN^F[P;%AY,F\.V2W)-\,:R3\[U53;\M<%"7OB^&I1%UF] 5M"MYV)!+
M-IAY<(KCE517".BYW02][>C<X^]/7WO=UQX+EG<%>Q=^YC,G3L8_)8ZU/2OT
M;D3X+=.Y5D=#8K6(9$:^*:&5CF2,<FZ*GJ+:64A+5:KD^33U37<T_!E76FFT
MTTTVFGS37-/UH  ^C!>TU+D4QCL*EZTF(?D(\L[&=<_W$[*159:4>06OOU?N
MME.>6LD^W/U,CHU56[(ED ,**7)):O5Z+35^/M,N3>FK;T6BU?)>"\%ZD  9
M, R9_-8OKZ:Q^]Q:^G<28S!DS^:Q?7TUC][BU].XDY#IYZ(SOF?[\#LNKSTW
ML[YZ7V4S/I !48N<                  ?-/3"Z,^'XQ<--8\-\X[J:>J<-
M9H0W6QMDEQ>21$FQ66@8[9'2XW(Q5K:1JJ-F;$ZO(O52O1=43Q?X49W0>JM0
M:+U/46CJ#2^6N87*UE;(UJ6J<JQK- LK8WR5+<75W*4RL:D]2>"=J(V1#<&&
M'?YS9Y.B:Y7H=(/26/ZR3'10X3B56JQ?LBXY'(S":J5C=N=E"5SL5F)$1\B5
M[.-MJC:U*[*V5^JSI*L;)>%;)*G+DG6V]%#(2TBO_>BE#Y:KTTXD.];W19Y6
M)'/IBW?AI]I&*XSQF]9/AQ]Y;=G#E!V/CHC"_ W!9$K"   ?J7!#C9J7AQJ[
M :YTAD'XO4>FLA'D,9;:BN9UC4=%/6LQ;M]T4KU:2:G=K*K6SU9Y8G*G-N;.
M7R9WE&-+=([A_5U-B'0X[4N.;#2UGI5T[9+>!S'5HKG1HO+)/B,ALZSB;_(C
M9H>:"7DMU[,,>K(/J7H;],;6_ O7&/UWH:\E>_5VK9''6>=^+S^)?(Q]G$9:
M!CFK)6FY4=%*Q6V*=AK+%=Z.:Y'\'TXZ'0VI0I0W89=2?8V/@I1U;=-C^+)O
M6+?F2XKA*:??= .FT]D9#C8Y3PKY+MZUQ<)<$KZU\>*6DTFM^'!IN,'';5@\
MZ/)T>4NX?]([2K<QIFTW':DQT,#-4Z-O2L3+X*V]B<TC&^]^J&(GD1WN'*UV
MK!,U.JF2O;9+6C]%RKN;A6X]LZ;ZY56UO2<)K1I_\4UQ36J:::;33+;X.?3D
MU0OQ[(VU6+>A.#3BUR?+DT]5)/C%III--  'E/6                   #C
M< Y                 !PIX\>6YZ [>/'!?)5\75;+KG1#YM5:+F:G[+-8K
MUW,S&#54V=)7SN,:^%(=^7ZIUL5;5LCJ;(G>Q!POL/=LW:%F)D59-+W;*9QG
M%]STYQ?C&2UC)=\6UWG@VGLZK+Q[L:Y;U5]<JYKD])+@T^Z47I*+[I)/N--D
M^-['.9(Q\<C'.8^.1JLDCD8JM?'(QR(YDC'(K7L<B.:Y%:J(J;'4R'_.%O)O
M2\*.)4W$O3&/2/A]Q)NS798JL2,K:<UE*CILMCECCC;'!1S3T?F,8B*K&6),
MC2:D,4%1K\=]O<7$V)M>K.QJ<FEZPM@GIKJX27"=<OQH2UB_'35<&FZ1[<V/
M;@9=V)<M)TS:4N2LASA9'7G&<=)+PY/BF<@ VQJ@>C'DR?*+:CZ-_$.OJC'1
MSY32^4]SX_6^F8Y$8F8PS9=_=%/G<V&/-XOK);.*EE5L4CUEHSR106WSP^<X
M/)G8-63391=!656Q<)QDN#3_ *TT^,6FG%I---)GKP,^[%NKR*)NNZJ2G":[
MFO4^#36L91?"46TTTVC;[\#..&E^)&E,-K31N6KYK3N>IQW,?=KN1?>O3]DK
MV(OV]:Y5DYH+=29&S5YV/BD:CFGZR:S+R3'E;=2]&S4;Z=R.YJ'ACG+"2:CT
MQ%(Q;%&R[D9]7]/=<]D4.2CC:B6J;WQ5<G$B-D?#99'.FQLX"\?=(<3M*XK6
MFA\Y2U!IS,P==3OTY$=RN:JLGJ6X5VEIWZ<S7U[M*RR.Q5L1OBFC:YJH54Z8
M=#[]E7/5.S%G)]A?IP??V=FG"-D5S7!22<H\-4K?="NFV/M>A:.->77%=OC\
MFN2=E>O&53>FC6K@VHSXZ-_L(&X.-.W                     !XD^6>\K
M!CNCOHYV&T[9IW.+.J:$K=,XV3DL-P-*1SZTFJ\K4W7_  >L]LS<17L(D.2R
M,#F*V:M4N1+_ &7E6?*ZZ/Z-^ 6E#[GU)Q,S%=Z:>TE#8CVI-?$_J\[J1[7]
M90PL+T:D<36NO92=S*]2-L"6[U/7"\;>-.I>(NK,[K?6&2DR^I=1W77LI?E1
M&<\G(R&&""-OO8*=.M%#3I5F;,KU8(H6=C-UE/J_Z!RS9PR\J#CAP>L(R7')
MDGRTY]BM/+E\+S(_"<8BZQ^L..!">%AS4LZ:W9S7%8D)+SM>*=[3\B'P//G\
M&,_S[,9FYDKEO(Y&W8OY'(6K%Z_>N3/L6[MVW*Z>U;MSRJZ2:Q8GD?+-+(YS
MI'O5SEW4MP!9.,4N"[N'U>'U%7/6^+[WW@ 'T ?>WDS>AC>X\\9=)Z"ABE^H
MJV4S>L;C-N7'Z2Q,D4N4D<Y6N1)K[GU\/1:K7(Z[D8%>WJ62O9\$[*JHC6JY
MRJB-:U%<YSE79K6-:BN<YRJC6M:BN<Y41$W4V/WD&?)TR<#^%$6<U)CTJ\1.
M(D5/-:ABE8B6L-B>1TN!TY,[;F98IUIW6\E#V)!E+=BMLY:W6R<7TZZ2K9N#
M.46O=%VM6.M>*E)>5;IX51\KPWW"+\X[CJ_Z+/:F?"$D_<U#C=DR[G",O)IU
M^-=);NG/<4Y+C$]O,%A*>-HT\;CZ\=6A0JP4J=6).6*O5JQ-@KP1M[=F11,8
MQJ*JKLU-U52[! 5+;UX^)<=+3@EHEP27<  #(               -7+Y9O[*
M?C=]U\7T#AC:-&KE\LW]E/QN^Z^+Z!PQ+W4W_#\KZ&_MZ2&>NST=B_3%]C:>
M9( +%%90 #YGR/F?(V,_FV/V*FE_NIUW_6:\>])X+>;8_8J:7^ZG7?\ 6:\>
M])3KI;Z4VA],R?M9%WNAWHG9OT+&^RB  <\=(
M                   #^$XI?P8U'_(67^C[!_=G\)Q2_@QJ/^0LO]'V#]*?
M/C\J/ZT?G;YDODR_4S3O8[][P?Q,7]!I,(>._>\'\3%_0:3"\4>_VLH$N;]K
M  /HR1;W[A-_%2?T%-OMT=/K?:$^XW3'T)1-03>_<)OXJ3^@IM]NCI];[0GW
M&Z8^A*)"?7/]ZV?\YD_LTD\=1OWW:/S>-^U<?L@ (#+$
M                           Q;?.LOK.</OOBM_J_E3*2,6WSK+ZSG#[[
MXK?ZOY4Z[H'Z8P/GO[DSB>L?T'M'YA?:0,$$ %N5R13.'(  R?1[+^0"^RIX
M=_Q.H?H:R;+DUHWD OLJ>'?\3J'Z&LFRY*V=;WI.KZ)7]K<6AZEO1=WTRS[*
MD  BHE\                           '\!Q7_ (+:E_D#,_1UD_OS^ XK
M_P %M2_R!F?HZR?I3Y\?E1_6C\[?,E\F7ZF:?.?]TD_C)/Z;BD59_P!TD_C)
M/Z;BD7D* PY+V+]0  /HBWOW";^*D_H*;@#@%_ 317W):<^AZ9I_[W[A-_%2
M?T%-P!P"_@)HK[DM.?0],A'KH^][.^7E?LXY/G49Y^T_DXGZ\D_6@ 0*6$
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M6L1LF@L02,F@GAD:CXY898U<R2-[%1S'L<K7-5%151=R80&6+3
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MQWH*AA   R
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MG%Z2A.+A*+\'&233]J)GQ\FNV$;*IPLKDM8SKE&<)+QC*+::]C.0 ?D?L
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MLYP^^^*W^K^5,I(Q;?.LOK.</OOBM_J_E3KN@?IC ^>_N3.)ZQ_0>T?F%]I
MP00 6Y7)%,X<@ #)]'LOY +[*GAW_$ZA^AK)LN36C>0"^RIX=_Q.H?H:R;+D
MK9UO>DZOHE?VMQ:'J6]%W?3+/LJ0 "*B7P
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MUW4^9W_5GL669M?&\G6K%?NJU]R[+C4N6FLKG7HN#T4FN,3(A0Y.$.2J)<$
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MNQA@K@X13D)_E  !D
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M\1/N"K?34)GB%6>M#TQ=\UC_ &42VW5+Z$Q_G<G[>8 !'I)0
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M;FV1TMO2X03T;IIUXJM->5+12L:3DDE&,0 .&)
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M_D#[M>T_Y/A?FW_YQLLOUP/T3_MG?_3&J_\ @P_7 _1/^V=_],:K_P"#&M-
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MT%-OMT=/K?:$^XW3'T)1(3ZY_O6S_G,G]FDGCJ-^^[1^;QOVKC]D ! 98@
M                                        &+;YUE]9SA]]\5O]7\J9
M21BV^=9?6<X???%;_5_*G7= _3&!\]_<F<3UC^@]H_,+[2!@@@ MRN2*9PY
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M%5QCJE)R+>]7'1']RL).U:9>3NV9&NC<-%[W3JOP:;WM-=;)2T;2B  <(2$
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M)HJOKXUW5PLA\F<5):^M:Z/P::*,[0PK,:^['M6EE%LZI_*A)K5>I\UZFF
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ML1SLUQA@K  )@  R
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ML>G&+7?&24EWI$$Y^SK\2QTY--E%L><+(N+T\5KPE%]THMQ?<SN #VGB
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M?GF!Y%[[%S@M]QE'_:3'I^4MV]_#LSZ5D?:R+T]'_P" 87T7'^R@  :DVX
M             /X3BE_!C4?\A9?Z/L']V?PG%+^#&H_Y"R_T?8/TI\^/RH_K
M1^=OF2^3+]3-.]COWO!_$Q?T&DPAX[][P?Q,7]!I,+Q1[_:R@2YOVL  ^C)%
MO?N$W\5)_04V^W1T^M]H3[C=,?0E$U!-[]PF_BI/Z"FWVZ.GUOM"?<;ICZ$H
MD)]<_P!ZV?\ .9/[-)/'4;]]VC\WC?M7'[( " RQ
M                       ,6WSK+ZSG#[[XK?ZOY4RDC%M\ZR^LYP^^^*W^
MK^5.NZ!^F,#Y[^Y,XGK']![1^87VD#!! !;E<D4SAR  ,GT>R_D OLJ>'?\
M$ZA^AK)LN36C>0"^RIX=_P 3J'Z&LFRY*V=;WI.KZ)7]K<6AZEO1=WTRS[*D
M  BHE\                           '\!Q7_@MJ7^0,S]'63^_/X#BO\
MP6U+_(&9^CK)^E/GQ^5']:/SM\R7R9?J9I\Y_P!TD_C)/Z;BD59_W23^,D_I
MN*1>0H##DO8OU   ^B+>_<)OXJ3^@IN . 7\!-%?<EISZ'IFG_O?N$W\5)_0
M4W ' +^ FBON2TY]#TR$>NC[WL[Y>5^SCD^=1GG[3^3B?KR3]: ! I80
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MAL]QS,U1LS=-:Z^$J\77P?%3NTX.:\F'%0U\]D.0"*R70
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M_ 1T[?Q?D*C7>A>\ KHNW8IW*2+Z%.R+MV+\0!6:_8JD<[-=L8:!6 W!G4
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M#_6-Q-_YP'ZW:Z(GVL<A_K&XF_\ . ^Z_LW\%G?H<?\ ZD?<3VI_*<'\^_\
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M?H_R-:HU?_@/;/%?N=E<'IYGZFGHUZUJC'^!D",\V<Z4"N:BU>'S6JYJ*_\
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M=&XG+LU$V1-UUANNR)Z5*OZW:Z(GVL<A_K&XF_\ .!8[[K^S./O.=S_!8_\
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MM-23.KCH-E;'GERR;:+.WC5&'8RL>G9N;>]OUPY[ZTTUY,O@ (R)4
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M[6.0_P!8W$W_ )P'W7]F_@L[]#C_ /4F?N)[4_E.#^??_P!.:U>ZJ]3-V?\
MHI/3_P"XIN N 7\!-%?<EISZ'IGE%)YNOT0W-<UW#'(*CD5JI_=&XG=J*FR]
MVL?4>SVG<!5Q6/HXNC&L-+&TZM"G$LDDJQ5:<#*]>-99GR2R*R&-C5DE>^1Z
MIS/>YRJJQUU@],L7:L<2./"^/82N<^VA7'7M%4H[NY;9KIN/773NTU[I.ZM^
M@^5L=YCR;:+/="H4.Q<WIV3MUWM^NOGVBTTUY/4O( (T)2
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M.S3V]G.>G_#O,=\&0%^MGNE#_P!CX??Z92?\%"^;/=*'_L?#[_3*3_@I^O\
MXUV3_+\;](C\O_ >V/\ 1V3^C_\ V8_H,CK ^:_=(>P]K;V6X?8YBOB17IF;
M]S9CEVD?RQ8V-5ZI-W<J=LFVS=E/H727FH7$&9T:YOBQI"C&NRRLQF$S%^9G
MK1JV9:43U1.[WR(OQ;GX6]/=CPYYU3^0K+/V(2/WHZN]M6+6.S[E\MU5_P!5
MED7_ %&)_N-S.!T%YISH"%6+JKB[K?)ILWK8].8?3VGW(NS>9L<V5AU2FV_,
MC7K6153E56(J*B^C'!WS>;HLZ16O-/H>]K&[77?W9K74&4S#)T]5C#UIL=IN
M5/\ ]"HOHWV[#0Y?6OLJM/LY7WON5=+C^5W.K1?4_8S?X?4]MBQKM%C8\>]V
M7*;7%=U*LUX:M<5R:;CJC6]Z?P5_+VF4<30NY6[)V,IXVI8OVG*J[(C:]2.6
M9=UV3L9\_8>I_1V\A_TF.)+Z\F/X<V],8F=6[Y[7=N#2^/B8]B/9,E*?W1J*
MY"]JIRRXW!76;]CG,5.S9$\+>COH+1%:&GH_1NF=,UJZ<L,6$PF/QR1-VY>5
MCJU>-[4V[-D=MMOZU/V/8XS:77'=+6.+B5UKDIWS=DO;N0[.*??HY36OBCN=
MF=2-$='F9MMO+6%$(TQ]:<Y]K)KNU2@]/!\5B:]%CS6#1F)=6R'%S6^0U?9:
MC7RX'3$+\!@VR<J*L,N0F?8R]YD4J<O6L^IS;$>_-5B54Y<DCH]]%+AOPHQ:
MX;AUHO3VD:,G(MKZCXZ"O;R$D:<K)\KD5:[(Y6RUFS&V,C:LS-8UL;7I&UK4
M^@P1IM?I-G9S_?6399'GV>NY4N_A5!1AJO'=U]9*>Q>BFS]GK]Z8M54N^W3?
MN?<];9[UFC\-[3P1UY3L :(Z$                  X5#S5Z6GDB^ 7&:2S
M?U9H/&U-0VD59=5:;8FG]02RKMM-=N8YL4>5E3E:U),K!=D;&WJHWLC5S5]*
MP>K#SKL>:LHMLIFOAUSE"7CIK%K5>I\#R9N!1DP=6135?6^<+81LCX:Z236O
MK7$PB^D]YJMJFC[JO\(>(&,SL#=Y(-/:VA?B,@J(JN=#7SV,@M49I.7:.LRW
MC:4;G(GNF_&USI&>"/';R8?2!X:K*NL.$^K*-:%51V2QU2'4>)5$7L<S*:<G
MRM'96[.Y73,E:U?V2-BHY&[6'8X5J*BHJ;HO8J>A47O14]/QDC;+ZV-I4)1O
M5.7%:<;(]G;HN[?KTC[7*N3?CSUC+:W4[LN]N6.[L.3U>E<E95J_&NU2DDNY
M0L@DN"7+3393L=%*^&5KHIHU5LD,C5CEC<G8K9(GHU['(O8K7-1R+WH==_9X
M\>K<VUG&#H1<(-?Q+%K/AKHO42;.VDR.G\;+88YR.19(K+8&6(IDYG*R:.1L
MK'+S->B]IY8<6?-K^B_J59'XS#ZNT//*O,Z;2.K;:M1_,JJZ*EJFOJC&P(J*
MC.K@HQPHUJ*R)KU>]_=8/7!A3T5^/D4-]\-RZ"]KUKGI[(-D>[0ZD\^&KQ\K
M&O2UT4U.B;Y:<-+8:\^<TN"\=%KHP9L6M_--=*OYW::XRZFI_P#Y*'/Z:P^5
M5>U.R2UC;6#1NR<R\S:3MUV3E1-U/D[4GFHG$N%7KB>*>BKS$7]C9=Q.;HS/
M;S(B<RQ>ZXFNY5553FVW[&JITM'61L:?_G%#U3IOC_\ QZ?UZ>LYB_JOVY6]
M/<6_SXUW8\EP]MJ?'N6FOJ,4X&1EFO-@ND5 [:GDN'U]NSEYESEVI[Y%7E;M
M)C)%]^B(N_\ B[[*B['\<GFS_2A_['P^_P!,G_\ !38+IMLEK7W?C?7/1_D:
M3_J-;_X#VSJU^YV5P_$U7U--I_4S'^!D KYL]TH?^Q\/O],G_P#!3^PTYYL'
MTB[3V)D,CP^Q;7<G,[ZNW;_5\SMG;MAQD2NY&^^][^V_:ILHETVV2EK[OQM%
MX3U?Y%JW]2"Z![9U2_<[)X_B)+ZVVDOK:,<XXW,MS0GFG>L)I&+J?B_IVA"O
M(LB8+3F1R4[&KMSHGN^[C(W.;[Y$]\UJJB>^1%7;T"X1>:P<#\1+7LZNUAQ#
MUI+$J==19=Q.F,):[E<DL&*QDF>CWVV3J-20JC7+^V<C7MU&7UF[(K\W)E:T
MO-JIM;?J3G&$/RR7M-QB=5.V[6M<:%"UXRNOJ27KTKE9+D]?-[M# B9[Y[(V
MHKGR.1D;&HKGO>Y=FL8Q$5SW*O8C6HJJO8G;V'I)T7?)%=(3B]+6?I;AWE,?
MAYW*C]3ZM5-+Z?KQHO*Z99\BUN0OHUZM:L.%QN4MHCTD]S=2U\K-B7P \FOP
M(X7I&NB>%^E,3:C:C$R<U!,MF7M1$Y4FS.8??RD_+WM6:V]6N<]R*CGN5?MY
M&(B(B=B(FR(G8FR=R;=R)[$.&VKUQ2:<</$2YZ69,M7[>RJ:2?>M;9+7FFCO
MMD=2,4U+/S'+DW5BQW5KWKMK$Y-/EPJ@].37=C!=";S9#AMH]:F8XNY9_$K-
MQ\LKL'69/B=&UY457(Q]=LB9+,,9NC7K=G@KV%C:]U&-CWP&2_I726*P6.IX
MC"8S'X?$X^%E:AC,73KT,?2KQIRQP5*=2.*O7A8FR,CAC8QJ=B(?T((GVOM[
M+SY[^5?.UIZQBWI7#Y%<=(1^J*;[]28]C='<+9\.SP\>NE/SI16MD]/PEDM9
MS_G2:7):(  U!N@
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M^<GQ/ +O&_Q[/R$ICO'CU%KC?M\!,8_Y%\?-^  N;'$ECO06UCB2QP!<&O\
M65T[?A]!":[UE9K@"4UWH7O*J.]"D;?YBJUWH7O *Z+MV>CT*=RBB^A>X[;[
M>U "LCMBJBD=%.R+L8:!7!U1Z'8)^(  ,@
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M                                       '&QR  #C8Y
M                                !QL-CD     XV.0 <;(-CD
M                                         XV.0 <;'(
M
M
M
M
M       .-CD       '&QR
M<;#8Y
M                  !2>GI.A7<FY0,)@I;=BIZBDY.PKN[%W*:F04'>OY2,
MY/02U3T>ON^$CO0 A/;Z"'(GI0N+T])$>WYP"W.;X\>H@2-]!=7H0I6^/'K
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M[;L4J P2-P4$4J(_UF =P -0  9
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MX1/0=N]=O0@!4:FR'=B=IU*K$[##8.X "0  ,@
M
M
M
M
M
M
M
M
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M%'??O^4Y3L^  K([8J(\H(]#L8T!(W!013LCP"J#JCD.QD  #4
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MFQ"H8  !D
M
M
M
M
M
M
M
M
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M;(=T3<X*C$](9@J
M
M
M
M
M
M
M
M
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M+9/'CN+.R0E,D]0!=6O]16:_XBV,D^+QX[B0U_S^/C +DU_K*S7EM:_8K-D
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MN+UPJY)^7-?^9:?#<B_O//>DNT6BC!RE,;Z?1X[2=#'Z3I%'NJ>K\9<&,]!
M98L[L9\A<(F>/:4HV=WCXRXQ1@%2-A.C9^<IL;^8G1L\>L J1,\>PGQM])28
MST?*36-]'J[_ !X[0"I&WQ\Y,8TIL82V-]/R %1C?026IZ#HUNQ(8WYP#NU-
MOB*K4^<Z(WM^ K-3< [)V)OZ5[CNU-CJG:OL0J '*)N5SHQ#N8  !D
M
M
M
M
M
M
M
M
M                                                     &&"D]#H
M5U3<H*$_Z@4O8OQ'14]!5<AU7M[?E,@C[>CTIW>TH/3TDIR>E.]"FY-TW^4
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MA58GI^0 [(FQ4]&WI4-3TKW'9J>GU@'9$V.S4W."LU-D#!V
M
M
M
M
M
M
M
M
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M#JQ/22$[/A ")OV>@JHGH.$38J=WPK\P!SW]GH0J'#4V.R)N =F(53A$V.3
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MH_6HJE_[WU&XPNN[-BU[HP\:Y=_92LID_9O.Y?[IN3!N:S?HE^73Z0W"F:I
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M7#7D9\_ZZ9X&?Y*\0/YOQO\ Q ?KIG@9_DKQ _F_&_\ $# 8!U_W*=D?$O\
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MV=ET"ZQ-I;0VG3BY,J75.%TI;E*A+6%<I1\K>?>D9=( (,)^
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MM5PL=&0__+WZ0E)^%<TW79ZE&6_IQ<$CU=!QN<G%'=@
M
M
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MHUKZNXRGHTUP:>J:X--<FGW-/BO7Q,T;R1'G#WU3L8KAIT@<E!#=E;%C]/\
M$ZQU=>O=G3DBJT-9*U(X*UJ=/V.+4+6LKV)D;]5&Q2S/NNS!8)V2L9)&YLD<
MC6OCD8Y'L>QZ(YKV.:JM<US516N151R*BIV&FQ<U%394147?=%[45%[TV[OB
M[C+U\@=Y:2;&6L/P*XLY9TN,N2PXWAYJW)6.9^/M2O2.KI/,6YE5SZEF1S8L
M%>GDWK2JW&3O6.2HL<%=/NKN,8SS=GU[NZG._&@N&[SE93%<E'G*M<--7#33
M=+ =776;*4J]G[2LU<FH8^5-K5M\(U7R>FK?*%CXMZ1FVWO&:\#A%.2#2P
M       !BK^=?_6GX6_?,E_JCGS!7-@+YRYP UQQ#X:<.,=H72F;U9?H<09;
M]VG@Z,MZ>K2_4QFJWNJ9D:>\A]T3Q0\[NQ9)&M[U,-S^]F=(;[3/$'^8+/Y"
MRW5GM+'JV35"R^FN7:WO=G;7"6CL>G"4D^/=P*M]:^S<FW;%DZL:^V'84+>K
MILG'51>JWHQ:U7>CX=!]Q?WLSI#?:9X@_P P6?R#^]F=(;[3/$'^8+/Y#O\
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M[?\  ?#H/N+^]F=(;[3/$'^8+/Y!_>S.D-]IGB#_ #!9_(/W:P_Y5C_IZ?\
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M]#9'R\?[:!)/5-Z<QOFLG[&1ET@ JP6X
M  /*SRVWV+/&/[EW_P"^536!&S]\MM]BSQC^Y=_^^536!%BNIW^ Y/TI_95%
M9NNWTAB?1']M,'"]RG)PO<I+KY,A=\F9NGFFG\"^,OW6:9^AKIENF)%YII_
MOC+]UFF?H:Z9;I4OK"],9ORJOL*BX_5IZ#V?\W9]O:  <8=T         >*'
MG$7V(7%+_/>&_P#XIZ*-:XG>OQ&RC\XB^Q"XI?Y[PW_\4]%&M<3O7XBQ_4_Z
M-N^G6_V?%*P==OI3%^@P^WR#L<;>/'L_+Z]^02PT0ZT9!_D//+"VN!N>9P_U
M_E)Y^$>H;;%BGM/DF;H'+SO1KLK3<JN?!I^]NBYNBQ'5ZTS&9>LRN]V36]L,
M\9DZUVM7N4YX;52W!%9JV:\C)H+%>=C989X)8U='+#+&YLD<C'*U['-<U514
M4TWAE:>0,\LR_1EK#\#.*.2__!"[*RAH/4UZPNVE[L\B^Y]-Y&67?EP-V5_4
MXJ=\C8\/86*ER)0GC6G#'6/T%[93VAAP]^BM<FF*^^QBN-T$OXV*\^*7OB\I
M>6GOSAU7=8/8.&S,V?O,GNXMTG]YE)Z*B;?\5)OWN3?O;>YYC3AG.@ZM=OVI
MVHNRHJ=RHOCY#L5_+(@      ^._*$?6-XL_<#J;Z+L'V(?'?E"/K&\6?N!U
M-]%V#V[-_A&/\]5^W$\.T_X-D?,6_9R-3=!^T9_W6_@0JE*#]HS_ +K?P(52
M[90Q<D#,4\TL_?G'+^)T%_2U08=9F*>:6?OSCE_$Z"_I:H.%ZR?0N9_[']HJ
M)!ZKO3F%_M']EN,SP %42X        *<TK8V.>]S6,8U7O>]R-:QK4W<YSE[
M&M:B*JJO8B)NO8 0,QF:>.J6;^0M5J-&G!+:N7;D\56I4K0,62>Q9L3N9#!!
M#&UTDLTKVQQL:KGN1J;F$AY6SSB+(ZC=D^'?1^REK$8'GFHYKB351]7+YEC'
M+'-7TB][6SXK&S;.:N=1D63L1;28Q]%KVV7_ (;Y=?RRMSBGE\APDX;9*2MP
MSPUA]34.7IS<LFO,I7D1)(FR1HBLTQCY6.CKPL>YN8G1]NSO695A3&BV)]Z!
M]7,80KS<^"E9+2=.-/S:USC.Z+7E6/G&M^3#X:<^$*Z=8?6;.<[,#9L]VJ+<
M,C*B_*L:X2KHDO-K7%2L7&;X0:AY4Y%RY-9FFLV)I;-FQ+)/8L6)'SSSS2.5
MTDT\TJNEEED<JN?(]RO<Y5557<H $U):$%?K?-@ X5=OSF0<@_N.'_"[5&K9
M75]*:9U%JBPQW(^'3F#RF<E8_EY^61F+J6UC5&>_<CT3E9[]VS>T^R]+>2CZ
M2>99')C^"VN7ME7E9[IQT&-7?E1_OFY.U3=&G*O:LK6-3M3?F143PY&T\>G[
M]?35\[;77^W)'NQ=F9-^G8XV1;KR=5-EB\.<(L\_ >D6:\CYTG\>SGM<%-9-
M;R22;P,Q5U>2--W^]I9.P[F1.YFW.[_$:Y>P^3.)'1CXE:.CDFU9P]UMIRM%
MSJ^YF=+YJACT2-$YU^J,])E!S6;HKW-LN:Q%17*WF3?XQ]KXMKTJR:+7W*NZ
MJ;?U1FS[R=CYE";NQ,FI+BW91;!+AKSE%(_$ 4HI6O3=KFN1>Y6JCD^5.PJF
MP3-<#[-\GOT4]2<9N+VC]#:8M7L59LY&/)934..EDKV],X#&R1SY;.0685;+
M!:KP[5\<YCD5^2LTXW*V-[WL^,'+LFZJB(G>J^A$-@;YN!T!).&_"Z7B?J.D
MD.KN*+(+M"*:/ELX?1,"JN%K/W55CGS;UDSEAO8K*D^-@D9'8@L-7D>FW2*.
MSL"RU:.Z?O5$7H];)I^4UQUC7'>F]5H]%%^<M>QZ"=&Y;4VC52U)45/MLF:X
M;M<&M(J7=*V6D(Z<4G*2\QF1GB,8RE5JU&269F5*\%9DMRS-<M2M@B;$V2U;
ML/DL6K#T:CI[,\DDT\BNEE>Y[G.6Y %1V]2YR6G!=P !@R
M
M
M
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M.-G[426/<H7:>5C7:0O7CI'5JQ+XU<II=^G(^PFR+\7CXBJU_J7;QZBV-?\
M$54D\(<J=<79LNWL]OH7\1(;-Z_E_,6ALA6;(GP>/D +PR7U*5VR^/069)%^
M'QX])69-[?B4 O+92NV7PA9FS?%X]G<5FR>W< O+9BLDWK+,DI4;+X0 O"2%
M5)/;X^,LZ2^TJME +LDAV20M:3>TJ)-[?GW +DDOM.R2_ 6U)O'Z#NDR %QZ
MSX#MUJ^%+<DJ'/6?" 7'K?A..M7PI!ZSVK\XZSV_A&J]?Y 3NM4YZWX2!UGM
M_".L]OX1JO7^30$[K5]ORG7K" LB!94 )JR_ =5E]I"69#JLP!-60Z]805F\
M;E-9O: 3UD]I360@+*4NM]H!<%F*+IO'>073>WY_Q%)90":Z7PI0=+X]!$=+
MZ^PHNE3X?F_#^( F.E\)^4HK(OP$)9_T)WE!9/B^'QN 3'3>I/E(SIE7V_@0
MC+)[=_G*+I?: 27O]I0=(1U?ZBBY_P H!660HN>?A''_ *3&A.%^'=G=>ZFQ
M>F\?LY:Z7IVI<OO;_P"BQU!G-<ORJNS-JT,C6.<U)',YD4Q7NFKYQ?J'+.MX
M'@IB6Z=QJJZ)VM<] VSG[;-WL63#X=W^!8=CDV?':R'N^\YKDY:F.F9SNZ38
M/1/.VE+3&I?9ZZ2OLUA3'3GY;3WFOBUJ<_Q=.)S'2+IA@;+CKE7)6::QQZ_+
MOG[*T_)3^/-PA^-J9+G2QZ<W#+@MBOJGK_4M;'3S-<N-P51%OZBS$C=DZO'8
M>MS67L1SV-ENV$KXZKSL=<N0,<U78?'3U\NAQ%XII=T]HAUSASHF?F@E;C[C
MV:JS55=VNCR69JNC?0K3-5634,4^/KXMXK-J:&22!WBWK77&:U)D[.:U#E<C
MG,O<<K[62RMR:[=G7=51KIYWO>D;5<O5Q-5L4:+RQL:FR)_,(3WT8ZM</!<;
M;OWUDKCO612JKEW=G4]=6NZ=F\]=)14'P*Z]*NM3.VAOTX^N%BO@XPD^WLCR
M:LN6FB??"O=33W9.:YO2JKVJJJJJO:KE7O5RKVJJ^E5W5?2 "22,
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M4^"WW,6/IS+&L"-G[Y$3[%/@M]S%CZ<RQ$/7'_ <7Z6OL;2:>I'^'Y?T3_\
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M@?LFKWWJ=7_3VC386E8NM?TL_H]/Z["UO4]Z&C])R/UQ  (T)3
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MQ&X;?RGQ%_\ $G5A[=E-^E/I/:/T[+^WL+Q]%O1FSOH.)]A6  :$WP
M/*#RX?V+/%[[GXOI*D>KYY0>7#^Q9XO?<_%])4C;]'_X?A?2L?[6!IND7H_.
M^B9/V,S6&IW(<G"=R')=!<D477)'*=Z&;-YIA_!+C3]TND?HC*F$RG>AFS>:
M8?P2XT_=+I'Z(RI'_6AZ&R/EX_VT"2>J;TYC?-9/V,C+I !5@MP
M                     >5GEMOL6>,?W+O_ -\JFL"-G[Y;;[%GC']R[_\
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M%1DX+A5#1-\(1U;X\9RDUHFD@ .3.R
M
M
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M'^^!#]#Y R@3%^\ZF^LQH?[X$/T/D#K.@OI? ^?7[,CC>L+T)M+Z-+]<3 P
M!;PIB#9^^1$^Q3X+?<Q8^G,L:P(V?OD1/L4^"WW,6/IS+$0]<?\  <7Z6OL;
M2:>I'^'Y?T3_ /FK/5, %=2RX   //'RK_%2KHWHZ\6\U:LMK+^H[)XVHJJU
M'3W\Q&F,I58^9KFK)9GM-B9S;)N[M5.]/N[5.J\9@\=<S&:R-'$8G'5Y+>0R
M>2M04:%&K$G-+8MW++XZ]>&-.U\DLC&M]*H8"WE[?*]XWC7>H<,>&UQUGAOI
MS(+DLQG&))$S6.H($=%3]R-=R.=@,.Q\\M=96?\ E+(31W>K8S'TWR==T+Z/
M79^=2HPEV-5D++[-/(A"#4G%O33>GINQCS;>NFZFUQ?3KI-1L[ O<YQ[>ZJ=
M>/5KY<YSBX*2BN.Y7KO2EP2TW==YQ3QM8V\K6M]2(GR)L=P"W13-#<V%'FR/
M!2SIGHYS:ANPK%-Q!UOGM14U>Q62KAL=#C]+44<UR(Y8Y;>#R5ZN]?>RU[L<
MK-XWM<[!/Z,'1XSO%GB#I3AUIN)\N6U5E8J$;F-YDITV,?:RF3EW[&U\7C(+
M=^=SO>I'77?O-L'P.X08G0&C=,:(P,748?2N#QN"QS$394K8ZK'68]VW>^3D
M6215W57O<JJJJJK#G6_MB,,:G"B_?+[%=->%->JCKX;]C\GYN1-G4ML25F7?
MGR7O>/6Z*WXW6[KEI\BKSE_K8GZJ "O190         &#!YV!]<[A/\ <)F?
MZP(9SY@P>=@?7.X3_<)F?ZP(=_U8^F,?Y&1]A81SUK^@LOY6-_::C%-3N0Y.
M$[D.2U)41<D4;'[F_P#[COZ*FVSZ$/UG.%OW Z4^A*9J3+'[F_\ [COZ*FVS
MZ$/UG.%OW Z4^A*9"G7-]YP?G;OV*R=>HW[_ +1^:Q_VK3ZC ! 18P
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MAZMQZ6?5V4IM^.B\"1.JW:KQ=L8\6](92GC3XO36:4J^')OM802\%)Z<S/U
M!58MX               >07E[/L2>,7\GZ8_KUI<UEALT_+V?8D\8OY/TQ_7
MK2YK+"R'4]Z-O^G6?V?&*N]=?I;'_P#3JO[3E@ $KODR('R9G&^:=?6XXM?=
M[C?ZMTC+#,3SS3KZW'%K[O<;_5ND9894CI]Z8SOG(?95ER^KGT)L[YF7VM@
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M/_2W;/6VI>W]TF<B=B;'[:4\Z4[>GM'-NR)-[FNY3#NA3%M07M?GS\9RD^7
MNST1Z.U[+P:<6*6^EOWS7\9?-)V2]B?DP7=",5Q>K8 '.G3
M           &*WYU]]:3A=]\]W]3]1F"F9UGG7WUI.%WWSW?U/U&8*9:+JL]
M$5?.W_:2*F=;OIJWYC'_ &&#A?1X]"G)PI(DN1&+Y&R6\W4^Q&X;?RGQ%_\
M$G5A[=GB)YNI]B-PV_E3B+_XDZL/;LIOTI])[1^G9?V]A>/HKZ,V=]!Q/L*P
M #0F^      !Y0>7#^Q9XO?<_%])4CU?/)_RXB[=%CB]]S\7TE2-OT?_ (?A
M?2L?[6!IND?H_.^B9/V,S6')W(<G"=QR707)%%UR1RG>AFS>:8?P2XT_=+I'
MZ(RIA,IWH9LWFF'\$N-/W2Z1^B,J1_UH>ALCY>/]M DGJF].8WS63]C(RZ0
M58+<                              'E9Y;;[%GC']R[_P#?*IK C9^^
M6V^Q9XQ_<N__ 'RJ:P(L5U._P')^E/[*HK-UV^D,3Z(_MI@X7N4Y.%[E)=?)
MD+ODS-T\TT_@7QE^ZS3/T-=,MTQ(O--/X%\9?NLTS]#73+=*E]87IC-^55]A
M47'ZM/0>S_F[/M[0 #C#N@        #Q0\XB^Q"XI?Y[PW_\4]%&M<3O7XC9
M1^<1?8A<4O\ />&__BGHHUKB=Z_$6/ZG_1MWTZW^SXI6#KM]*8OT&'V^0=@
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M26L*V]-=*8RW=.6]OR7G,  XL[H
M
M
M
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MPARDA 1_9OLNWK]!RC_::TV9<$D3QN=^L3U_/^4M_.ISS@%PY_4J_,=N=?\
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MTI)/P(MVQTMVEGZK+R[;(-Z]DFJZ?5[U6HUO3N<HMKQ.J-1.S;L.P!T!SN@
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M?I)4<149$3(XO'CN .D<7C\A-9'L=V1^/426,_. =6,^7\!+9'X_(=F1DQC
M#JQA+9'Z0R,EM9\OCY_8 <,9X\?-ZR2UH:STJ26M]( :TD-;Z0UGK*[6[]H
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M*X1BN27>]67#V1LC'P<>O%QJU756M$N;DWQE.;YRG)ZN4GQ;]6B  ->;(
M      &#!YV!]<[A/]PF9_K AG/F#!YV!]<[A/\ <)F?ZP(=_P!6/IC'^1D?
M86$<]:_H++^5C?VFHQ34[D.3A.Y#DM25$7)%&Q^YO_[COZ*FVSZ$/UG.%OW
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M[;'K^/.4OZM="]^R,-8^+C416BIHJJ7/X%<8]^KXZ:\7JWQ?$  \!L0
M    ?R.O=$T-28+-Z<R<:RXS/XG)87(Q(NRR4<K3FHVXT7MV5]>>1J+LO?Z3
M^N!F,FFFGHTTTUW-<4SYE%---:IIIKQ3X-&G+U3I&]I[*Y33^3:C,G@<ED,'
MDF)S(C<AB+DV/NM1KMG-1MFO*B-<B.3N<B+NA8S[;\I9IZ/%](?C=4BVY%XG
MZQN)RHK41V4S-G*R)LJKMM+=>B]J)ONK41JHU/B0N[@W]K35;P7:55V:+EY<
M5+AK[2A>=C]C??2M?>KK:^.FOD3<>.G#N[N /1?R0_$9=*])[@AE6N5GNC7N
M,TXY4[4<W6<-G1W(Y%5J*CESR)V[\KN5[4<YK4/.@^A^A]F'8[B]PFR#.97X
M_BAP]O,1KN1RNJ:OPUAJ,>G:QW-&B->G:U514[6GX[6I5F+DUOBK,>ZMKQ4Z
MY1?]3/VV1<Z\S$L3T=>31-/P<;8-/ZM-4;<D %)R^               !Y!>
M7L^Q)XQ?R?IC^O6ES66&S3\O9]B3QB_D_3']>M+FLL+(=3WHV_Z=9_9\8J[U
MU^EL?_TZK^TY8 !*[Y,B!\F9QOFG7UN.+7W>XW^K=(RPS$\\TZ^MQQ:^[W&_
MU;I&6&5(Z?>F,[YR'V59<OJY]";.^9E]K8  <>=L               ?S>LO
M^A\K_)M[_=933B8K]ZUOXB'_ &;3<=ZR_P"A\K_)M[_=933B8K]ZUOXB'_9M
M)WZEO-VE[</]640!UY\MF?[9_P#C$\ $XE?C]SZ/'27UYPFU _5?#G4EO2FH
MI,;:P[\I2K8VW,[&79JEBU46+*TLA5Y)IJ-21SO<_6M= SDD:BN1WW#_ '[_
M *6'VZ]0?S)HK_E@\JP:W*V-AWRW[\3&NGHEOVT563T7);TX-Z+N6NB-KA[=
MS<>'9X^9DT5ZN6Y5?;7#>?-[L)):O3B].)ZJ?W[_ *6'VZ]0?S)HK_E@?W[_
M *6'VZ]0?S)HK_E@\JP>;_PULW_1^%_1*/\ +/7_ .+-J?Z1SOZ5?_C/53^_
M?]+#[=>H/YDT5_RP/[]_TL/MUZ@_F317_+!Y5@?^&MF_Z/POZ)1_EC_Q9M3_
M $CG?TJ__&>JG]^_Z6'VZ]0?S)HK_E@?W[_I8?;KU!_,FBO^6#RK _\ #6S?
M]'X7]$H_RQ_XLVI_I'._I5_^,RYO(0^4RX\<5.D!3TEQ"XDY;5&G)-':HR3\
M5<QNFZL+KU%<:E2PLN+PM"US0=?+RL]T=6[G57L<J-VS:C76^;0_914?N UG
M^'#FQ2*[]:&'31M-0HJKIA[FJEN55QKAJY6:O=@DM7HM7IJ]"S'55G7Y&RE9
MD767V>Z+H[]LY63W5N:+>DV]%KP6O   CHD@      'X#TK-<+IKAAQ$U V1
M(I,/HG5&1@D7N;9JX6[+5]"_MK#8VIV*FZ[KV'[\>=_E9\C)4Z-?&FQ"K4D9
MH/,HU7-1R;21LC=NU>Q=VN<B>I>U.X]NS*>TR<>ONLOJA^=9&/\ Q/!M6_LL
M7)M_!T76?F5RE_P-5Q7WY&?]U%^5-_'C:N=(TV:U/4B?@.Y=I(H;'DO8@>R?
MD!^#\>K^E-P^6>)LU72<.<UI/$]G,U7X;'/JXZ55W3D6KF,GC;<;_??LU>-N
MWOMT\;#)7\ULQ4,O'K5%M[=YZO#N_' [?;E9:R^,ZY-O3S=1%ZMN7VG-=,LA
MU;*SYQX/W-9%/P[2/9ZKU^7P?=S.IZ$XT;MK[.A):Q]U5R:\>SUL7<^&L%JN
M37!\&9_*  IZ78                           ,5OSK[ZTG"[[Y[OZGZC
M,%,SK/.OOK2<+OOGN_J?J,P4RT759Z(J^=O^TD5,ZW?35OS&/^PP "1B,CU4
MZ+_EG./'![1.*X?:&S>"I:9PLV4GH5KNGJU^RR3,96[F;RR6I)F/D1]^_9>Q
M%:B1L<V--T;N?0'ZXWZ4W^4NE_\ 1*G_ &@\*P:"[HMLVR<[+,'&G.<I3G.5
M4'*4I-N4FVN+;;;?>SHZ.E^U*X0KKS\J%=<8PA"-LE&,(I1C%+7@DDDEX'NI
M^N-^E-_E+I?_ $2I_P!H'ZXWZ4W^4NE_]$J?]H/"L'Y_^$-E_P"C\7]##_D?
MK_XUVO\ Z1R_TTO^9[J?KC?I3?Y2Z7_T2I_V@?KC?I3?Y2Z7_P!$J?\ :#PK
M _\ "&R_]'XOZ&'_ "'_ (UVO_I'+_32_P"9[J?KC?I3?Y2Z7_T2I_V@?KC?
MI3?Y2Z7_ -$J?]H/"L#_ ,(;+_T?B_H8?\A_XUVO_I'+_32_YGNI^N-^E-_E
M+I?_ $2I_P!H/QGI">6[Z07%#1V;T)J[/8"UIW4-9M3)P5--U:5B2!LL<R-B
MLLF<Z)>LC8O,C5[$V/)$'W5T5V;"49PP<:,X24HR5,$XRB]4T].#36J/SMZ8
M;4LA*$\_*E"<7&47;)J49+22:UY-/1@ '0'-G*=Z&;-YIA_!+C3]TND?HC*F
M$RG>AFS>:8?P2XT_=+I'Z(RI'W6AZ&R/EX_VT"2.J;TYC?-9/V,C+I !5@MP
M                              >5GEMOL6>,?W+O_P!\JFL"-G[Y;;[%
MGC']R[_]\JFL"+%=3O\  <GZ4_LJBLW7;Z0Q/HC^VF#A>Y3DX7N4EU\F0N^3
M,W3S33^!?&7[K-,_0UTRW3$B\TT_@7QE^ZS3/T-=,MTJ7UA>F,WY57V%1<?J
MT]![/^;L^WM  .,.Z         /%#SB+[$+BE_GO#?\ \4]%&M<3O7XC91^<
M1?8A<4O\]X;_ /BGHHUKB=Z_$6/ZG_1MWTZW^SXI6#KM]*8OT&'V^0=@ 2R0
M\;!_S8/[&^RO_P#L'4_^SQJ'\UY=GR-[.+>)N<5N&N+A;Q0PE-),UB:S6PNU
MWAZ4*HL3$8SEFU/1KQM9C'RJQV1KQMQLDR.93V_IO-@OL;K'WP=3_P"SQID7
M.*I[;VS?@;>S,G'ENSAE6:I^;9!R\JN:U6L)<FM4UP::DDU;W8.Q,?:/1W!Q
M<F&]7/#JT:TWJYJ/DV5OX,XOD_:FG%M/3;V:TL$LL$\<D,\$LD$\$T;XIH)H
M7K'+#-%(C7Q2Q2-=')&]$>Q[7,<B.14*)FG^7Z\C$_*LRG'?A-B5=E(89+O$
M;26-@<Z3*0PM8Z75N&JQ(O\ AU2NR1^>IQ-5;M>-N0KL]UQ6TMX5S7(J(J=J
M*B+\OCPA8SHUTBHVGC1OI>C\VVIO65-G?"7BGSA+324>/!ZQ59.D_1K(V5E2
MQKTVN,J;DM(75:\)Q\&O-G#G"7!ZIQE+L?3?0^Z6NK^"&OL/Q"T5;ZC)XQ7U
M[E*621M#.X>RYBW\)E8XU1)Z5M(XY&\[7K5NP5+\+4LU87-^9 ;K(QX6PG79
M!3KG&4)PDM5*,EI)/U-<#1X^1.JR%M4G"RN49USCPE"<6G&2?BFE_P 3; ]
M_IR:,Z0/#_':ZT?8Y>?:GG\%9?%]5=-9R)C76\3DX8WO1KF\R3T[+56"_1E@
MN5W.CE3;[/-53Y.GRA6L.CIKVIJO3LDMW"7'P5-7Z5=*C:>H\,DF\D:<Z*RM
ME::*Z?%9!J-?#.WJ9E?3GLQ/V;W1HZ2.DN+6B\)KS1&4BRN SE9)896*B3U+
M+/>7,9D(-^>KD<?81]:Y6D1'1RL7;FC<Q[JL=..AL]EW;]:E/#N;[&;XNM\^
MQL>GG):[DOAQ6JXJ25N.@'3FO:]&Y8XPS:8KMJUP4XKAVU:Y[C>BFOXN;T\U
MP<OW@^._*$?6-XL_<#J;Z+L'V(?'?E"/K&\6?N!U-]%V#D=F_P (Q_GJOVXG
M:;3_ (-D?,6_9R-3=!^T9_W6_@0JE*#]HS_NM_ A5+ME#%R0,Q3S2S]^<<OX
MG07]+5!AUF8IYI9^_..7\3H+^EJ@X7K)]"YG_L?VBHD'JN].87^T?V6XS/
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M]B$H I07N0
M
M
M                                                    *+F[%8&&
M".4U3;M0K.;L=3(**IZ4[OP%-S=RLJ;=J=QU5OI0 C[;_"4G-)*MW*;OG_"
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M+FLL-FGY>S[$GC%_)^F/Z]:7-9860ZGO1M_TZS^SXQ5WKK]+8_\ Z=5_:<L
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MTUTY]N//_P"CF-_M(^Z?L?\ E$OT-W^6/N4;<_DU?](I_P 1Y2^;0_914?N
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M3TBLNJ+?#@K'V;;UX)+?U?J7#CP-G<BG(!3LNT
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ML'7;Z4Q?H,/M\@[  EDAXV$'FP7V-UC[X.I_]GC3(P,<_P V"^QNL??!U/\
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M*H[GJY"G6O5G]GOZ]N%D\+NQ53WT<C5[%5/4I>"D[6G#P+WIZ\5R8 !@R
M
M
M
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MBW+PKL>;KOIMIL7.%M<JY?DFDSN #TGF
M                  .'+LFZ]B)WKV?CV/WS@CT6.)'$FVRGH/1&HM42O_\
M2XW'O2A&F_+SV,K:6MBZL2.['36KD,+%_;2)Z/QOR*ZHN=LX5P7.<Y*$5[92
M:2^MG[8^/9=-5U5SML?*%<)3F_9&*;?U(_!#HZ1$VW[-U1$]JJNR(B=ZJJ]B
M(G:J]R*9-W1B\VRUGE?<]_BOJJAI6J[E?)I_3*QYO-(U6H[JK65>C</5E:[=
MDC*292-6KS17$7L,BWHO>2^X)<(UKVM*Z(QEC/5TW;JG4$;,_J)CU39[ZE[(
M,E;BE<BJUWU)AHJZ->KE61%4CO;76CLW&UC3*698NZG15:^NZ7DM>NN-B)*V
M'U2;4R])7J&#4^^[RKM/%41XKV6SJ9A<=%+R-W''BLM6W7TXNCM/6.1_ZH-9
M-GQ4*P/3F2:IC.J=EKJ.:K71\E6-DC7MD;(L?OS)IZ(?D N$/#Y*V3UFZ?BA
MJ2+E>Z7-5F4=,U94_P"P:;AFL)(C'>^;-EK^2EYT22%M;=8T]X&Q^CN39$3X
M$[$3;U)Z$]!51B?"0_MWK'VEF[T(V>Y:7K[WCZQDUX2M^^/AP:BX1EWQ)KZ/
M]6&R\!QFZGEWK3WW)TG%/QA2DJH\>3<93C\?QM6)P]6C6AITJM>E4KL2.O5J
M015JT$:?M8X:\+611,1.YD;&M3U%T2/XR2V)?@^#O)3(40X)O7B^9(J\.XB-
MB5?'C\!+9"B$AL979$8!0:SV$ID7CTE9D7CTDMD(!09$2F1%=D97;'\8!39'
M^DD-C*K(_'H);(P"BR+V$IC-BHUGJ0E,C]GC\8!3;%Z_D)#8_'Y#NUGC\I):
MP ZM:5V,_2=FL^)"0UGQ '5K/45T38Y:WU(5FL .&L*NWR^HYV]7?Z_4=VMV
M #6_*5$3TKW!$]*G9$W[?0 $3?X$[BH#LUNX!PB;E9$V")L<F&@  9
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MGW\^8 !^1^H      ,&#SL#ZYW"?[A,S_6!#.?,&#SL#ZYW"?[A,S_6!#O\
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MTWD1EUI=*(X.SYT0E^^<V,J813\J%4EI=:US2W6X1?QY)KS7I\!HAR 6C*F
MR??-9^!;\QQ@UAKV:-5J:-TB[%U7NC58URFIKD+7*R3;9)Z]#&S)R[[]5==O
MWH8P*KMW]QL</-VNBM+PZZ.^&SF2J.JYWB=;EUO<9(U6S,PUG_!M*,?VKNVQ
M@HJ^6C[&N8W*]2]$=&I'O69M58^RKH)Z3R91QX>R7E6</#LXRBWW.4>]HD?J
MJV4\K;%,VM88D9Y,WH]$XK<J6O+5V34DN]0EP>C/>$ %62W(
M  !Y!>7L^Q)XQ?R?IC^O6ES66&S3\O9]B3QB_D_3']>M+FLL+(=3WHV_Z=9_
M9\8J[UU^EL?_ -.J_M.6  2N^3(@?)F<;YIU];CBU]WN-_JW2,L,Q//-.OK<
M<6ON]QO]6Z1EAE2.GWIC.^<A]E67+ZN?0FSOF9?:V  ''G;
M  '\WK+_ *'RO\FWO]UE-.)BOWK6_B(?]FTW'>LO^A\K_)M[_=933B8K]ZUO
MXB'_ &;2=^I;S=I>W#_5E$ =>?+9G^V?_C$\ $XE?C(C\V!^R:O?>IU?]/:-
M-A::]+S8'[)J]]ZG5_T]HTV%I6+K7]+/Z/3^NPM;U/>AH_2<C]<0 "-"4P
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M>DT-J8%5Z:[:"563#OC=%:2>GQ;/OD'\66C\J,DNP .6.N
M          ,5OSK[ZTG"[[Y[OZGZC,%,SK/.OOK2<+OOGN_J?J,P4RT759Z(
MJ^=O^TD5,ZW?35OS&/\ L,'"^CQZ%.3A?1X]"DB3Y$8ODS9+>;J?8C<-OY3X
MB_\ B3JP]NSQ$\W4^Q&X;?RGQ%_\2=6'MV4WZ4^D]H_3LO[>PO'T6]&;.^@X
MGV%8 !H3?       \H/+A_8L\7ON?B^DJ1ZOGE!Y</[%GB]]S\7TE2-OT?\
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M"2(
M
M
M                                                "FYOI0J QR!'
M.JM^4K.;Z4*9G4%)>WV*=%3UE9S=SI[%^)09*"IM\'J.BH2%38IJWTH#!%<T
MI*W<F;?$OJ*3F $%S/E([V%P5/0I2<SXT +:Z/QZ/S$=T?CQ^+XRYN81W,]7
MCX "V/B(SF%V<SQX_"1W,]?C\2@%I?%X]'QD5T9>'1^HCK& 6=T9'=&7=T7Z
M/R$9T0!:7P^PBNB+RZ/]"E!T8!97Q>/21W1_&7I\)%?$ 6=T7Q>Q>XCNA^%/
M@[OF_(7ET106, LSHUV3TH45B^7QZ_Q%X='\7P%!T'Q_,OCY "RV*C)8Y(I8
MV2Q2-5DL4C6OCD8[L<R2-R*U[7)V.:Y%:J=BHIYP]([R2W 7B>Z6SGM"TL9E
MI4=_Y=TM(_3F51[D7:61^/1E.XL>ZK''D:=RNBJKEA7<],'1?#[$7Q^,I*SU
MH>O#VA?CS4Z+K:9KX54Y0?L;BUJO%/@SQYNSZ,F#KR*:KZW\"VN-D?;I)-)K
MN:XKN,/_ (]^;+9:JDUKACQ&ARD:<SH<-K2@RE>V_P 6),WB$]PV9%[.:27$
M8R-.U49W(>*G'CR7_'CARZ=^H.'.=LT(%=OE].P+J/&.8Q-W3++B4L6((&I^
MVFN5:T:+_C;;*;*CJD_-^DIJSX_'PD@[+ZU=ITZ*[LLJ"_"15=FGJG5NK7US
MA-^.K(VVOU/[*R-94=MAS?'WF;G7KZZ[=_1>J$H)=VBX&I@9,URJB.:JHJM<
MB*FZ.:NSD<G>BHJ*BHJ(J*BHJ;H5#9_\;.ACPHXC<S];\/=*:BLN[/JC=Q%:
M/+(BHC=FYBJROE4:B(FS4N<J<J>]W0\D^,OFY?!//=?/I?(ZIT39DYGQQT[T
M>6QS9%1>5ON3*1S2,@3LYHXK#9.SWLJ*I(6S^M_ LT611?CR[VMVZM?SH[D_
M_B(WVEU+;0JU>-D8^3%<E+>HL?\ -EVD/RV_U\\&P&1UQ?\ -J.*^,5\VB]9
MZ-U; WF=[FRJ9#2N3<G9R1PHL.:QD\BKOS/L9''1[)S)LJ]6GF;Q-\E'TBM(
M)._,<)]2R5ZZ.=)<PGU/U+22-O=)[IT_=R4;6JB;HDBL>FZ(]C7;M3M\'I=L
MS)T[+.QFWRC.Q53_ #+=R?\ N^'B<#G]#-K8K]^V?E)=\JZW?!:>,Z>T@OKD
MM>.G)GGN#^AU/I#+X23J<UB<IAY=^5(\KC[F.>JIZ$;<AA55[%[$W[C^=1R*
MFZ*BIZT7L.AC)-)III\FGJG[&CG)Q<7NR3BUS36C7U/B<@ ^CYU &X
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M]9SA;]P.E/H2F0IUS?><'YV[]BLG7J-^_P"T?FL?]JT^HP 0$6,
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M2=D-7X0G."BWX;^XO6B.<3KKV=.W<MQ\JFMO17-5S2X\YPA)R2\=SM'ZC8_
M^-^@UTY]"=(#0];7&AKDJP),M#-86^UD.9TYF8XXY9\5E:S'R-;(D<D<U6U"
M^6I?J216JLSV.5&?9!%N3C64V3JMA*NRN3C.$EI*,ES33_[:XK@2]BY5=U<+
M:IQLJLBIPG%ZQE%\4T_^VN3X@ 'X'[@
M
M
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MORG*(5-MN_Y #AK=SGO39#E$W^#T;'=$ ")L<A$*S6[?"&P=6L]94 ,   R
M                           8OWG4WUF-#_? A^A\@90)B_>=3?68T/\
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M\^Y*OP</S5_R/KW5;^%L_23_ .9^D_W9]9_Y8:K_ -(\S_;1_=GUG_EAJO\
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M=J55I2E3FN-%U<8N3U>O96I+5ZU2;<M$_>W9PUT:V0 .$4Y*KEO@
M#%;\Z^^M)PN^^>[^I^HS!3,ZSSK[ZTG"[[Y[OZGZC,%,M%U6>B*OG;_M)%3.
MMWTU;\QC_L,'"^CQZ%.3A?1X]"DB3Y$8ODS9+>;J?8C<-OY3XB_^).K#V[/$
M3S=3[$;AM_*?$7_Q)U8>W93?I3Z3VC].R_M["\?1;T9L[Z#B?85@ &A-\
M   #R@\N']BSQ>^Y^+Z2I'J^>4'EP_L6>+WW/Q?25(V_1_\ A^%]*Q_M8&FZ
M1>C\[Z)D_8S-8:G<AR<)W(<ET%R11=<D<IWH9LWFF'\$N-/W2Z1^B,J83*=Z
M&;-YIA_!+C3]TND?HC*D?]:'H;(^7C_;0))ZIO3F-\UD_8R,ND %6"W
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MMN%.4U5KKY*G7"<HQ?+3>UEHN3E)OF  1(3*
M
M
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MB1>Q"?U7L^<[I#[/FW ("1J5$A\?H)Z1>PJ)![ " D7A$*B1>%+@D)42- "
MV%2LV$FI'["HD?Z$ (C82JD9*;%["LD0!$2,JMB\*3&Q>$*K8@"(V(D,B\>@
MDMC]GC\!6;& 1FQE=L?L)#6>S?Q\JE9&>/S?E ([8T\>-BNV,K)'ZBLD8!1:
MWV?!X[BJC"NV/XBJUGL *36?(5FL]151A41 "FUFQ51NY41GQE1$3T_(@!T:
MS])43V=OM]!V1-_8GJ.Z)Z@#JC?2O>=T3<[<J)W_ "'/?\ !U^ J(TY1-CD
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MO"U&105Z\+610Q1L1&LCC:UK6HB(B(74 CMO7B^9):6G!+1+@DNX  P9
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MD=7/07*V/;ESR+*+%?"J,>QE-M.N4V][?A#GO+334_J@ 1D2L
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MN:)BZ.]"MG;,XXU"=NFCR+7VES7>E)K2"??&N,(OO3.$0Y .7.L
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MDWP)^Z)[)LP-G8N);*$K**W"4JVW!MSE+R7)1>FC7-(  T)T(
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M:S@_GC,_VT?W@OHK?:S@_GC,_P!M'W8=G?@,O\RK_.'W%-I_RC"_/N_R#6?
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ME?AN-.13;)1G;O.-=L9M+6E+5J/#5I:GJ@#A%.2OI8\            '&QR
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M=&UKR;+&;%PY8V'B8\VG.C&HIFXZN+E77&$G%M)Z-IZ:I/3N0 !K#9@
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MGH^6A+W1SH+LW9FDL>C>NTXY%S5EW+1[LM%&O5-IJJ,$TVGKJ=>5#L <J=@
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M&,=7NPC&.KTU8 &A.B
M
M
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M^KO]8!PC?7V'*+Z$.R-]9VV .J,.X*B,]?R '5K=RJB;'(,   R
M
M
M
M
M
M
M
M
M
M                                                          <*
MAR##!25GJ.A(.%3<>W\H*!35GJ*ZL.AG4%)5]:'"M]7:550Z*W;N *2HBG79
M4]J>TJJOK0<OJ[0"/LGP*=',]:$A4.O+ZOD (JL*:M]9,5/6FWX#JK?C (75
ME-S/6A-5GQ'3D4 @JSU%-8_83^5/4=%8 6]8RFYGK0N"L]AT5@!;5C\=_P"'
M\IPL?J)ZQ^PZ+'\0!;UC]GC\!26-/5L7%8_5^0Z]7[/Q@%M6+U>/P'58U+BK
M/9X^,Z=7ZO'R %N6/V%-8_B+GU?C])PL:^I/'P %LZOQL=5A0N2Q^S\'XSKU
M2 %M6'Q^DZ]2OC8N2Q)XW.JQ[>/S %NZI?"'7JO&Q<NJ]OX#GJ_@\?& 6WJ_
M:.K]I<NI7Q^D=2H!;>K]HZOVEQZE3GJ5\?I +9U2>$.W5+X0N/5?!X^,=5X[
M "W]2OC8Y2$GI&=NI\=H! ZD[=5XV)_5)X_.ISU2>K\'YP""C$.Z1^SQ\9.2
M-?5X^9#GJ_'9^( B)&OZ#MU7K4F)'X_2=DC3U>/B_* 1$B3U>/C*C8_'C8EH
MSV>/C.R1@$=(_B.R1DE(_"%1(_8 149ZO'RE3JR3U941GJ0 C-C^,J(SUDA&
M'=&H 1T8GJW*W(54;ZD.Z,]8!11J%5&*5>7X/F0[=GPJ 4T9\94VV[_D.W*O
MP? =T38 Z(F_L.R-1"HC?D.>ST)NH!U1OR';L3VG/*J]_8=T:B '3E5>_L.Z
M)L<G9&[@'4[M:=T:B'8QJ#A$V.0#(
M
M
M
M
M
M
M
M
M
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MLB;')V1J@'4[(W<J(W8[&-0=4:AV &GB  #(
M
M
M
M
M
M
M
M
M
M
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M R
M
M
M
M
M
M
M
M
M
M                                                =58AV!A(%-6>
MHZ*BE<!OZP1P5U1%.JL#8*'*GJ..3XBLK%.JM5#.H*>R^LZ]OJ^8J@ I=GJV
M\>T;)ZRJ<*U/4 4E;[4'*I4Y4..3U*#)3V7U'"IZT*G*OK.=G :%#E3U#D3U
M%?M]2'7M_P"JGCY0-"ER)ZCCD0JJO_N_/^8;IZOG T*?+[5^4<OM7Y2HNWM.
M.SV^/B!@Z<OM7Y1R^U?E._9[3E-O4H!3Y$'(GJ*FZ>KYSC?_ -WYU_(!H=.1
M/4.1/45=U_ZOCY$.45?5\P!31OJ3YCG9?45/?? <;+ZP9T.G*OJ.>7X/E._)
M[3GD0&#ILGK'9[5._*GJ.=@"G\"?,ISLOK\?(5  =.3VG/*GJ.Z)N=D8H!T!
M4ZOVG9&H8U!21J^H[(PJ@<?^_P#M?\0=.1#ML<@R
M
M
M
M
M
M
M
M
M
M
M                                              #C8XY4]1V !TY$
M..K*@,+4%'E4XV7U%<&01P2#C8 H K\J>HXY$]1C7_O_ /P%$%7D0<B#7_O1
M@I'&R>HK<B''5^T:_P#>C!2V3U#8J]7[3GD&O_>C!2!5Y$'(@U_[T8*0*W(G
MJ'*GJ&H*(*^WL.0"ALOJ.>5?45@9!2Y#GD*@,/4'7D0YV3U'("  !D
M
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MN6LX16B<HKGKQ/N( '/G2@
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MA5.Z=M:UH483A#=C8]-^3<TTX*4-$_+UT3]F@ <L=8
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M$56EJE9RL;U6G9J4.?E<-'[T  Y0[
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M>U<?-ICD8MJNIDY*,XJ23<6XR6DE%\&FN1R #PFP
M
M
M
M
M
M
M
M             !B_>=3?68T/]\"'Z'R!E F+]YU-]9C0_P!\"'Z'R!UG07TO
M@?/K]F1QO6%Z$VE]&E^N)@8&Q#\V6^Q@I?=WK+_>:AKO#8A^;+?8P4ON[UE_
MO-0FKK<]%P^ET_9WD%=3'IBSZ#=]MCF0: "M):<
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M4[ZN?36S_GG]E,V H *AES@                                 <'(
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M7]!,S9EN1E9FY"=M2IKIA)3:CO1G*<Y1\E/6,5%1<N<FVN!4 !$Q,@
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M1],7_-T?91)3ZIO0F/\ .9'VTP "/"20
M
M
M
M
M
M
M
M     8OWG4WUF-#_ 'P(?H?(&4"8OWG4WUF-#_? A^A\@=9T%]+X'SZ_9D<;
MUA>A-I?1I?KB8&!L0_-EOL8*7W=ZR_WFH:[PV(?FRWV,%+[N]9?[S4)JZW/1
M</I=/V=Y!74QZ8L^@W?;8YD&@ K26G !AY>6J\L5QQX)\<K>A= Y; U-/1:3
MTWEV09' 0Y&RES)?5!+3O=+K$3EC=[FB5C%;[Q>;9RHJ(FZV!L&_:-_N?'<%
M9N2L]\DXQW8M)\4I/7REPT-%TAZ0X^S,?W5D[_9*<:_>X[TMZ>NG!M<.''B9
MAH-<?'YQ_P!*17,:N?TE[Y[&_P $J_\ C.1O_;$]9EH=/SRRVANCWI#3:Y>.
M35G$K4VGZ&3QFCL5)%"L;9Z,4LF8U#<<KHL)AG67]57;RV,ED)7*S'49J]>_
M<H[S:?5_M'%LQZ7"%UN2[%5"F3D_>U%S<W*,%"*4DW)O=23;:T-!LKK'V9EU
M9-RLLIJQ%6[9WPW%[ZY1@H)2E*<FX-**6K;22>I[/]H-91TG_+F](_B9;MJF
MO,CH3"SO<L&!T!-+IU*L6[DC:[.U7-U%/*UB\KY6Y*".14ZQ*[%VV\XLAT@=
M?W)GV;>O=;V[$J\TEBUJ[4-BQ*[_ *TDTV2?)([VN<Y?:=9A=3N5.*=^733)
MK7<A"=VGJ<M:UKX[N\O!LX[-Z[L*,FL?#OOBGIOSG"E2]<8Z6RT\-Y1?BD^!
MM]$W.34_<)_*.<?-$3PSZ:XP\0Z;:_+U5*[J;)9W$MY6HQ&_4;/S93%*WD:U
MFRTOVC6IV(QJMR,.@;YT#D:]RG@.D!AX;&-E>R#]7NE:,C+6/148Q+&;T[$Z
M5UNJS;K;%C#(Z\WF>Z'&6=FQ&LVMU5;0QX.RB5>7%<7"M2A=HO"N2TE\F$Y3
M;U2B^&NTV-UP[,R9JN^-N%*324[=V5.K[G9!ZPX_"G",$M&Y+5Z9J(/YG1FL
ML3J+$X_.X+)4LQALM4AO8S*8ZS%;HWZ=AB206:MF%SXI8I&*BM<QRIWHNRHJ
M)_3$8RBTVFFFGHT^#37--=S1+$9)I----)IIZII\FFN:?<P #!D \_?*E=(+
M4O"S@1Q U[I">M6U%I['5;.-FN56W:S)9<E3K/ZVJ]S&RM6*9[=E<FRJCD7=
M$,(Y/.0.E+_Z_P!)?Z)5_P"V'8='NA&9M.F=V,Z5"%CK?:3E&6\HQEP2A+AI
M)<3BNDO3W!V5="C*5V_96K8]E6IK=<I0XO>CQUB^[P-CF#%O\B%Y7;7?%6/C
M1F>-^IM-4=-<.\%I',1Y1F.@P53&PY2QJEF2GNSI-+UK7,Q51L,>W/UB*R)L
MDDK6GP'T^?.<]4YFY?P' 3'MTW@HGRUF:WS]&&UJ#)HU7L]W8G#3++2Q%654
M;+2=DX[EY\'*^Y1IRROJU_WIZOMHV9EN'"$'*CL^VNWFJ*^TKC9%.;BFY;LE
MY$8RES>FBU/PR.LC9=6%3FSLFHY"L=%&XGD6=G.5<M*U+2,=Z+6_.48<EO:O
M0SBNTY-2CQ*Z<7&?65F2UJ?BQQ$S#Y7K(L$VK\Y!CHWJK55U;$4[E;%4^98V
M.5M2E U7,:JINUNW\7I[I-\3,/.EK$<2.(.*M(J?X3C-;:GH6/>[[)UU3*12
M=F[NSF7O=V=J[]E#J9OW=7G5*6GFJF<HZ^"DYQ>GKW$_4</+KQQ][R=GW.&O
MG.ZM2T^0H27U;_/AJ;>)#DUK_1@\X"Z1W#JS69D]4IQ'PD2M;+A];1,N6G0I
M^V;!J"LR',,E>J)^S7)\BJ=J(Q.95,U+R;?E:N&W21QDD6"DET]K;&UUGSFA
MLO/"N3KP,<R-V2Q=B/EBS.'5\D;?=M=D<U=\C(K]2I*YC9.+Z1= L_9T7;9&
M-U"YW4MRC'7EVD7&,X>&\X[FO#>;TU[CHQUB[.VI)55RG1D/E1D)0E+3GV<D
MY0L[WNJ6_HM7!)/3U. !Q1W@   !^7\7^-.D] 8*YJ;6NHL3IC 4&(^UE,S=
MAI58]W-:R-KI7(Z::5[FQQ00-EGFD<V.*-SW(U<6WI=>=.Z9QLMO%<%M&V]4
M21N?%'JS5G787#2KRJB3XW",1<S:AW5'QR93ZD2*YCF/I.C<V0WFQNC>;M!M
M8N/.Q1>DK.$*HOPE9-J&NG'=3<M.2.?VYTIP-FQ3S,F%4I+6-?&=LTN^-4%*
M;CW;VBBGP;3,N(X-8[QK\NATH-;R3I-Q,NZ8I3)LN.T52IZ>AC3==EBO11SY
MMCD1=E<W*IOMS<J.WW^!=2=*7BAFI>NS/$WB+EYN97];E=<ZIR,B.5J-54?;
MRLSFKRM:WWJHG*UK4]ZB(DB8G4[ER2=V7CU-_!A&RW3VM]DO;IJO61EE=>&%
M%M48>3:NZ4Y5TI\=-=$[6EIQXI/Q2-NXJ^/'C\)R:AC!=)7B3B9TLXKB-Q Q
M=E%;M9QNM=34+"*UR.9M-5RD,B<KD1S??>]<B*FR]IZ.='/R[W27X>3UFNUY
M9UOB8.1K\1KN)F=66)JMYT3-.2+/-F>QO*DT^1MM:N[^J5RN5S,ZGLN";HRJ
M+I+X,X3I;]2>MD=?E.*\6C.%UW84I)7XF13%ZZSA*%RCRT;7O<M/'1-KAHGJ
M;,L'B1Y,3RWO#SI#/BTO=@70_$QE=9G:7R%EDM#.LA8UUBQI7*N2-,@L6ZR3
M8JS'7RT$39)F06JD,MMOMN1=M+9>1AVRHR:I56QXN,N]/E*+6L91>G"46T_'
M@2WLK:V-FTQR,6V-U4N4H]SX:QE%I2A):K6,DI+5:KB "UYRT^"E<FC5$DAJ
MV)6*J;HCXXGO:JIZ4YD3L/ C8ZET,6WSJ_ZS_#[[X/\ ^I+YX)T/.1NE-)!#
M([/Z1YGQ1O=_^"-=/?.8BKLGNQ?2I\D=,SRJ_&+CU@L7ISB-D\)=Q>(RGU7I
M1XS"18R9MWW/)5YY)HYY5DC2&5Z=6K43=>;?T$V]&.K?:&'M#&R;98_9TV;T
M]RR3EINR7!.M)\7XH@7I?UG[-S-G9F)2LCM;JG7#?J48:[R?&6^]%HGW/V'G
M(;%+S:+[%O#_ '::U^E&FNM/4?HF>6,XX\%-'0:$T%E<!3T]6R&0R<4.1T_#
MD;26LI*D]M76GV(G+&LB;QLY-F(JHBKNI(O3[8%^TL*./CNM6+(KM?:2<8[L
M861>C49<=9K1:<M? C7J[Z2XVRL^>1E*SLY8UE2[.*G+?E93)<&X\-(/C[#:
M$@UQGZY Z4O_ *_TE_HE7_M9]K^3C\NGTAN)''+AKH75.:TW8T]J;43,=E8:
M>FH*EJ2JM2U,K8;+;+UA<KXF^_1BKMOMZTA3*ZKMI4U6W3EC;E5<[):62UW:
MXN<M$ZUJ]$]%KQ)TQ.MO95UM5,%E;]UM=4-ZE);]DXPCJ]_@MZ2U?<N)G.
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MYS(^VF  1X22
M
M
M
M
M
M
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M*TWWN,)*+?#5K4MMT/VT]H;-Q,N>G:65Z6Z+1=K7)UV-+N3G!R2XZ)Z:O0
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MIO0F/\YD?;3  (\))
M
M
M
M
M
M
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MS<EKRJ::ZH:]W;RE*37=JE2ERU2EP>C9_9  KZ60!\W],1/_ #2\3ON!U=]
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MS32?]1R #@"1@
M
M
M
M
M
M
M                                              8OWG4WUF-#_? A
M^A\@90)B_>=3?68T/]\"'Z'R!UG07TO@?/K]F1QO6%Z$VE]&E^N)@8&Q#\V6
M^Q@I?=WK+_>:AKO#8A^;+?8P4ON[UE_O-0FKK<]%P^ET_9WD%=3'IBSZ#=]M
MCF0: "M):<&NL\Y>^RBO?<!HW\.7-BF:ZSSE[[**]]P&C?PY<DSJG]*_[-;^
MU617UQ>AG]*Q_P"^> L7[>/^,C_VC3<%<(OX)Z8^Y["_1M8T^L7[>/\ C(_]
MHTW!7"+^">F/N>POT;6.LZY_,V?\K)_52<=U&>?M+Y.)^O(/T, $#EA08<?G
M:_[VX#_YUQ%_V&C3,<,./SM?][<!_P#.N(O^PT:=WU:>FL/_ &G^RWD>]:GH
M'.]N+_;,<PRS9D>0)^Q*X1_YKJK^O.IC6;FS(\@3]B5PC_S757]>=3$I]<'H
MZGZ=5_9\DA[J2]+9'T"[^TX9[$  KB6C/)#RZOV*O%O^1Z/TSCC6.IZ?'H0V
M<7EU?L5>+?\ (]'Z9QQK'4]/CT(6+ZGOX!?]+G]C25CZ[/26-]"C]O>9>_FE
M/\(>/'\C<-O]]UT9K1A2^:4_PAX\?R-PV_WW71FM$8]9OIK+]F/_ &:DEOJM
M]!X7^T?VFX  X(D$_F]9?]#Y7^3;W^ZRFG$Q7[VK_P 3%_0:;CO67_0^5_DV
M]_NLIIQ,5^]J_P#$Q?T&D[]2_F[1]N)^K(*^=>?G;-]F7^O'/<;S=[[*K17\
MCZL^AYC9,FMF\W>^RJT5_(^K/H>8V3)S76YZ3K^B5_:W'3]2_HFSZ;=]G2#^
M,XB:]QFEL#F=29JPE3$8'&7<MDK*[?L5.A7?9L.1%5J.?U<;DC9S(KWJUJ+N
MJ']F>*7G"'$ZSIGHL:^]QR]58U#9T]I;O1.LJ9K-TX,G'WHJ\V,;<V1NZ[[;
M[-YG)'NR<'W3E8^/KIV]]56O@K)J+?U)ZDE;8S_<N)DY.F][GHMNW>"WG7"4
ME'CHN+6G/O,!WIW=,K4G'CB9J+B#J*S,Z*];FK:;Q3I'NJZ>TQ7FD;B,13B<
MJMCY*ZI9R$K&L6]D[%R[(QKI^K9\MZ6TGE<]DZ.%P>-O9C,9.Q'3QV*QE6:]
MD+]J9>6.O4J5F23SRO7]JR-CE[%5>Q%5+"AFF>:T]#+$+@=7<<LQ3BM9F?-S
MZ,T>ZQ$U_P!2\=C:=2UG<K4<[F1MC*WL@S%=8B-EKPX>PQKNKO/1;7[=VI3L
M?9SMC6MRB,*J*4]U2D](PAKIR23E)Z-[L9/C)E.M@;'OVYM*-4[6K+YSOR+Y
M+><8KRK)Z:K63;4(+712E%<(IZ?*71'\USX@ZDI4\OQ;U74X?PV6LE73.%BK
M9_4D$3XT<UM_(),[!TK;7>]DK5799C6[;VDD1T;?4W!>:T<"(*R1WM3\0\A9
M3OM-R>-IH[WC&_O>/&O8GOVO?NBI^WY>YJ*N3*"NV=UB;7OFY>ZI4IOA71&-
M<(KP3T<W[9SDWWLLWL_JTV+CP4/<<+VEQLR'*V<GPXM-J$>7*$(I=RXO7$?X
MI^:A:/GK2NT7Q5U%C+_9U,6H<3C\MCTV3MZUU)V/N=JHFW++LB*O8JHF^/WT
MS_(E<?N"L5C*Y/3":PTI!SO?JK0ZSYJI4A15VDS&+ZF+-X=.39TUF6C-BH7.
M2/ZJ2/5O-LY#JYB.14<B*BHJ*BINBHJ;*BHO8J*G>A[]E]9^U*)+M9QRZ]>,
M+HI2T[]VRM1DGX.6_%<]UFMVQU2[)R8OL:YX=FCW9T3DXZ\UO53<HM:]T=QM
M<-[1+338-7=$,A[S83[)JU]ZW5_TUI$Q],TU&WKR(B(B7KB(B(B(B)9E1$1$
M[$1$[$1.Q$[#(+\V$^R:M?>MU?\ 36D2=^FWHG.^C6?J17KH _\ ZULWZ0OV
M9&PS !4,NF#%M\ZO^L_P^^^#_P#J2^921BV^=7_6?X???!__ %)?.NZ!^F,#
MY[^Y,XOK$]";1^CO]N)@@FQ2\VB^Q;P_W::U^E&FNM-BEYM%]BWA_NTUK]*-
M)HZW?1=?TRK[*\@_J7]+6_0;OML<]_@ 5I+2 _C.(R;Z>SR(F^^&RB;)V[_X
M#/V;']F4IX&RL?&].9DC',>W=4W:]%:Y-T5%3=%5-T5%3T*?4):-/P:?Y&?,
MXZIKQ37Y4:<C.[_5#(;]Z9"ZG;WI_A4O81*E*:Q(V&O#-8F?^TA@B?-*_9-U
MY(XVN>[9$W7E:NR)N?KO2/T/8TQQ%U]INTUS+.!UKJG#SL=ONR7'YR]5>U=^
MW=%CV5%3?=%W/K?R17$JGI3I)\(<ID71LQ\^JX,+;61C9&<N>KV,36;RN16[
MOOVZ;$5>Y7%T[LQUXEF1"':.%$KH03TW]VO?C%-)Z;VB2>CY\BB6+@JS,AC3
MGV:GE1HG8UKV>]:JY2<6X^9Q;3:Y'P1^HG-_^I<Q_-=_^SC]1.;_ /4N8_FN
M_P#V<W"*:>Q__8:?_P M!_\ 8<_J>Q__ &&G_P#+0?\ V$.?=G?^CU_2?_Z2
M<_N&P_TC+^C+_.-/;^HG-_\ J7,?S7?_ +./U$YO_P!2YC^:[_\ 9S<)?J>Q
M_P#V&G_\M!_]@_4]C_\ L-/_ .6@_P#L'W9W_H]?TG_^D?<-A_I&7]&7^<:>
MW]1.;_\ 4N8_FN__ &<?J)S7_J7,?S7?_LYN$OU/8_\ [#3_ /EH/_L'ZGL?
M_P!AI_\ RT'_ -@^[._]'K^D_P#](^X;#_2,OZ,O\XP7/-7^'^0@XU\0LQ;Q
M]^I'4X6S8QLMJM)5C5^5U9INTC$;89&^5ZMPSG-6-',C:QZ2*U9(D=G=(0:N
M,K0*KH*\$*N39RQ0QQJY$[4158UJJB+VHB[]OH)Y%_2GI ]IYDLIU]EO0K@H
M;^_HH1T\[=CS>KY+34E;HET<CLK"CAQM[;=G98['!0U=DM?-3ERX+F^0,=3S
MG_[&JK]\O27^XY\R*S'4\Y_^QJJ_?+TE_N.?/OH;Z5V?]*I_;1\]-O1&TOH6
M1]G(U[1GU^:T?6*U/]\#)?1] P%#/K\UH^L5J?[X&2^CZ!/76OZ(E](H_OE>
M.I_TS'Z-D?W#)E !6 M>"QZFT]3R^.O8G(0ML4,G3M8^[ []K-5N0OKV(U[^
MQ\4CV[^C?<OAPJ&4VN*YKBM/%&&DUH^*?!KU&I(Z9G1WM\)N*^O^'%QCF.TG
MJ2Y0J*]'(LV(L-BR6!MMYU5ZQ7<'=QUR%SU5SHIV.=LY51/OSR#72F;PNZ1F
ME?=EI*V#UW%-H3,*]R-AWR\L$V&EEW:Y=XLY6H-B5B(]SIUB149*\]2_.H>B
M8W'ZET3QGQE?EBU!471>J'1I[U<ABFR7-/WI$:S]TFH27<=--*_=S*6-@C3:
M,Q*:%^S4G@N4YY:ERI/#;J6H'*R>M:K2,GKV89&[*R:":..6)S>UKV([L4MK
MLJ^&V=CP4W_"<:5-SYN-T8NN<M.YJQ=I#7NW64SVQCSV'MR79K18N5&^E<E*
MB4E9"'L=<NSEI^,C<CF)7YU%TK_J5I#0_!O'6-KFK[TNK]31,<J+'I[3\S(,
M+6F:J(CF97/OEMPN:YW*NFYV2-1)8W+D$^3_ .D[7XP<&.'O$9KHF6<_INF_
M.11N3JZ6HL<UV.U'51557-AKYFG>;7=)RODJ=3,YK4D1#74^5]Z4W]UWI!:^
MU)!8]T8;%Y!=):=<UV\?U(TVZ2BDL6SG,Y+=Y+UQ'QKU<R3I,F_/S+#'5QT?
ME/:\NVCI^Y[G*Q/DKXR==<?;&>]8O77X$[=:'22%>Q8]C-/]TE"%<D^>/.*M
MMDO5*O2M^JP\SU7;QMX]OL-B?YN#T4%X>]'^MJG(5EBS_%;*/U=8=(U6RQ:=
MAA3'Z3I[]G- ZC'9SL:JU'LES]B)7/9''M@:=$S@'<XI\3="\.Z#7.GU=J.A
MBI%8CW+#CU<ZUE[:]7L](Z6(K7KDTC53JH8))55&L54VU.CM*4<%B<9A,9"V
MOCL10J8VC U&HD52E!'6@9LU&MW;'&W=4:B*NZ[=IV/6_MG<HHP8/C?+MK=/
MP=3TA'V2LUE[:CANI78>_D9.T)KR:(]A3JOXVQ)V23\8UZ1]EKY=_P#1H<@%
M?RR         !PIK*/+E=*=O%3I&ZVL4K26L!HNQ^H+!.CD<^O(FG998,U;A
M]\Z)R6L^[(L98@7J[5.M3F1SFJU38(>4"Z2T/"'@WK_B Z1L=K!Z?N+AT<YB
M++G;K/<6&C8C_>O=]4+$$G5+^Z-8YB*BKN:GJ2Q+*]\T\CY9YGOFFED<KWRS
M2N6261[W*KG.?(YSG.<JJY5555552;.IW9&]9DYTEYB6/4^[>GY=K7KC%07L
MFR!NNW;6[7B;/@_ODI9-R[]VOR*D_5*<IR]M:9'E:JM<B+LKD5-^_;=-D[/R
M=OS&5IP>\Y[M:'TGIO1V$X(8J+$Z8PF,P6/;^J^PUSJV,IQ5&2R(W!HBS3]5
MUT[TW5\TDCWJKG*JXJ]>I-,JI##-,K417)#%)*K47N5R1M=R[^C?;?9=NXE?
M4:[_ -AN_P#R=G_]T3#MCH_AYZA',J[:-;E*$799!1<M$W[W.&O!:+773CIS
M9".Q>DF9LZ5DL+(["5BC&QJNF;:BVXKWVNS31MZ[NFO#7DC+F_79V>^TIB_]
M,;7_  0?KL[/?:4Q?^F-K_@AB,_4:[_V&[_\G9__ '0^HUW_ +#=_P#D[/\
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M;%(C+K;]*Q^BT_MVDL=3?H=_2[_U5@MN9_>=O_-I_P#9.+D6W,_O.W_FT_\
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MI;&/UPKA!_D::)XZNJG#8FSTTTW2Y\?"=DYI_7%I_6  <>=J:C_IE_7CXO\
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MD5  1\20            <;'5C&M1&M:C6M1$:U$1$1$[D1$[$1/1L=P
M
M
M
M
M
M
M
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MTECU3?"$++4]W>F^'D[R@]%-QUX9JH.$7?X/0OK.3C3N
M
M
M
M
M
M
M
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MWX[LO(IKA+6/'3RHOOY'?=!MCW8&S,;$R%%75=KOJ$M^/EW636DM%KY,EW(
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MV?=#-S+NTR:VW553*2IK<EHY3FU&5LM&UNZ1K6KU5G!KA#D B<F0&.IYS_\
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M0WJ7&+;:?%[STY>!L>B'5GM7"VEB95\<?LJ;'*;A?O2TW)1X1W%KQ:UX^)[
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M#:CQ=S":@Q6/S>'R$+ZU[&96G!>H6X)&JU\5BK9CDAE8YJJBH]B]_9LICO\
M2:\V,X':NMV<GH7*:CX87;#GRKC<9-'GM+I*]$<Y8,5F%?D*+7R;NZBEF8:%
M=KW1U:$43(XV3ST<ZV:90C7M*,H6):.^J&]79I\*=<?*A-]^Y&<&]6E!:(KO
MTGZFKHV2MV7.%E4GK[FMGN65M]U=C6Y."[M]QDDDM9OB:_6.-&/9+'O'+&Y'
MQR1JK)&/:N[7,>Q4<UR*FZ.:J*B]J+N5;CG6)GV+#WV)Y.7K)[#WSS2<K6L;
MSRRJ^1_*QK6-YG+LQK6IV-1$RM]4>:A\1H97+A^*NC[L"OV8E[#9BG.UFRKS
M2=3-8B<NZ(WE:J=B[HO9LE+3?FHG$F:5OU5XJ:-I0I(U'^X\/F+D[H^]SHTD
MEKQ->G:B->JHO?NAV_W0MC:;WNV'Z.[7\G9:_P# X3[FFV]=/W/G^EQ]/R]M
MI[.)BE;(B=B=B>@^TNA/Y/[B9Q_U)!I[06"DGII.R/-:HR#):^F=/57*G76<
MGD>K>V22.-5?'C:3;.1M/Y(X*R\RO;F,='/S7C@KIJS!?U]J'5/$>Q$YC_J6
M^9FE].O<WE<K;%;$/7,6FM>G8GU;KP2Q[LL59&N5J9$_#'A3IG1>&IZ=TC@<
M3IO!8^-(J>)PM"OCJ-=C41$1E>M'''S=GOGJBO<O:YRJNYQO2#K:QX1<-GUR
MNM:X76Q<*H:_"4&U9.2\&H1UT>LEP.UZ.=3&19.,]I3C13%INBF2G;8EW2FM
M:ZXM=\7.6FJ\EZ-?G?11X)7>&_#K2.ALCJ?*:RN:9PU;%S:DS/)]4,BL',C%
MDY-U2&NQ6U:B323V4J00I9LV9^LGD^A0" ;K963E.7&4Y2G)I))RDVVTHI)<
M7R227))(L?35&N$*X+2,(QA%-N348I12;DVWP2XMMOFVV  ?F?H
M
M
M
M
M
M
M
M
M
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M^T^NI78G9XV1GSCI+)FJ:6UQ[*EO?DO5.U[K7C5X:'( (<)O
M                                                   !;<S^\[?^
M;3_[)Q<BVYG]YV_\VG_V3C*YHP^3-.?E/WW<_P \M_[Q*>NGD!_LO^#'^<Z_
M_P#";7QY%Y3]]W/\\M_[Q*>NGD!_LO\ @Q_G.O\ _P )M?%R>D_HO:'T#+_L
M]A2+H=Z5V9].Q/MH&S. !34N\
M
M
M
M
M
M
M
M
M
M
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M*\N?=QG/>D_6P #6FT
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M##LHRLW(=N13.NV%5'DTPL@U*+E.2W[=))/@JH]S4D=@ 1"34
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
3                      ?_V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
